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ABSTRACT 
 
Background and aim: Asthma is one of the major public health problems in Australia 
with prevalence in West Australian children reported up to 31%. The rise in asthma 
prevalence in Western societies may be related to changes in dietary habits, as diets 
are often low in antioxidant nutrients and omega-3 fatty acids (n-3) and high in 
omega-6 fatty acids (n-6).  
 
The association between antioxidants, fatty acids and asthma is however 
controversial and there is a need for further investigation to clarify the role of these 
nutrients on asthma.  
 
The aim of this study was to investigate the dietary exposures of n-3, n-6 and 
antioxidant nutrients proposed to have protective effects against asthma symptoms. 
Data gathered over fourteen years in a prospective pregnancy cohort study were 
analysed. We hypothesised that n-3 fatty acids and antioxidant nutrients (vitamins A, 
C, E, β-carotene antioxidants manganese and zinc) would be protective against 
asthma symptoms.  
 
Methods: The Western Australian Pregnancy Cohort (Raine) study is a longitudinal 
study following 2868 children from birth to 14 years of age. This project consisted of 
two analyses as part of the overall study. Study One was a cross-sectional analysis of 
1531 children at age 14 identified as having current asthma (n=167) or no asthma 
(n=1364). Study Two was a longitudinal analysis from a subset of the overall study 
whereby children were identified as having current asthma or no asthma at eight 
(n=335) and 14 (n=242) years of age. Dietary information was collected from food 
frequency questionnaires (FFQ) in both studies and red blood cell fatty acid content 
was measured in children for Study One. Student’s t-tests and ANOVA allowed 
comparisons of food and nutrient intakes between children with asthma or no asthma 
for both studies. In Study One depending on the outcome of interest, multinominal or 
binary logistic regression was performed. In Study Two, food and nutrients that 
showed a significant difference between asthma groups in ANOVA analyses (p 
iv 
<0.05) were included in analysis of covariance (ANCOVA) to determine whether 
they made an independent contribution after adjustment for age, sex, BMI and total 
energy intake. The Bonferroni post hoc test was applied to control for false positive 
results. 
 
Results of Study One: The participants were 50.8% male (n= 778) and 49.2% female 
(n=753). One hundred and sixty seven adolescents (10.9%) had asthma categorised 
as mild (4.0%), moderate (4.4%) or severe (2.5%). Two hundred and eighteen 
adolescents (14.2%) had current wheeze. The most common allergy outcome was 
atopy (44.5%) n= 682. The least common allergy outcome was eczema (10.7%). 
 
The large majority of dietary antioxidants and fatty acids tested were unrelated to 
asthma and asthmatic symptoms. However, after performing regression analysis and 
adjusting for potential confounders (BMI, age, gender and total daily energy intake) 
increased intake of vitamin C showed protective association with asthma (adjusted 
OR= 0.997, 95% CI= 0.994–0.999) and increased consumption of berry fruits 
showed protective effects on atopy (adjusted OR= 0.988, 95% CI= 0.976–0.999).  
 
Increased level of docosahexaenoic acid (22:6n3) in RBC membrane showed 
protective effects on BHR (adjusted OR= 0.814, 95% CI= 0.669–0.989). The 
adjusted ratio of n6:n3 showed detrimental association with asthma (OR= 1.072, 
95% CI= 1.009–1.139) and wheezing episodes (OR= 1.064, 95% CI= 1.007–1.124). 
 
Results of Study Two: None of the antioxidant nutrients were shown to be associated 
with asthma. Unadjusted ANOVA analysis demonstrated a significant association 
between asthma diagnosis and arachidonic acid (20:4n6) (p=0.039). However, after 
performing ANCOVA and controlling for the confounders (age, sex, BMI and total 
energy) the association became non-significant (p=0.330). In crude analyses the 
n6:n3 ratio was higher for asthmatic adolescents at eight and 14 years (3.38) 
compared to those with no asthma (2.78) (p=0.013). This ratio remained significant 
after adjusting for the confounders (p=0.030)  
 
Conclusions: Study One and Two provide some evidence on protective effects of 
antioxidants and fruits on asthmatic symptoms in adolescents. We found that while 
v 
controlling for potential confounders, increasing intake of vitamin C by 1 mg/day 
results in a 0.3% reduction in the risk of developing asthma. We demonstrated that 
for every 1 g/day increased intake of berry fruits there was 1.2% reduction in the risk 
of having atopy. We showed that by increasing 1 mmol/L in the level of 
docosahexaenoic acid in RBC membrane there was 18.6% reduction in the risk of 
having BHR. We also demonstrated that for every 1 unit increase in n6:n3 ratio, 
there was 6.4% increase in the risk of developing wheezing episodes and 7.2% 
increase in the risk of having asthma. Therefore, Our study suggests that the ratio of 
n6:n3 in diet may play a modulatory role in the expression of asthma, suggesting that 
promotion of increased total n-3 and reduced n-6 may protect against asthmatic traits 
in childhood and early adolescence. 
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 1 
Introduction, objectives and hypotheses 
 
The prevalence of asthma in children and young adults has increased over the last 
two decades in many Western countries including Australia. Asthma affects millions 
of Australians, including one in four primary school children and one in seven 
teenagers (Lincoln et al. 2006). Asthma is one of the major public health problems in 
Australia. In Perth, asthma has been diagnosed in 31% of children (Oddy et al. 
2004a) which is even higher than the national prevalence of 25%. There is however 
emerging evidence suggesting that the prevalence of childhood asthma in Australia 
has reached a plateau (ACAM 2008).  
 
The rise in asthma prevalence in Western societies may be related to changes in 
dietary habits. Despite the fact that there have been several studies on the impact of 
diet and its role in relation to asthma, the effect of diet on asthma remains unclear 
and requires further investigation. 
 
Asthma is characterized by the chronic inflammation of the airways. Inflammatory 
cells generate large amounts of oxidants on the epithelial surfaces, leading to 
epithelial cellular injury (Patel et al. 2006). Antioxidants provide a defensive system 
in which the survival and development of cells in an oxidant-containing environment 
is possible (Hoffmann et al. 2007). Western diets are low in antioxidant nutrients 
which raises the possibility that a lack of these nutrients might explain the rising 
number of asthmatic children in Western countries (Devereux & Seaton 2005). 
Currently however, information on the relationship between asthma and antioxidants 
in the diets of children is scarce although some studies in adults have found modest 
beneficial effects (Kirkham & Rahman 2006; Troisi et al. 1995). 
 
There is also increasing evidence that a diet with high levels of n-3 fatty acids has a 
protective effect against cough and wheeze both in children and adults (Castro-
Rodriguez et al. 2008; Peat et al. 2004).  
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Consequently this project presents data gathered at 14 years in a prospective cohort 
study of 1799 adolescents of whom 1531 completed the food frequency 
questionnaires (FFQ). This study was designed to investigate the dietary exposures 
of fatty acids and antioxidant nutrients that have been proposed to reduce asthma 
symptoms.  
 
This project consisted of two studies. Study One, using FFQ in Western Australian 
adolescents at 14 years investigated whether there was any association between the 
intake of antioxidants and n-3 fatty acids with asthma manifestations (wheeze, 
asthma, atopy and bronchial hyperresponsiveness). Also, for this study red blood cell 
fatty acid data were used to investigate the possible association of individual fatty 
acids, total n-3, total n-6 and the ratio of n6:n3 fatty acids on asthma. 
 
In Study Two, two sets of data were used. The first used the FFQ when the children 
were eight years old (Oddy et al. 2004a) and the second when they were 14 years of 
age. These data were used for the analyses of the previously selected cases and 
controls at eight years of age and re-assessing their asthmatic and dietary status six 
years later when they were 14 years of age.  
 
Therefore, the aim of Study One was to establish if there is an association between 
the intake of dietary factors of antioxidants and n-3 fatty acids and asthmatic traits 
(doctor diagnosed asthma, bronchial hyperresponsiveness (BHR), atopy, and 
episodes of wheezing) in adolescents. The aim of Study Two was to assess current 
asthmatic symptoms and dietary intake (fatty acid and antioxidant nutrients) of 
previously selected cases and controls and re-assess their asthmatic and dietary status 
six years later at 14 years of age through the follow up of participants who were 
assessed at eight years of age and had reached 14 years of age. Thus, Study Two 
allowed investigation of any possible causal associations of previous dietary 
exposures with current asthmatic symptoms. 
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Specific hypotheses of the study 
 
The specific hypotheses of Study One were that: 
 
1. consumption of specific antioxidants i.e. vitamins A, C, and E, ß-carotene, 
zinc and fruits containing these nutrients will reduce asthmatic symptoms in 
14 year old adolescents.  
2. consumption of n-3 fatty acids reduces asthmatic symptoms in 14 year old 
adolescents.  
3. higher level of n-3 fatty acids in red blood cells is associated with less 
asthmatic symptoms.  
 
Study Two was hypothesised that: 
 
1. consumption of specific antioxidants i.e. vitamins A, C, and E, ß-carotene, 
zinc and fruits containing these nutrients is the lowest in adolescents with 
asthmatic symptoms at eight and 14 years compared to the non-asthmatic 
group and those with asthma at eight and 14 years only.  
 
2. consumption of n-3 fatty acids is the lowest in adolescents with asthmatic 
symptoms at eight and 14 years compared to the group with no asthmatic 
symptoms and the groups who had asthma at eight and 14 years only.  
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CHAPTER ONE 
CHARACTERISTICS OF ASTHMA 
Asthma is a chronic illness involving the respiratory system in which the airway 
occasionally constricts, becomes inflamed, and is lined with excessive amounts of 
mucus, often in response to one or more triggers (Rodrigo & Nannini 2006). It is 
characterized by chronic inflammation of the airways. Inflammatory cells generate 
large amounts of oxidants on the epithelial surfaces, leading to epithelial cellular 
injury (Patel et al. 2006).  The precise basis for the development of airway 
inflammation is not fully understood. One traditional theory postulates the 
development of an allergic response in the airways (Hoffmann et al. 2007). 
 
1.1  DEVELOPMENT OF ASTHMA 
 
The traditional inflammation theory in asthma development proposed that asthma is 
caused by increased recruitment of inflammatory cells from the bloodstream to the 
bronchial mucosa and also by enhanced survival of these cells in the inflamed 
airways (Pearce et al. 2007; Vignola et al. 2000). There are two cell death pathways 
by which an organism can discard cells that are superfluous or potentially harmful: 
necrosis and apoptosis (programmed cell death). Necrosis involves breakdown of the 
cellular membrane, which leads to leakage of intracellular proteins to the 
extracellular space and subsequently, inflammation (Figure 1). Necrosis usually 
affects large groups of cells while apoptosis typically involves single cells. In 
apoptosis cells undergo organised destruction of the cellular cytoskeleton and 
formation of apoptotic bodies, which are phagocytosed without an inflammatory 
reaction (Figure 1). Apoptosis is the most common form of physiological cell death 
and serves to eliminate cells that are potentially harmful to the body (Hoffmann et al. 
2007; Simon 2003). Delayed apoptosis of inflammatory cells in inflammatory 
responses contributes to their accumulation in order to efficiently eliminate the cause 
of inflammation (Simon 2003). The survival of inflammatory cells in airway tissues 
depends on several factors including lack of antioxidants and the prolonged activity 
of reactive oxygen species (Simon 2003; Tripathi et al. 2007). Increasing amount of 
 5 
evidence lends support to the concept that a dysregulation of cell apoptosis may play 
a central role in the development of airway inflammatory associated with asthma 
(Jeon et al. 2007; Radinger et al. 2007; Stern et al. 2007). 
 
 
   
 
 
 
 
 
 
 
 
 
 
Figure 1 - Cell death pathway necrosis and apoptosis  
(Simon 2003) 
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1.2  PHENOTYPES OF ASTHMA 
 
Asthma phenotypes are differentiated based upon the development of symptoms and 
the severity of asthmatic lung inflammation (Janeway et al. 2001). Asthma symptoms 
are typically manifested at certain stages in life and can be classified into three 
general categories: childhood asthma, late-onset asthma and occupational asthma. 
Childhood asthma can arise from several different factors (Hang et al. 2003). 
Typically, a co-viral infection such as the rhinovirus, a family history of allergy, or 
atopy (an allergic hypersensitivity) can result in the development of childhood 
asthma (Pearce et al. 2007; Vignola et al. 2000). In childhood asthma, atopy usually 
results from innocuous substances such as dust mites, pet dander, and fungi (Hang et 
al. 2003). Late onset asthma (which starts in the middle or later in life) and 
occupational asthma exhibit different characteristics from childhood asthma and 
probably have a different aetiology (Pearce et al. 2007). Asthma’s causation in these 
circumstances may arise from constant exposure to environmentally innocuous 
antigens. The current distinction between late-onset asthma and occupational asthma 
occurs because the latter happens usually because of specific antigen exposure 
related to work, while only 10 to 15 per cent of cases of late-onset asthma are work-
related and the majority are triggered by viral infections (Pearce et al. 2007; Vignola 
et al. 2000).  
 
Asthmatic inflammation is differentiated into three broad categories: acute, subacute 
and chronic. Acute asthmatic inflammation involves the early recruitment of cells in 
to the airway, while subacute asthmatic inflammation is characterized by the 
activation of recruited and residual effector cells resulting in incessant inflammation 
(Hang et al. 2003). Chronic asthma is defined by constant inflammation leading to 
cellular damage, which in turn activates cellular repair (Hang et al. 2003). 
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1.3  ASTHMA SYMPTOMS AND MANIFESTATIONS 
 
Common asthma symptoms include: coughing, wheezing, shortness of breath, chest 
tightness, pain, or pressure (Janssens et al. 2009). People with asthma experience 
symptoms when the airways tighten, are inflamed, or fill with mucus. Not every 
person with asthma has the same symptoms in the same way. Symptoms may vary 
from one asthma attack to the next, being mild during one and severe during another 
(Chen et al. 2006; Ritz et al. 2001). 
 
Bronchial hyperresponsiveness (BHR), atopy and wheeze are the manifestations 
associated with asthma (Cornejo-Garcia et al. 2007; Floistrup et al. 2006; Marks et 
al. 2006; Stern et al. 2007; Sumi et al. 2007). These asthma manifestations are 
explored in more detail in the following sections. 
 
1.3.1 Bronchial hyperresponsiveness (BHR) 
 
Bronchial hyperresponsiveness (BHR) is defined as an increase in sensitivity to a 
wide variety of airway narrowing stimuli. In asthma, this hypersensitivity is 
accompanied by excessive degrees of airway narrowing (Sumi et al. 2007). It is 
currently believed that both muscular and non-muscular components of the airway 
wall are important determinants of the degree of airway narrowing that result from 
smooth muscle stimulation (Southam et al. 2007). Non-muscular components of the 
airway and the lung parenchyma can affect the degree of smooth muscle shortening 
and airway narrowing that occurs in response to airway smooth muscle stimulation 
(Southam et al. 2007; Weissman 2002). 
 
1.3.2 Wheeze 
 
Wheezing is a high-pitched sound associated with laboured breathing. Wheezing 
occurs when one tries to breathe deeply through air passages that are narrowed or 
filled with mucus (Southam et al. 2007; Varraso et al. 2007). Wheezing is also very 
closely associated with respiratory syncytial virus (RSV) (Anderson et al. 2005; 
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Schauer et al. 2002). Wheezing is commonly experienced by persons with a lung 
disease; the most common cause of recurrent wheezing is asthma, a form of reactive 
airway disease (Orient 2000; Pearce et al. 2007). In previous studies it has been 
documented that wheezing in the previous 12 months is positively correlated with 
atopy (Weissman 2002). Therefore, wheezing is the symptom most associated with 
asthma (Cornejo-Garcia et al. 2007).  
 
1.3.3 Atopy 
 
Atopy is an allergic hypersensitivity affecting parts of the body not in direct contact 
with the allergen. It may involve eczema (atopic dermatitis), allergic rhinitis and 
asthma. There appears to be a strong hereditary component (Floistrup et al. 2006; 
Socha et al. 2007). Although atopy has various definitions, most consistently it is 
defined by the presence of elevated levels of total and allergen-specific IgE in the 
serum of patients, leading to positive skin-prick tests to common allergens (Floistrup 
et al. 2006; Stern et al. 2007). 
 
Among asthmatic patients reporting wheezing in the previous 12 months, a stronger 
relationship has been noted with atopy for those reporting more than 12 episodes of 
wheezing than for those reporting 1 to 3 episodes ([OR] 8.70 vs. 3.27, respectively) 
(Marks et al. 2006). Atopy has also been found to be more strongly associated with 
hospital attendance for asthma than with ever having had asthma (OR, 16.95 vs. 
2.09, respectively) (Marks et al. 2006). The proportion of “asthma-ever” attributable 
to atopy is reported as 33% in one study (Weissman 2002), while for hospital 
attendance in 1999, this proportion was 89% (Marks et al. 2006). Based on these 
findings, it is suggested that atopy may contribute more to frequent or severe asthma 
than to infrequent or mild asthma (Weissman 2002). 
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1.4  IMMUNOLOGICAL RESPONSES IN ASTHMA 
 
The immune system is divided into the innate immune system, and the acquired or 
adaptive immune system. The latter is further divided into humoral and cellular 
components (Berrington et al. 2005). Humoral immunity is the aspect of immunity 
that is mediated by secreted antibodies, produced by B lymphocytes. Secreted 
antibodies bind to antigens on the surfaces of invading micro-organisms which flags 
them for destruction (Tripathi et al. 2007).  
 
Cellular immunity on the other hand, is an immune response that does not involve 
antibodies but rather involves the activation of macrophages, natural killer (NK) 
cells, and the release of various cytokines in response to an antigen. This type of 
response is what is typically observed in asthma. Cellular immunity protects the body 
by activating antigen-specific cytotoxic T-lymphocytes that are able to induce 
apoptosis (programmed cell death or cellular suicide). Cellular immunity also 
protects the body by stimulating cells to secrete a variety of cytokines that influence 
the function of other cells involved in adaptive immune responses and innate 
immune responses. 
 
Asthmatic symptoms arise from the activation of sub-mucosal mast cells by 
innocuous antigens (allergens) in the lower airways resulting in mucous and fluid 
accumulation subsequently followed by bronchial constriction (Radinger et al. 2007). 
The immune response to asthmatic allergens is mediated by CD4+ T helper 2 (TH2) 
cells, eosinophils, neutrophils, macrophages, and IgE antibodies (Jeon et al. 2007; 
Radinger et al. 2007; Stern et al. 2007) (Figure 2). 
 
1.4.1 Lymphocytes and lymphoid cells  
 
Lymphocytes are a type of white blood cell (leukocytes) in the immune system. 
Lymphoid cells are considered to be the precursor for the mature lymphocytes. An 
average human body contains about 1012 lymphoid cells (Radinger et al. 2007). The 
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lymphoid tissue as a whole represents about 2% of the total body weight (Berrington 
et al. 2005).  
 
The three major types of lymphocyte are T cells, B cells and Natural Killer (NK) 
cells (Stern et al. 2007). The small lymphocytes are the T cells and B cells. 
Lymphocytes play an important and integral role in the body's defences.  
 
T cells and B-cells are the major cellular components of the adaptive immune 
response (Tripathi et al. 2007). T cells are involved in cell-mediated immunity 
whereas B cells are primarily responsible for humoral immunity. The function of T 
cells and B cells is to recognize specific non-self antigens, during a process known as 
antigen presentation. Once they have identified an invader, the cells generate specific 
responses that are tailored to maximally eliminate specific pathogens or pathogen 
infected cells (Tripathi et al. 2007). B cells respond to pathogens by producing large 
quantities of antibodies which then neutralize foreign objects like bacteria and 
viruses (Radinger et al. 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-Development of systemic allergy (including asthma)  
(Compiled by the candidate) 
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In response to pathogens some T cells, called helper T cells produce cytokines that 
direct the immune response whilst other T cells, called cytotoxic T cells, produce 
toxic granules that induce the death of pathogen infected cells. In general, allergens 
induce a CD4 T helper (TH) cell response, whereas viruses recognize CD8+ cytotoxic 
T cells (Tc). In the asthmatic airways, there are CD4+ and, to a lesser number CD8+ 
cells with a type 2 cytokine phenotype (i.e., Th-2 and Tc-2 type) (Jeon et al. 2007). 
These cells produce interleukin (IL) 3 and 5 and granulocyte-macrophage colony-
stimulating factor which recruit, mobilize and activate eosinophils for subsequent 
mucosal damage, as well as IL-4, an essential cofactor for local or generalized IgE 
production (Stern et al. 2007) (Figure 2). The activation of eosinophils also leads to 
epithelial shedding, mucus hypersecretion and bronchial muscle contraction. Thus, 
although the eosinophil may damage the mucosal surfaces in asthma, its function 
appears to be under T cell control (Jeon et al. 2007; Radinger et al. 2007). 
Eosinophilic inflammation represents an essential element in the pathogenesis of 
asthma (Hasala et al. 2008).  
 
1.4.1.1 T-lymphocytes 
 
Helper T cells have two important functions: to stimulate cellular immunity and 
inflammation and to stimulate B cells to produce antibody. CD4+ helper T cells are 
capable of differentiating from an initial common state (TH0) into two apparently 
distinct types called TH1 and TH2. These subtypes differ in their cytokine secretion 
(Radinger et al. 2007).   
 
The balance between TH1 and TH2 represents a switch mechanism which can be used 
to bias the immune response in one direction or another. The commitment of TH0 
cells to become TH1 or TH2 is influenced by cytokines secreted by the two subtypes 
themselves and by macrophages. The outcome of the differentiation switch between 
different subtypes of TH cells is activation of the two different pathways of immunity 
which are associated with different antibody isotypes (Berrington et al. 2005). 
 
The TH1 pathway is essentially cell mediated immunity, with the activation of 
macrophages, NK cells, cytotoxic T cells and a prolonged inflammatory response. 
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The cytokines secreted by TH1 cells also boost production of IgG2 antibody 
production in mice (Radinger et al. 2007). TH1 cells produce IL-2, IFN γ, and TNF ß, 
which activate macrophages to stimulate cellular immunity and inflammation. TH1 
cells also secrete IL-3 and Granulocyte Monocyte Colony-Stimulating Factor (GM-
CSF) to stimulate the bone marrow to produce more leukocytes. 
 
The TH2 pathway is essentially a humoral pathway, with the production of cytokines 
which promote B cell growth (like IL-4, IL-6) and production of IgG (IL-4), IgA (IL-
5) and IgE (IL-4) in mice. TH2 also stimulates effectors which use these antibody 
isotypes; eosinophils (via IL-5) and mast cells (IL-4) (Radinger et al. 2007; Tripathi 
et al. 2007). 
 
The balance between TH1 and TH2 activity may steer the immune response in the 
direction of cell-mediated or humoral immunity (Figure 2) (Cornejo-Garcia et al. 
2007).   
 
T lymphocytes play a central role in the development of airway inflammation. They 
are present in increased numbers in the airways of patients with fatal asthma or in 
patients with asthma of variable aetiology including occupational asthma (Sumi et al. 
2007; Tripathi et al. 2007). It has been reported that there is an inverse association 
between childhood infectious illness and the development of atopy, suggesting that 
certain forms of infection protect against asthma. This may involve a shift in the 
balance of CD4+ T- lymphocyte helper cells from a TH2 to a TH1-type cytokine 
profile (Mawson 2001). 
 
1.4.1.2 B-lymphocytes 
 
B-lymphocytes play a vital role in the body’s specific immune system. These cells 
are not only produced in the bone marrow, but also mature there. B-cells mature into 
plasma cells and are responsible for the production of antibodies, which primarily 
play a role in bacterial infections (Sumi et al. 2007). In asthma, B cells can play an 
important role as an antigen-presenting cell (APC) in the development of primary 
CD4+ T cell responses (Cornejo-Garcia et al. 2007). 
 13 
1.4.2 Cytokines and eosinophils 
 
Cytokines are small secreted proteins (between 8 and 30 kilo Daltons or kDa) which 
mediate and regulate immunity, inflammation, and hematopoiesis (Jeon et al. 2007). 
They mostly act over short distances and short time spans and at very low 
concentration. They act by binding to specific membrane receptors, which then 
signal the cell via second messengers, often tyrosine kinases, to alter its behaviour 
(gene expression) (Cornejo-Garcia et al. 2007) (Figure 3).  
 
 
Figure 3- Schematic diagram of the role of the inflammatory cells in asthma  
(Hasala et al. 2008; Knutsen et al. 2008; Larocca et al. 2008) 
 
Responses to cytokines include increasing or decreasing expression of membrane 
proteins (including cytokine receptors), proliferation, and secretion of effector 
molecules. 
 
The largest group of cytokines stimulates immune cell proliferation and 
differentiation. This group includes Interleukin 1 (IL-1), which activates T cells; IL-
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2, which stimulates proliferation of antigen-activated T and B cells; IL-4, IL-5, and 
IL-6, which stimulate proliferation and differentiation of B cells; Interferon gamma 
(IFN γ), which activates macrophages; and IL-3, IL-7 and GM-CSF, which stimulate 
hematopoiesis (Radinger et al. 2007). 
 
Other groups of cytokines include interferons and chemokines (Cornejo-Garcia et al. 
2007). Interferons IFN α and IFN ß inhibit virus replication in infected cells, while 
IFN γ also stimulates antigen-presenting cell MHC expression. Cytokines act on their 
target cells by binding specific membrane receptors. The receptors and their 
corresponding cytokines have been divided into several families based on their 
structure and activities (Cornejo-Garcia et al. 2007).  
 
In asthmatics eosinophils release a variety of pro-inflammatory cytokines including 
IL-3 and IL-5. They also release highly toxic granule-derived basic proteins (such as 
eosinophil cationic protein or ECP) that are responsible for epithelial cell damage in 
chronic asthma (Jeon et al. 2007).  
 
The balance between eosinophil maturation, recruitment and removal largely 
determines the number of eosinophils in the blood and tissues (Bratke et al. 2007; 
Hasala et al. 2008). As discussed earlier apoptosis, or programmed cell death, is a 
controlled process of cell suicide that allows the removal of aging cells or those 
whose continued survival would be detrimental for the organism (Hasala et al. 2008; 
Knutsen et al. 2008; Radinger et al. 2007). Furthermore, failure in the apoptotic 
process of eosinophils has been associated with pulmonary and allergic diseases 
(Hasala et al. 2008). NK cells are a part of the innate immune system and play a 
major role in defending the host from both tumours and virally infected cells by 
recognizing alterations in levels of a surface molecule called Major 
Histocompatibility Complex (MHC). NK cells are activated in response to 
interferons. Activated NK cells release cytotoxic granules which then destroy the 
altered cells.  
 
 15 
1.4.3 Histocompatibility molecules 
 
Histocompatibility molecules are glycoproteins expressed at the surface of almost all 
vertebrate cells. They get their name because they are responsible for the 
compatibility (or the lack of it) of the tissues of genetically different individuals 
(Bratke et al. 2007). Only monozygotic (identical) human twins have the same 
histocompatibility molecules on their cells, and therefore, they can accept transplants 
of tissue from each other. The rest of us have a set of histocompatibility molecules 
that is probably unique to us. A graft of our tissue into another human will provoke 
an immune response which, if left unchecked, will end in the rejection of the 
transplant (Bratke et al. 2007). So the histocompatibility molecules of one individual 
act as antigens when introduced into a different individual and are also called 
histocompatibility antigens. 
 
There are two categories of histocompatibility molecules: class I and class II. Class I 
molecules serve to display antigens on the surface of the cells so that they can be 
recognized by T cells. These molecules provide tissue identity and serve as major 
targets in the rejection of transplanted tissue (Bratke et al. 2007; Cornejo-Garcia et 
al. 2007). Three different types of class I molecules are: human leukocyte antigen A, 
B and C designated as HLA-A, HLA-B, and HLA-C. Class II molecules are 
designated HLA-D (Radinger et al. 2007). Class II molecules, in contrast to class I, 
are normally expressed on only certain types of cells. These are cells like 
macrophages and B lymphocytes that specialize in processing and presenting extra 
cellular antigens to T- lymphocytes (Cornejo-Garcia et al. 2007; Radinger et al. 
2007). Most of the T cells of the body belong to one of two distinct subsets: cluster 
of differentiation 4 (CD4+) or cluster of differentiation 8 (CD8+). CD4+ and CD8+ are 
surface glycoproteins (Radinger et al. 2007). The CD8 molecules on CD8+ T cells 
bind to a site found only on class I histocompatibility molecules while CD4 
molecules on CD4+ T cells bind to a site found only on class II histocompatibility 
molecules (Radinger et al. 2007). In asthma most cells bear CD4+ receptors while 
CD8+ cells are rarely identified (Sumi et al. 2007). 
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1.4.4 The allergic response and development of the asthma 
phenotype 
 
Antigen is inhaled into the airway and is taken up and processed by an antigen-
presenting cell (APC) (Hoffmann et al. 2007). The APC then migrates from the 
airway mucosa to the regional lymph nodes. Upon arrival at the lymph node, the 
APC cell, which has matured along the journey, presents the processed antigenic 
peptides to T cells. Rare antigen-specific T cells sample the peptides being presented 
in the lymph node; when an antigen-specific T cell finds an APC cell that presents 
the peptides for which the T cell is specific, it begins to proliferate (Floistrup et al. 
2006; Hoffmann et al. 2007) . Simultaneously, the APC, through various signals, 
attempts to skew the cytokine profile of the developing T cells to cause them to 
become T helper type 1 (TH1) cells (which primarily produce interferon gamma 
[IFN-γ]) and interleukin 12 [IL-12]) or TH2 cells (which produce IL-4, IL-5, and IL-
13) (Galli & Tsai 2007; Hoffmann et al. 2007). These cytokine profiles may be found 
in both CD4+ and CD8+ T cells; both types of T cells have been implicated in 
causing asthma (Galli & Tsai 2007). 
 
The allergic response in general and the asthmatic allergic response in particular 
depend on a TH2 response to an antigen. TH2 cells produce IL-4, which causes B 
cells to switch from usual production of IgM or IgG antibody to production of IgE 
antibody (Jeon et al. 2007). Once produced, IgE antibodies bind to the surface of 
mast cells and basophils, where subsequent antigen cross-linking causes the 
generation and release of mediators that drive the asthma phenotype (Galli & Tsai 
2007). 
 
In an experimental model of the allergic response to inhaled antigen, TH2 cells alone 
were not sufficient to cause the asthma phenotype, because TH2 cell recruitment to 
the allergic site depends on help from TH1 cells (Jeon et al. 2007). TH1 cells are more 
readily recruited to the airway tissue and are responsible for tumour necrosis factor 
(TNF) dependent expression of vascular cell adhesion molecules; the presence of 
TH1 cells in the airway tissue in turn allows TH2 cells to enter the tissue (Jeon et al. 
2007; Stern et al. 2007). The TH1 cells do not need to be of the same antigenic 
specificity as the TH2 cells. This finding may help explain why inflammatory stimuli, 
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such as respiratory viral infections, may facilitate the allergic response and contribute 
to flares of allergic asthma. 
 
Allergens may also be sufficient to produce airway inflammation. When a sensitized 
individual is re-exposed to an allergen, the subsequent cross-linking of IgE on the 
surface of the mast cells and basophils can lead to the release of immediate-phase 
reactants such as histamine and TNF (Jeon et al. 2007). Within 4 to 6 hours after 
exposure, the activated immune cells produce chemokines and cytokines, 
proteinases, enzymes, and lipid mediators such as the cysteinyl leukotrienes 
(Radinger et al. 2007). Chemokines recruit and help activate additional TH2 cells and 
eosinophils in the airway. Proteinases and other enzymes may lead to airway 
damage, which promotes collagen deposition in the subepithelial basement 
membrane region. Cysteinyl leukotrienes can cause airway smooth muscle 
constriction and mucous cell secretion that further obstruct the airway lumen 
(Duramad, Tager & Holland 2007). 
 
Leukotrienes in concert with chemokines (e.g., eotaxin) and cytokines (e.g., IL-5) 
may also recruit and activate eosinophils in the airway. Eosinophils are granulocytes 
that have a very short life span in the periphery and do not appear in large amounts in 
the circulation. These cells are produced in the bone marrow under the influence of 
TH2 cell production of IL-5. Newly produced eosinophils are released into the 
circulation and settle in the lung tissue, guided by a similar set of cell adhesion 
molecules that direct TH2 cell traffic. Upon entry into airway tissue, eosinophils and 
TH2 cells secrete their products, which, in addition to the mast cell/basophil products, 
are thought to lead to mucous cell metaplasia and smooth muscle hyperplasia 
(Duramad, Tager & Holland 2007). These changes in cellular behaviour are the basis 
for the hypersecretion and hyperresponsiveness that is characteristic of the asthma 
phenotype. The TH2 cytokines IL-9 and IL-13 are especially effective in driving 
differentiation of mucous cells. Eosinophil granule constituents such as myelin basic 
protein, eosinophilic cationic protein, and eosinophil-derived neurotoxin may also 
contribute to airway inflammation, damage, and re-modelling, although recent 
findings in mouse models and human subjects suggest that the contribution of the 
eosinophil may not be necessary for the asthma phenotype, at least under some 
conditions (Haldar & Pavord 2007). Recently, an additional type of T cell, the 
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regulatory T cell (Tr) also known as suppressor T cell, was identified (Kapp & Bucy 
2008). Tr cells produce IL-10 and transforming growth factor-β (TGF-β), which may 
down regulate the immune response. Studies in experimental models suggest that an 
inhibition of the Tr function may also drive the asthma phenotype, but its role in 
humans is not yet clear (Duramad, Tager & Holland 2007).  
 
Nutritional deficiency is frequently associated with impaired immune responses, 
mostly cell-mediated immunity, including cytokine production, secretory antibody 
responses and the complement system (Calder 2006; Chandra 1991). Mazari & 
Lesourd (Mazari & Lesourd 1998) compared the influences of aging and nutrition on 
immune responses of healthy elderly (80 ±5 years) with different nutritional status to 
young healthy adults (25 ±5 years). They reported that the influences of aging and 
undernutrition are cumulative and that some changes in immune response that have 
been attributed to aging may, in fact, be related to nutrition and not aging. For 
instance, minor changes in nutritional status, such as lower folate levels, were 
associated with lower CD4
+ subsets in peripheral blood in healthy young adults as 
well as their healthy elderly counterparts. The associations between nutrition and the 
development of asthma will be further discussed in section 1.7. 
 
1.5  ATOPIC AND NON-ATOPIC ASTHMA 
 
Asthma that results from sensitivity to specific external allergens is known as atopic 
(extrinsic) asthma (Hasala et al. 2008). In cases in which the allergen isn’t obvious, 
asthma is referred to as non-atopic (intrinsic) asthma (Hasala et al. 2008). Allergens 
that cause atopic asthma include pollen, house dust or mould, feather pillows, food 
additives containing sulphites, and any other sensitizing substance (Wichmann et al. 
2008). Atopic asthma usually begins in childhood and is accompanied by other 
manifestations of atopy such as eczema and allergic rhinitis (Knutsen et al. 2008). In 
non-atopic asthma, no extrinsic allergen can be identified. Most cases of non-atopic 
asthma are preceded by a severe respiratory infection. Irritants, emotional stress, 
fatigue, exposure to noxious fumes as well as changes in endocrine, temperature, and 
humidity may aggravate non-atopic asthma attacks (Moreira et al. 2008; Varraso et 
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al. 2007; Wichmann et al. 2008). In many asthmatics, both forms of intrinsic and 
extrinsic asthma coexist.  
 
The expression of messenger ribonucleic acid encoding IL-13 (IL-13) mRNA in the 
bronchial mucosa of both atopic and non-atopic subjects is shown to be significantly 
higher compared with non-asthmatics (p≤0.02) (Chanez et al. 2007). IL-13 cytokines 
are involved in airway hyperresponsiveness, which as discussed earlier, is a critical 
event in patients with asthma (Knutsen et al. 2008; Larocca et al. 2008). Thus, it is 
not surprising to observe more BHR positive reactions in both atopic and non-atopic 
asthmatics as opposed to non-asthmatic individuals due to a higher level of IL-13 in 
them. 
 
There is increasing evidence that inflammatory mechanisms other than eosinophilic 
inflammation may be involved in producing the enhanced bronchial reactivity and 
reversible airflow obstruction that characterises asthma (Haldar and Pavord 2007). At 
most, only 50% of asthma cases are attributable to eosinophilic airway inflammation. 
It is hypothesised that a major proportion of asthma is based on non-eosinophilic 
(neutrophilic) airway inflammation, possibly triggered by environmental exposure to 
bacterial endotoxin, air pollution and viral infections (Haldar and Pavord 2007). 
Distinguishing between the two subtypes of asthma (eosinophilic and non-
eosinophilic), could have major consequences for the treatment and prevention of 
asthma. Non-eosinophilic asthma represents a stable phenotype associated with a 
distinct lower airway pathology and structure. Eosinophilic asthma is considered a 
consequence of allergen-mediated activation of mast cells and T cells in the airway 
with release of TH2 cytokines. In contrast, non-eosinophilic asthma is the product of 
innate and cell mediated immune responses.  
 
A Western diet (low antioxidant and high saturated fat intake) may activate innate 
immune responses in asthma by initiating an NFκB-mediated inflammatory cascade 
(Wood and Gibson 2009). A high fat diet results in production of pro-inflammatory 
mediators such as IL-6, IL-8, TNFα and may lead to activation of neutrophils. Low 
antioxidant intake reduces the host’s ability to scavenge reactive oxygen species 
produced in response to triggers such as viruses and endotoxin. This will exaggerate 
the inflammatory response by further activation of NFκB (Wood and Gibson 2009). 
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1.6  ASTHMA RISK FACTORS 
 
Asthma, like many other allergic reactions can be associated by a variety of different 
risk factors. Many of these factors, as we shall see are closely related. For instance 
low socioeconomic status is closely related with low income and the latter is usually 
closely related with lower level of education. This will be discussed in more detail in 
future sections (1.6.1-1.6.3). 
 
1.6.1 Socioeconomic status 
 
Socioeconomic status covers a wide range of living aspects of every human being. It 
determines the location where a person can afford to live; this in turn could 
determine the level of exposure to environmental pollutions. For instance, although 
asthma is only slightly more prevalent in the United States among minority children 
than among whites, it accounts for three times the number of deaths (Moreira et al. 
2008).  
 
Poverty, substandard housing that increases exposure to certain indoor allergens, lack 
of education, inadequate access to health care, and the failure to take appropriate 
prescribed medications may all increase the risk of having a severe asthma attack or, 
more tragically, of dying from asthma (Moreira et al. 2008; Pearce et al. 2007; 
Wichmann et al. 2008). Poverty contributes to disease in numerous ways. It reduces 
people's access to health care, reduces treatment availability, lowers overall 
educational levels, and subjects people to reduced standards of housing and related 
utilities (Moreira et al. 2008; Pearce et al. 2007; Wichmann et al. 2008). Poverty is a 
substantial health risk even in developed countries, but is particularly serious in 
undeveloped countries (Pearce et al. 2007). 
 
In a recent study, a significant positive association between income and asthma 
stressed the importance of improvement in economic situations as a means for 
preventing asthma occurrence and improving quality of life (Moreira et al. 2008).  
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1.6.2 Family history  
 
Family history of asthma in one or more first-degree relatives has been consistently 
identified as a risk factor for asthma in several studies (Burke et al. 2003; Pole et al. 
2008; Scirica et al. 2007; Socha et al. 2007; Varraso et al. 2007). In one study it was 
shown that having a parent with a history of asthma doubles the risk of asthma for 
their children (OR 2.05, 95% CI 1.34 to 3.16) (Haby et al. 2001). 
 
In another study, investigators (Burke et al. 2003) identified 33 studies from all 
geographic regions of the world for review. The asthma prevalence ranged from 2% 
to 26% (Burke et al. 2003).  Positive predictive value of family history was 
calculated as 11% to 37%, and negative predictive value from 86% to 97% (Burke et 
al. 2003). Therefore, for a person with no family history of asthma it could be more 
reliably predicted that this person would not become asthmatic compared with a 
person who had a positive family history of asthma.  
 
Hundreds of gene linkage analyses studies have identified several chromosomal 
regions which harbour asthma susceptibility genes like chromosomes 2q, 5q, 6q, 11q, 
12q and 13q (Bierbaum & Heinzmann 2007). However, studies performed in 
farmers’ children have shown that exposure to bacterial endotoxin early in life 
reduces the risk to develop asthma or atopy later on life (Koppelman et al. 2002). 
Therefore, this demonstrates the complexity of asthma incidence and highlights the 
fact that genetic predisposition is not the only factor that plays a crucial role in the 
incidence of asthma as environment factors may also play a significant role.  
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1.6.3 Virus infection 
 
Children with recurrent virus-induced wheezing episodes are at great risk for chronic 
childhood asthma (Gern et al. 2005). Infancy is a time of increased susceptibility to 
viral infections, and a time for extensive re-modelling of the airways to 
accommodate growth. The observation that children with asthma can have structural 
lung changes and functional deficits at an early age, suggests that viral infections 
could adversely affect lung development. Infections with respiratory viruses can 
acutely impair lung function by directly damaging lower airway tissues and by 
provoking an acute immune response with both antiviral and pro-inflammatory 
properties (Gern et al. 2005). Virus induced epithelial damage can also increase the 
permeability of the mucosal layer and facilitates allergen contact with immune cells 
to promote inflammation. Viruses initiate inflammatory and antiviral responses by 
binding to specific receptors on the surface of cells, activating intracellular signalling 
pathways, and generating oxidative stress. These events lead to the activation of 
innate antiviral pathways, and the release of a variety of cytokines. As a result, 
neutrophils and mononuclear cells are recruited to the area of infection and are in 
turn activated to secrete pro-inflammatory cytokines, such as IL-1, IL-8, IL-10 and 
TNF-α. Changes in IL-8 levels in nasal secretions have been related to virus-induced 
increases in airway hyperresponsiveness suggesting that neutrophil activation 
products contribute to airway obstruction and symptoms during viral infections and 
asthma. Animal experiments confirm the concept that viral infections may have to 
occur in a genetically susceptible host at a critical period in the development of the 
immune system for asthma inception to occur in early childhood (Wood and Gibson 
2009). 
 
1.6.4 Diet 
 
Diet is another factor proposed to play a role in the incidence of allergic 
manifestations including asthma and is the main focus of this research. In a recent 
study conducted on Japanese female university students (n=153, 32.7% asthmatics, 
25% with wheezing episodes), meat consumption was related to wheeze (OR=2.00; 
95% CI 1.12–3.60) and respiratory infections (OR=2.10; 95% CI 1.08–4.09) 
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(Takaoka & Norback 2008). Fish consumption was related to less respiratory 
infections (OR=0.49; 95% CI 0.28–0.86), and milk consumption to less daytime 
breathlessness (OR=0.72; 95% CI 0.55–0.95). Fast food consumption was also 
related to wheeze (OR=1.89; 95% CI 1.23–2.91 and daytime breathlessness 
(OR=1.50; 95% CI 1.00–2.28) (Takaoka & Norback 2008). Those university 
students consuming butter (OR=2.65; 95% CI 1.11–6.32) and rapeseed oil 
(OR=2.35; 95% CI 1.03–5.38) had more wheeze. Those consuming margarine had 
more breathlessness (OR=4.40; 95% CI 1.42–13.70) (Takaoka & Norback 2008). An 
asthma symptom score was related to fast food (p<0.05) and margarine consumption 
(p<0.01). It was concluded that fish, seafood and milk consumption were beneficial, 
while butter, margarine, rapeseed oil, fast food and soft drinks could be risk factors 
for allergy and poor respiratory health.  
 
Diet during infancy is also a significant factor in the development of asthma. The 
introduction of milk other than breast milk to infants before four months of age is 
shown to be a significant risk factor for all asthma and atopy related outcomes in 
children later on at six years of age (Bush 2009; Hanson, Korotkova & Telemo 2003; 
Oddy et al. 1999; Peroni, Chatzimichail & Boner 2002) 
 
It has also been recently shown that the Mediterranean diet which is rich in fruits and 
vegetables, nuts, grains, olive oil (as opposed to butter) and grilled or steamed 
chicken and seafood (as opposed to red meat), is an independent protective factor for 
current wheezing in preschoolers, irrespective of obesity and physical activity 
(Castro-Rodriguez et al. 2008). 
 
1.7  NUTRITION AND ASTHMA 
 
As discussed above, nutrition and diet can play an important role in the development 
of asthma. In this chapter the nutrients potentially implicated in the development of 
asthma and their proposed mechanism of action are discussed in detail.  
 
The incidence of asthma in children and young adults has increased over the last two 
decades in many countries including Australia. However, this trend is not the same 
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among all countries (Patel et al. 2006). In fact there is, greater than 15-fold difference 
in incidence between countries worldwide. The prevalence of asthma is also different 
between countries. It is low in Eastern Europe and Asia for instance but much higher 
in the United Kingdom, Australia, New Zealand, Ireland, and America (Tabak et al. 
2005). Diet is one of several causal factors implicated in the substantial increase in 
incidence of childhood asthma over the last two decades and the evidence based on 
the relation between diet and asthma has increased dramatically (McKeever & 
Britton 2004). Therefore, the rise in asthma incidence in Western societies may be 
related to changes in dietary habits. Emerging literature is now relating diet with 
asthma prevalence, an area of research which requires more in depth investigation 
(Bolte et al. 2006; Devereux & Seaton 2005; Kuiper et al. 2006; Patel et al. 2006; 
Tabak et al. 2005). 
 
Several epidemiological studies have investigated diet as a potential risk factor for 
asthma, although the results from these studies have been inconclusive (Wiesch, 
Meyers & Bleecker 1999). Dietary fatty acid intake for example is proposed to 
contribute to asthma development with n-6 polyunsaturated fatty acids (PUFA) 
having detrimental effects and n-3 PUFA, protective effects (Bolte et al. 2006; 
Hodge et al. 1996). Frequent consumption of products containing milk fat in pre-
school children has also been associated with a reduced risk of asthma symptoms 
(Wijga et al. 2003). In one study on teenagers, asthma has been positively associated 
with protein-rich and fat-rich foods of animal origin (Huang, Lin & Pan 2001).  
 
Increased amount of saturated fatty acids intake has been associated with asthma risk 
in schoolchildren (eight to 13 years of age) in one study (Rodriguez et al. 2010). 
There are changes in the hormones derived from fat tissue that may affect the 
airways (Kattan et al. 2010). One of these hormones, leptin, is pro-inflammatory and 
obese individuals have higher leptin levels than lean individuals (Johnson et al. 
2007). Leptin is produced by adipocytes and is thought to act primarily through 
specific receptors at the hypothalamus (Guler et al. 2004). Leptin receptors also exist 
in lung tissue, and leptin may have stimulatory effects on the proliferation of cells of 
a human cell line through its specific leptin receptor (Litonjua and Gold 2008). It 
may provide a link between inflammation and T-cell function in asthma. In animal 
models leptin up-regulates production of TNF-α, IL-6, and IL-12 (Guler et al. 2004). 
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It is found at higher levels among asthmatics regardless of the extent of obesity 
(Kattan et al. 2010). Leptin level has been suggested as being a predictive factor for 
having asthma in children (OR= 1.98; 95% CI, 1.10-3.55; P = 0.021) (Guler et al. 
2004). 
 
In contrast, blood levels of another hormone; adiponectin (an insulin sensitizing 
hormone) has anti-inflammatory properties and correlates inversely with obesity 
(Shore 2008). Adiponectin acts on macrophages and monocytes to inhibit production 
of pro-inflammatory cytokines and to augment IL-10 and IL-1 receptor antagonist 
expression (Shore 2008). 
 
Therefore there are many studies which suggest that dietary factors have an 
important role in the worldwide increases in asthma. There are however, other 
studies, which do not suggest a role for diet in the incidence and manifestation of 
asthma. In a recent study, there were no significant differences between the serum 
antioxidant levels in the asthmatic group compared with the control group (Emecen 
et al. 2009). Another study found that dietary intake of n-3 and n-6 fatty acids are not 
associated with any respiratory or allergic outcomes (Almqvist et al. 2007). 
 
1.7.1 Dietary antioxidants and the prevalence of asthma 
 
Antioxidants are defined by their mechanism of action, i.e. the prevention of the 
formation of free radicals or the conversion of oxidants to less toxic species 
(Kalantar-Zadeh, Lee & Block 2004). Well known vitamin antioxidants are vitamins 
A, C and E. β-carotene is a pro-vitamin A molecule that can be cleaved by β-carotene 
di-oxygenase enzyme into two molecules of vitamin A, hence offering antioxidant 
activity (Bjelakovic et al. 2007). Other minerals including selenium, manganese and 
zinc are cofactors for antioxidant enzymes (Hennig et al. 1999; Kalantar-Zadeh, Lee 
& Block 2004). Fruits, vegetables and also whole grain products are rich in 
antioxidant vitamins and minerals (Tabak et al. 2005). 
 
Antioxidants provide a defensive system in which the survival and development of 
cells in an oxidant-containing environment is possible. Currently, information on the 
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relationship between asthma and antioxidants in children is scarce although some 
studies in adults have found modest protective effects (Troisi et al. 1995). 
 
1.7.1.1 The role of antioxidants in modification of immune 
responses 
 
Antioxidants are important in protecting against oxidative stress (Sackesen et al. 
2008). Nuclear transcription factor kappa B (NFκB) acts as the main controller of 
inflammation which is activated by reactive oxygen species (Sackesen et al. 2008). 
Antioxidants in the diet can help to scavenge reactive oxygen species by inhibiting 
NFκB-mediated innate immune response. In vitro studies have shown that vitamin C 
through suppression of NF-κB activity has a direct effect on innate immune 
activation. High circulating levels of serum vitamin C are associated with enhanced 
neutrophil function. Vitamin C can reduce the levels of TNFα, IL-6 and IL-8 in acute 
pancreatitis. Vitamin E has been shown to inhibit: reactive oxygen species 
production by leukocytes and cyclo-oxygenase activity.  β-carotene has strong 
antioxidant action through quenching of reactive oxygen species (Kirkham & 
Rahman 2006; Sackesen et al. 2008). β-carotene can also inhibit NF-κB activity in 
lipopolysaccharides exposed cells (cells infected with gram negative bacteria) 
(Sackesen et al. 2008). 
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1.7.1.2 Mechanism of action of antioxidants on asthma  
 
Because asthma is characterized by the chronic inflammation of the airways, it has 
been postulated that epithelial injury due to oxidant–antioxidant imbalance may 
represent a major pathogenic mechanism in asthma (Tan-Un, Chang & Chan-Yeung 
2004). 
 
Reactive oxygen species are continuously produced in the human body (Kalantar-
Zadeh, Lee & Block 2004). The survival and development of cells in an oxidant-
containing environment require an antioxidant defence system. Inflammatory cells 
generate considerable amounts of oxidants on the epithelial surfaces, leading to 
epithelial cellular injury. Sources of reactive oxygen species include primarily the 
membrane associated NADPH oxidase dependent complex, the cytosolic xanthine 
oxidase system, and the mitochondrial respiration chain (Yeum et al. 2009). 
Superoxide anion is then converted to hydrogen peroxide (H2O2), either 
spontaneously or under the influence of superoxide dismutases (SOD) (Emecen et al. 
2009; Nauta et al. 2008). Both O2 and H2O2 are moderate oxidants and are critical 
for the formation of potent cytotoxic radicals in biological systems through their 
interaction with other molecules. For instance, the lysosomal enzymes 
myeloperoxidase (MPO) from neutrophils and monocytes/macrophages and the 
eosinophil peroxidase (EPO) catalyse the oxidation of halides (Cl2, Br2, and I2) by 
H2O2 to form hypohalous acids (HOCl or HOBr) (Southam et al. 2007). MPO 
produces predominantly hypochlorous acid (HOCl) whereas EPO produces more 
hypobromous acid (HOBr). Hypohalous acid production is important in the host 
defense against infectious agents, but during this reaction the hydroxyl radical (OH2) 
is also produced, which is a powerful and indiscriminate oxidant. Eosinophils 
possess several times greater capacity for generating oxidants than neutrophils, and 
the eosinophil peroxidase content of eosinophils is several times higher than that of 
MPO in neutrophils (Emecen et al. 2009; Nauta et al. 2008).  Myeloperoxidase and 
eosinophil peroxidase derived reactive oxygen species can also interact with nitrite 
(NO2) and H2O2 leading to the formation of reactive nitrogen species (RNS; 
nitrosants) (Southam et al. 2007). A powerful oxidant, the radical peroxynitrite 
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(ONOO2), is produced from the reaction between O2 and nitric oxide (NO) which is 
increased in the asthmatic airways (Yeum et al. 2009). 
 
The inflammatory cells recruited to the asthmatic airways have special capacity for 
producing oxidants. Once recruited in the airspaces, inflammatory cells may become 
activated and generate reactive oxidants in response to various stimuli (Emecen et al. 
2009; Nauta et al. 2008). Activated eosinophils, neutrophils, monocytes, and 
macrophages, and also resident cells such as bronchial epithelial cells, can generate 
oxidants. Antioxidant–oxidant imbalances in bronchoalveolar fluid may contribute to 
oxidative stress in respiratory disease, since an excessive free radical generation in 
the blood of children suffering from asthma has been shown (Shanmugasundaram, 
Kumar & Rajajee 2001b) (Figure 4).  
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Figure 4- Antioxidant–oxidant imbalances in bronchoalveolar fluid may contribute to oxidative 
stress in respiratory system   
(Compiled by the candidate) 
 
It is suggested that vitamin E and β-carotene in the diet may reverse the imbalance of 
oxidants/antioxidants and thereby reduce airway inflammation and the severity of 
asthma in some patients (Butland, Strachan & Anderson 1999). As a part of my 
project, I investigated the association between asthmatic symptoms and consumption 
of vitamins A, C, and E, ß-carotene and zinc in adolescents at 14 years of age.  
Eosinophils 
Macrophages Neutrophils 
Release of cell derived oxidants 
Inflammation Mucus hypersecretion Apoptosis 
Antioxidants prevent 
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1.7.1.3 Epidemiological studies on association of asthma and 
antioxidants 
 
In a study conducted on young adult smokers Omenaas and colleagues (2003) found 
that dietary vitamin C intake was inversely related to symptoms of cough and 
wheeze, indicating that there may be a protective antioxidant effect. The same 
outcome was observed in another study in which it was demonstrated that high 
dietary intake of vitamin C and the subsequent rise in serum concentrations of this 
vitamin had a protective effect against respiratory symptoms in asthmatic children 
(Forastiere et al. 2000). However, in a large cohort study of adult women, no such 
protective effect of vitamin C was observed on the symptoms of asthma (Dow et al. 
1996). Differences in smoking prevalence, gender and/or age of the subjects may 
explain the observed differences between these studies. 
 
1.7.1.4 Vitamins A, C, and E 
 
Regardless of the nature of the study whether being population based or in-vitro, 
there is either limited evidence or mixed results on the relationship between asthma 
and different antioxidants (McKeever & Britton 2004). For instance in one study it 
was found that asthmatic adult patients have a lower intake of vitamins A, C, and E 
compared with non-asthmatic subjects, although  after adjusting for smoking, age, 
and sex with the dependent variable of forced expiratory volume in 1 second (FEV1) 
only vitamin C remained in the model (de Luis et al. 2005). 
 
The free alcohol form of vitamin A (retinol) can be reversibly converted by 
enzymatic activity to the active form of vitamin A, retinal, in a variety of tissues. 
Retinal can be further converted to the potent transcription factor, retinoic acid, but 
this reaction is not reversible. Except in the retina, retinal concentrations are 
normally very low in all tissues due to enzyme kinetics that favour either its re-
conversion to retinol, or transformation to retinoic acid. In addition to its enzymatic 
conversion from retinal, retinoic acid may be extracted by most cells from the plasma 
where it is transported bound to albumin. Once in the cell, retinoic acid is bound to 
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cellular retinoic acid binding protein (De Oliveira et al. 2009; Emecen et al. 2009). 
The latter may facilitate the delivery of retinoic acid to responsive transcription 
factor binding sites, where it binds with vitamin D3 and thyroid hormones. Vitamin 
A can act as a chain breaking antioxidant by combining with peroxyl radicals, before 
these radicals can propagate peroxidation in the lipid phase of the cell and generate 
hydroperoxides. Retinol was shown to be an effective peroxyl radical scavenger by 
its inhibition of peroxidation in a homogeneous solution of methyl linoleate and in 
model phosphatidylcholine liposomes (De Oliveira et al. 2009). 
 
Vitamin C is an effective antioxidant of the hydrophilic phase. It can also protect 
from lipid peroxidation in the hydrophobic compartments by scavenging lipid 
peroxides or reducing tocopherol radicals to tocopherols. At low concentrations and 
in the presence of transition metal ions such as iron (Fe), vitamin C facilitates NADH 
dependent lipid peroxidation through reduction of Fe (III) to Fe (II) (Yeum et al. 
2009).  
 
Vitamin E is a lipophilic chain-breaking antioxidant that acts by stopping the chain 
reaction involved in lipid peroxidation (Greene 1999). Vitamin E is the major 
antioxidant soluble in lipids protecting cellular membranes and lipoproteins against 
peroxidation. The reaction of α-tocopherol with free radicals generates tocopherol 
radicals, which can be reduced by vitamin C or reduced glutathione (GSH).  
 
Information on the relationship between asthma and antioxidants other than vitamins 
C and E and some cations (zinc and manganese) in children is scarce. In an 
investigation in adult asthmatics, asthma was associated with a low dietary intake of 
fruit, antioxidants, vitamin C and manganese (Patel et al. 2006). People who 
consumed more than 46.3 g/day of citrus fruits had a reduced risk of diagnosed 
asthma OR 0.59 (95% CI 0.43 to 0.82) and symptomatic 0.51 (95% CI 0.33 to 0.79) 
asthma compared to those who had zero intake (Patel et al. 2006). Dietary vitamin C 
and manganese were inversely and independently associated with symptomatic 
asthma (adjusted OR per quintile increase 0.88 (95% CI 0.77 to 1.00) for vitamin C 
and 0.85 (95% CI 0.74 to 0.98) for manganese). Adjusted plasma levels of vitamin C 
were significantly lower in symptomatic cases than in controls (54.3 v 58.2 µmol/l, p 
= 0.003) (Patel et al. 2006). Some papers in adults have found modest beneficial 
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effects of vitamins C and E, some cations (zinc and manganese) and other 
antioxidants (Castro-Rodriguez et al. 2008; Willers et al. 2007). 
 
1.7.1.5 Selenium 
 
Selenium is also involved in antioxidant defenses as a coenzyme in glutathione 
peroxidase (GSH), the enzyme believed to be an important component of the 
pulmonary antioxidant system (Chatzi et al. 2007; Stone, Hinks & Beasley 1989). 
Most of the selenium in mammalian tissues is associated with the amino acids 
selenocysteine and selenomethionine in proteins (Bjelakovic et al. 2007). Glutathione 
peroxidase does not only protect cells against damages by free radicals, but also 
protects membrane lipids against such oxidation generated by peroxides and permits 
regeneration of membrane lipid molecules through re-acylation (Chatzi et al. 2007). 
 
Further evidence of the role of nutrients on asthma was provided by Stone and 
colleagues who found that patients with symptomatic asthma had a reduced plasma 
selenium concentration (Stone, Hinks & Beasley 1989). The asthmatic patients had 
significantly lower concentrations of selenium measured in plasma (p<0.001) and 
whole blood (p<0.001), and the OR were highly significant  with a 3.54 fold 
increased probability of asthma for the lower range of plasma and 5.08 fold for 
whole blood selenium concentrations (Stone, Hinks & Beasley 1989). However, in a 
case-control study conducted by Shaheen et al., the protective role of antioxidants on 
asthmatic symptoms in adults was shown to be weak, as the intake of selenium was 
also negatively associated with asthma (OR per quintile increase 0.84 [0.75 to 0.94]; 
p=0.002) (Shaheen et al. 2001). This could be due to several factors including 
reluctance of participants to complete a long food frequency questionnaire and the 
consequent low response rate as stated by these investigators. 
 
Baker and Ayres suggest that sub-optimal nutrient intake of antioxidant vitamins A, 
C and E, and selenium in adults may enhance asthmatic inflammation, consequently 
contributing to bronchial hyperreactivity (Baker & Ayres 2000). 
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1.7.1.6 Zinc 
 
Zinc is an essential dietary factor with antioxidant properties present in all organs, 
tissues, and body fluids, and mediates a wide variety of physiological processes 
(Zalewski et al. 2005). With an average presence of 3 grams in the human body it is 
the second most abundant trace element after iron which has an estimated around 4 
grams (Amerio et al. 2003). According to the American Dietetic Association, the 
recommended daily allowances of zinc are 5 mg/day for infants, 10 mg/day for 
children, 15 mg/day for teenagers, adults, and pregnant women, and 16–19 mg/day 
for lactating women (Arsenault & Brown 2003). Zinc is normally obtained from red 
meat and other animal proteins. Other sources of zinc are sea food, dairy food, 
cereals and nuts (Arsenault & Brown 2003). Most vegetables are not ready sources 
of zinc due to the presence of phytate, the principal storage form of phosphorus in 
many plant tissues, as phytate inhibits zinc absorption (Arsenault & Brown 2003). 
 
Diets low in animal protein and rich in phytate contribute to the high incidence of 
zinc deficiency in many developing countries. Another cause of human primary zinc 
deficiency can be low zinc content of soils (Lambein et al. 1994). The bulk of body 
zinc is tightly bound within cellular enzymes and zinc finger proteins, the protein 
domains that can bind to deoxyribonucleic acid (DNA) (Zalewski et al. 2005). This 
fixed pool of zinc turns over very slowly and is mainly responsible for housekeeping 
functions in cellular metabolism and gene expression. The remaining 10–15% of zinc 
(labile zinc) comprises more dynamic pools that are readily depleted in zinc 
deficiency (Arsenault & Brown 2003). 
 
Henning et al (1999) describe the role of zinc as an antioxidant. They propose that 
zinc inhibits oxidative stress-responsive events in endothelial cells after treatment of 
these cells by either fatty acids or Tumour Necrosis Factor (TNF)-α (Hennig et al. 
1999). The antioxidant property of zinc has also been described by Powell (2000) 
who demonstrated that zinc is capable of reducing post ischemic injury in a variety 
of tissues through a mechanism that might involve the antagonism of copper 
reactivity. As mentioned earlier (section 1.7.1.1) antioxidant–oxidant imbalances in 
bronchoalveolar fluid may contribute to oxidative stress in respiratory disease 
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(Shanmugasundaram, Kumar & Rajajee 2001b). Zinc therefore, as an antioxidant, 
may have a protective effect in contributing to the establishment of antioxidant–
oxidant balance in bronchoalveolar fluid. 
 
The epithelial airway is vulnerable to a range of oxidants derived internally. Reactive 
oxygen species are continuously produced in our bodies as a result of biochemical 
reactions, or externally from atmospheric oxidants and from inflammatory cells 
during acute or chronic inflammation of the airways (Shanmugasundaram, Kumar & 
Rajajee 2001a). 
 
To combat these oxidants, epithelial airway and its secretions contain a variety of 
anti-oxidants including catalase, vitamins C and E, glutathione, and two forms of 
superoxide dismutase (Arsenault & Brown 2003). Zinc is a component of a major 
anti-oxidant enzyme in epithelial airway (Ho et al. 2004; Zalewski et al. 2005). Zinc 
is reported to be essential for many components of the immune system including 
phagocytic function, cellular immunity, humoral immunity, and NK cell function 
(Ho et al. 2004). Some of the anti-oxidant effects of Zn are due to stabilization of 
sulphydryls and membrane lipids and suppression of nitric oxide production 
(Zalewski et al. 2005). Zinc is also a component of a major anti-oxidant enzyme in 
airway epithelium, Cu/Zn superoxide dismutases (SOD). Although the role of Zn in 
Cu/Zn SOD is unclear, its removal is known to promote catalysis of peroxynitrite-
mediated tyrosine nitration, resulting in protein oxidation and consequent cellular 
damage (Zalewski et al. 2005). 
 
Zinc is essential for many components of the immune system including phagocytic 
function, cellular immunity, humoral immunity, and natural killer cell function (Ho 
et al. 2004). Mast cells have a well-developed mechanism for uptake of zinc as well 
as mechanisms to concentrate zinc into their granules (Ho et al. 2004; Zalewski et al. 
2005). The role of granular zinc in mast cells is unclear but it may act in a feedback 
loop to down-regulate secretion of histamine and other mediators. Zinc exerts a 
potent anti-apoptotic effect for immature T cells in the mouse thymus; zinc regulates 
the balances between CD4+ and CD8+ T cells and between Th1 and Th2 subsets. Zinc 
is required for secretion of various T-dependent interleukins and cytokines including 
IL-1, IL-2, IL-4, and IFN-γ (Zalewski et al. 2005). 
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Due to the important role of zinc as an antioxidant, we investigated a possible 
association between dietary zinc intake and asthma in adolescents. 
 
1.7.1.7 ß-carotene 
 
β-Carotene belongs to a family of molecules called  Carotenoids. These molecules 
have strong antioxidant actions therefore can be useful for restricting the damaging 
excess of free radicals in the body (Bjelakovic et al. 2007). The most common 
carotenoids in biological systems are lycopene, α- and β-carotene, lutein and β-
cryptoxanthin (Wood and Gibson 2009). ß-carotene is composed of two retinyl 
groups, and is broken down to retinal, a form of vitamin A in the mucosa of the small 
intestine by ß-carotene dioxygenase.  
 
ß-carotene can be stored in the liver and converted to vitamin A as needed, thus 
making it a provitamin (Bjelakovic et al. 2007). ß-carotene is lipid soluble and is 
concentrated in cell membranes; it protects against lipid peroxidation of membranes 
and has demonstrated antioxidant effects (Greene 1999). Studies show β-carotene 
scavenge free radicals to prevent lipid peroxidation in chest disease (Genovese et al. 
2005; Klings & Farber 2001), however, there is no evidence of the possible role of ß-
carotene in asthma in children. 
 
1.7.1.8 Flavonoids 
 
Flavonoids are a class of secondary plant phenolics with significant antioxidant 
properties. They are most concentrated in fruits, vegetables, wines, teas and cocoa 
(Heim, Tagliaferro et al. 2002). A high flavonoid intake has been associated with 
lower mortality from coronary heart disease and lower incidence of myocardial 
infarction in older men and reduced risk of coronary heart disease by 38% in 
postmenopausal women (Heim, Tagliaferro et al. 2002). The protective effects of 
flavonoids in biological systems are attributed to their capacity to transfer electron 
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free radicals, chelate metal catalysts, activate antioxidant enzymes, reduce alpha-
tocopherol radicals, and inhibit oxidase (Heim, Tagliaferro et al. 2002). 
 
1.7.2 Fatty acids 
 
Fatty acids are the building blocks of triglycerides and phospholipids (predominantly 
in cell membrane). Fatty acids occur in free form or are esterified to other lipids. 
 
Over 70 different fatty acids have been isolated from cells, and they all possess a 
long hydrocarbon chain with a terminal carbonyl group located at one end (Schubert 
et al. 2007). The long chain may be either saturated or unsaturated, depending on the 
presence or absence of double bonds.  
 
The adipocytes are a class of specialized cell types for the storage and release of fatty 
acids. Adipocytes are unique in that they can accommodate without deleterious 
effects the massive storage of triacylglycerol during energy profusion and releases 
free fatty acids into the plasma for the use by other tissues during times of energy 
need (Ogwok, Muyonga & Sserunjogi 2008). This process of fatty acid uptake and 
storage balanced by lipolysis is a highly regulated process that takes cues from 
nutritional and efferent signals to store and supply energy as the body dictates. The 
adipocyte has a unique cellular organization as well, with greater than 90% of the 
cell volume being triacylglycerol. These results in limited cytosolic space and an 
adjacent endoplasmic reticulum, nuclear, plasma membrane interface (Howe et al. 
2006; Radmark et al. 2007).  
 
This geometry may accommodate the transport of hydrophobic molecules, such as 
fatty acids and fatty acetyl coenzyme-A (a key intermediate molecule in aerobic 
metabolism of lipids and carbohydrates) to and from the membrane during uptake 
and lipolysis. The insolubility of fatty acids may also be accommodated by 
intracellular carriers such as the fatty acid binding proteins and acetyl coenzyme-A 
binding proteins (Bolte et al. 2006).  
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Differences between the 70 fatty acids are primarily in the length of the hydrocarbon 
chain, and the number and position of double bonds. Nearly all the fatty acids in 
biological systems have an even number of carbon atoms, typically 14 to 24 carbons 
with 16 and 18 carbon atoms being the most common found in the body (Murakami 
et al. 2007).  
 
The primary sources of fatty acids are dietary (mainly fish, flaxseeds, walnut, and 
canola) and mobilization from cellular stores. Fatty acids from the diet can be 
delivered from the gut into the cells via transport in the blood stream. Fatty acids are 
stored in the form of triacylglycerols primarily within adipocytes of adipose tissue. In 
response to energy demands, the fatty acids of stored triacylglycerols can be 
mobilized for use by peripheral tissues. Nutritionally, a majority of saturated fatty 
acids tend to lead to higher levels of blood cholesterol, because saturated fatty acids 
have a regulating effect on cholesterol synthesis and unsaturated fatty acids do not 
(Socha et al. 2007).  
 
The increase in childhood allergy and asthma rates may be partially attributable to 
temporal trends in dietary intake, particularly during pregnancy and early childhood 
(Gold et al. 2006). These trends include decreases in intake of foods containing n-3 
polyunsaturated fatty acids (PUFAs), such as alpha-linolenic acid (ALA), 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), found in fish, nuts, 
or seeds and increases in intake of foods containing n-6 fatty acids, such as linoleic 
acid (LA) and arachidonic acid (AA), found in vegetable oils and animal products 
(Gold et al. 2006). Therefore, there is increasing evidence that a diet, with high levels 
of n-3 fatty acids has a protective effect against cough and wheeze both in children 
and adults (Castro-Rodriguez et al. 2008; Peat et al. 2004). Consumption of oily fish 
(which has a high content of very long chain n-3 fatty acids such as EPA and DHA) 
in the diet is also shown to be associated with a reduced prevalence of asthma 
(Hodge et al. 1996; Hodge et al. 1998). N-3 may reduce asthma prevalence by 
influencing the development of allergic sensitization through reducing the formation 
of immunoglobulin E (IgE) in lymphocytes (Baker & Ayres 2000; LeGros et al. 
1990; Mosmann & Coffman 1989).  
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An epidemiological study in children has shown inverse associations of asthma with 
intake of whole grain products and fish (Tabak et al. 2005). For current asthma the 
adjusted odds ratios for the independent associations with whole grains was shown as 
0.46 (95% CI 0.19 to 1.10), and for fish 0.34 (95% CI 0.13 to 0.85) (Tabak et al. 
2005). Also for atopic asthma with BHR the adjusted odds ratios for whole grains 
was shown as 0.28 (95% CI 0.08 to 0.99) and for fish 0.12 (95% CI 0.02 to 0.66) 
(Tabak et al. 2005). Therefore, whole grain products and fish played a protective role 
against current asthma and atopic asthma in this study.  
 
Early-life exposure to n-3 fatty acids has been hypothesized to decrease asthma or 
allergy risk through immune modulation, decreasing T-Helper type2 cytokine (eg, 
IL-13 and IL-4) secretion, subsequent IgE production, and the risk of chronic allergic 
inflammation, including airway inflammation (Gold et al. 2006). In one study, all 
neonates whose mother had been taking fish oil supplementation (n = 40) during 
their pregnancy, had significantly higher proportion of total n-3 PUFAs in their 
erythrocyte membranes (mean=17.75 ± 1.85 SD), compared with the control group 
(n=43) (mean =13.69 ± 1.22 SD) (p < 0.001). Conversely, total neonatal n-6 PUFA 
composition was significantly lower: mean =25.21% ± 1.82 SD in the fish oil 
compared with the control group: mean=29.50 ± 1.35 SD (p < .001). Also the group 
with higher n-3 PUFA had lower cytokine responses (IL-5, IL-13, IL-10, and IFN-γ) 
to different allergens compared with the control group (Dunstan et al. 2003).  
 
In another study, children who received n-3 fatty acids supplementation from six 
months of age had fewer wheezes in the first 18 months of life than control subjects 
(Mihrshahi et al. 2003). If the child was breast-feeding before the age of 6 months, 
no supplement was given, because the concentration of n-3 in breast milk was 
believed to be equivalent to that of the supplement. However, if bottle-feeding was 
introduced before the age of 6 months, the parents were asked to add the n-3 
supplement to the child’s formula (Mihrshahi et al. 2003)This could be due to the 
effects of dietary and free fatty acids in milk on the immune system (Mihrshahi et al. 
2003). However, later on when these children were five years of age, it was shown 
that fatty acid exposure was not associated with any respiratory or allergic outcomes 
(Almqvist et al. 2007). 
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Several studies have shown that n-3 polyunsaturated fatty acids might possess anti-
inflammatory effects in patients with inflammatory bowel disease and in animal 
models of colitis (Babcock et al. 2002; Hegazi et al. 2006; Stark, Lim & Salem 
2007). These anti-inflammatory properties may be mediated by a decrease in 
inflammatory eicosanoids and decreased secretion of inflammatory cytokines 
(Caughey et al. 1996). On the contrary, other studies have shown that fish oil induces 
the pro-inflammatory cytokine tumour necrosis factor (TNF) and inhibits the 
secretion of the anti-inflammatory cytokine, interleukin-10 (IL-10) (Babcock et al. 
2002). The Cochrane review of  n-3 and  n-6 fatty acids supplementation on atopic 
dermatitis and asthma is inconclusive, with only one trial reporting a statistically 
significant effect of n-6 supplementation on lowering serum immunoglobulin E (IgE) 
levels (p<0.01) in atopic participants (Anandan et al. 2009). N-3 supplementation 
effects in immunological responses are reported as either short term or inconsistent 
(Anandan et al. 2009). 
 
Therefore, the role of fatty acids in the modulation of chronic diseases is 
controversial. In this research the role of fatty acids (both from dietary and red blood 
cells) on the modulation of asthma will be examined. 
 
1.7.2.1 N-3 and n-6 fatty acids structure 
 
The n-3 fatty acids (n-3) are long-chain polyunsaturated fatty acids ranging from 18 
to 22 carbon atoms in chain length with the first of many double bonds beginning at 
the third carbon from the methyl end of the fatty acid structure (Holub 2002) (Figure 
5).  
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 (A) Eicosapentaenoic (n-3) 
 (B) Arachidonic acid (n-6) 
 
Figure 5- Demonstration of differences between chemical structures of n-3 and n-6 fatty acids. 
A) Eicosapentaenoic acid (EPA) C20:5 (n-3),  
B) Arachidonic acid (AA) C20:4 (n-6). 
 
Fish and fish oil-based n-3 polyunsaturated fatty acids, consist of docosahexaenoic 
acid or DHA and eicosapentaenoic acid or EPA. DHA and EPA can be abbreviated 
as 22:6n-3 (i.e., 22 carbon atoms with 6 double bonds) and 20:5n-3, respectively. 
The number before the colon indicates the number of carbon atoms in the fatty acid 
chain and the number after the colon indicates the number of double bonds between 
adjacent carbon atoms (unsaturated sites) in the structure. 
 
DHA contains 22 carbon atoms and 6 double bonds and fish is one of the richest 
sources of this nutrient (Willers et al. 2007). EPA contains 20 carbon atoms and 5 
double bonds (Holub 2002; Marangoni et al. 2007). Walnuts are rich sources of EPA, 
in a recent study levels of EPA were significantly raised in blood lipids by the intake 
of four walnuts a day in humans (Marangoni et al. 2007).  
 
Linoleic acid (LA) 18:2n6 and α-linolenic acid (ALA) 18:3n3 are essential fatty 
acids. Eicosapentaenoic acid (EPA) 20:5n3 and docosahexaenoic acid (DHA) 22:6n3 
are not essential nutrients because EPA can be synthesised from ALA and DHA from 
EPA (DHA can be reconverted into EPA) (Holub 2002; Marangoni et al. 2007). 
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1.7.2.2 Sources of n-6 and n-3 
 
Foods that are rich in n-6 fatty acids include poppy seed oil, palm oil, sunflower oil, 
soybean oil, coconut oil, egg yolks, peanut oil, rice bran oil, wheat germ oil, grape 
seed oil, macadamia oil, pistachio oil and sesame oil (Cunnane, Trotti & Ryan 2000). 
 
The increased consumption of polyunsaturated fats in Australia in recent years 
followed by the campaigns to reduce heart disease (by reducing saturated fat 
consumptions) could be partly responsible for the increase in the prevalence of 
asthma (Haby et al. 2001). Polyunsaturated fats are a rich source of n-6 fatty acids, 
such as linoleic acid and they can increase the synthesis of prostaglandin E2 
(Marangoni et al. 2007). The net effect is the increase in the risk of inflammation, 
which may increase the risk of asthma (Black & Sharpe 1997; Bolte et al. 2006; 
Haby et al. 2001). 
 
Foods that are rich in n-3 fatty acids include whole grains, fresh fruits and 
vegetables, fish, olive oil, garlic (Marangoni et al. 2007). Beef and lamb has a high 
concentration of docosapentaenoic acid (DPA) (Mann et al. 2003). N-3 fatty acids 
may have the opposite effect of n-6 by inhibiting the formation of prostaglandin E2 
and protecting against inflammation (Haby et al. 2001; Marangoni et al. 2007), 
however, this is controversial. 
 
The incorporation of linoleic acid (18:2n6) and α-linolenic acid (18:3n3) from the 
diet into serum and tissue phospholipid stores appears dependent on the ratio of n6: 
n–3 in the diet, rather than the absolute amount of either fatty acid present (Meyer et 
al. 2000). 
 
N-3 fatty acids may have the opposite effect of n-6 by inhibiting the formation of 
prostaglandin E2 and protecting against inflammation (Haby et al. 2001; Marangoni 
et al. 2007), however, this is controversial. 
 
The n-6 fatty acids, dihomo gamma-linolenic acid (DGLA) 20:3n−6 can be 
converted to either the anti-inflammatory prostaglandin E1 or into arachidonic acid 
 42 
(AA), a precursor of prostaglandin E2. Conversion of DGLA into prostaglandin E1 
does not require any enzymes, but conversion of DGLA into AA requires the enzyme 
delta-5 desaturase. In diets high in n-3, most of the delta-5 desaturase will be used in 
the n-3 pathway; few delta-5 desaturase will be available to convert DGLA into 
arachidonic acid, and subsequently, prostaglandin E2. DGLA ends up being 
converted into the anti-inflammatory prostaglandin E1 and inflammation is therefore 
decreased (Babcock et al. 2004; Calder 2006; Calderon & Kim 2007; Lands 2008). 
 
In a diet low in n-3 fatty acids, large quantities of delta-5 desaturase enzymes are 
available to convert DGLA into AA. The available AA is then converted into the 
inflammatory prostaglandin E2. Thus, the more n-3 fatty acids present in our body, 
the fewer enzymes are available for converting n-6 fatty acids into the inflammatory 
prostaglandins. A balance of n-6 and n-3 fatty acids is therefore essential for proper 
health. However, the typical Western diet has evolved to be high in n-6 and low in n-
3 fatty acids (Calder 2006; Calderon & Kim 2007; Lands 2008). 
 
1.7.2.3 Fatty acids and the immune system 
 
The effects of the fatty acids on the immune system and its responses are complex, 
because they depend on many different factors including the type and concentration 
of fatty acids, cell types and species of experimental animals (Almqvist et al. 2007; 
De Pablo & De Cienfuegos 2000; McKeever 2007; Wong 2005). Therefore, it is not 
surprising that several conflicting results on the effects of dietary and free fatty acids 
on the immune system have been reported (Almqvist et al. 2007; De Pablo & De 
Cienfuegos 2000; McKeever 2007; Wong 2005). Linoleic acid (n-6 fatty acid) is a 
precursor of arachidonic acid, which can be converted to prostaglandin E2 (PGE2), 
whereas eicosapentaenoic acid (n-3 fatty acid) inhibits the formation of PGE2. 
Prostaglandin E2 (PGE2) acts on T-lymphocytes to reduce the formation of 
interferon-γ (IFN-γ) without affecting the formation of interleukin-4 (IL-4). This may 
lead to the development of allergic sensitization, since IL-4 promotes the synthesis of 
immunoglobulin E (IgE), whereas IFN-γ inhibits the synthesis of immunoglobulin E 
(IgE) (Bolte et al. 2006; Haby et al. 2001; LeGros et al. 1990; Mosmann & Coffman 
1989; Nagel & Linseisen 2005; Oddy et al. 2004a). Therefore, an increase in the ratio 
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of n-6:n-3 fatty acids associated with a change in diet may result in a higher synthesis 
of IgE by lymphocytes and this in turn can explain the increase in the prevalence of 
allergic reactions including asthma in recent decades in Western countries due to 
changes in diet habits.  
 
Results from observational studies support the hypothesis that a diet that includes 
fish with high levels of on-3 fatty acids has a protective effect against cough and 
wheeze both in children and adults (Bolte et al. 2006; Broadfield et al. 2004; 
Mickleborough, Ionescu & Rundell 2004; Peat et al. 2004; Wong 2005). Inclusion of 
oily fish in the diet is also proposed to be associated with a reduced prevalence of 
asthma (Oddy et al. 2004b; Wong 2005). On the other hand, it is proposed that a high 
margarine intake (which is high in n-6) significantly increases the risk of onset of 
asthma in adulthood (Bolte et al. 2006; Haby et al. 2001; Nagel & Linseisen 2005). 
 
Many mechanisms involved in modulation of the immune system by fatty acids are 
either unknown or poorly understood. Four factors that are most frequently cited in 
the literature are: (i) membrane fluidity, which is modified as a consequence of 
changes in phospholipid composition; (ii) eicosanoid production from long-chain 
fatty acids, showing different biological properties depending on their precursors; 
(iii) formation of lipid peroxides, which are toxic to the cells; and (iv) influence on 
the regulation of the expression of genes encoding proteins that participate in cellular 
responses (De Pablo & De Cienfuegos 2000; Hasala et al. 2008; Park et al. 2007). 
 
Some studies suggest that n-6 fatty acids have a detrimental effect on allergic 
responses and asthma (McKeever 2007), however, a clinical trial of n-6 fatty acids 
supplementation in adults found that some n-6 fatty acids, such as γ-linolenic acid 
(GLA), might have similar effects to those of n-3 fatty acids on the decrease in 
proliferation of activated lymphocyte (Thies et al. 2001). Also increased foetal levels 
of arachidonic acid (AA) has similar effects as increased foetal levels of EPA in 
attenuating of immunologic responses, specifically a reduction in allergen-stimulated 
lymphocyte proliferation and IFN- γ production (Gold et al. 2006). These researchers 
proposed a protective role for n-6 fatty acids against allergic reactions and asthma 
while the others (McKeever 2007), suggest a detrimental role for these fatty acids on 
asthma. 
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In one study (Salam et al. 2005) monthly maternal consumption of oily fish was 
significantly protective against persistent asthma in five year old children born to 
mothers with a history of asthma (OR = 0.45; 95%CI = 0.23–0.91). No associations 
were found in the children born to non-asthmatic mothers. In another study maternal 
fish consumption was shown to be beneficially associated with doctor-confirmed 
eczema in 5-year-old children (OR = 0.57; 95%CI = 0.35–0.92) (Willers et al. 2007). 
 
Linoleic acid is a precursor of arachidonic acid, which can be converted to 
prostaglandin E2 (PGE2), whereas α-linolenic, a precursor of eicosapentaenoic acid, 
inhibits the formation of PGE2. Prostaglandin E2 (PGE2) acts on T-lymphocytes to 
reduce the formation of interferon-γ (IFN-γ) without affecting the formation of 
interleukin-4 (IL-4). This may lead to the development of allergic sensitization, since 
IL-4 promotes the synthesis of immunoglobulin E (IgE), whereas IFN-γ inhibits the 
synthesis of immunoglobulin E (IgE) (Bolte et al. 2006; Haby MM et al. 2001; 
LeGros et al. 1990; Mosmann & Coffman 1989; Nagel & Linseisen 2005; Oddy et 
al. 2004a) (Figure 6). Arachidonic acid is abundant in phospholipids from meat and 
that acts as a substrate for 5-Lipoxygenase (5-LO). 5-LO catalyses the first two steps 
in the biosynthesis of leukotrienes, a group of pro-inflammatory lipid mediators 
derived from arachidonic acid. Leukotriene antagonists are used in the treatment of 
asthma (McNamara, Sullivan & Richtand 2008; Radmark et al. 2007). 
 
Polyunsaturated fatty acids are major constituents of the membrane phospholipids of 
inflammatory cells (Riediger et al. 2009). During inflammation, intracellular 
concentration of calcium ions (Ca2+) increases and the ionized calcium binds to 
calmodulin (a calcium-dependent regulatory protein) (Wong 2005). When the four 
binding sites of calmodulin are fully occupied by Ca2+, calmodulin undergoes a 
conformational change that enables it to phosphorylate an active site residue (Ser505) 
within the catalytic site of phospholipase A2 (Hegazi et al. 2006; Wong 2005). The 
activated phospholipase A2 hydrolyzes the second-position ester bond of the 
phospholipids and releases n-6 fatty acid (linoleic acid 18:2n6), which is then 
converted into pro-inflammatory arachidonic acid (AA) based eicosanoid (Hegazi et 
al. 2006) (Figure 7).  
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Depending on the levels of dietary intake, n-3 fatty acids compete with and displace 
n-6 fatty acids for the acylation sites in the cellular membranes (Mickleborough et al. 
2009). It has been shown that the saturation of n-3 in cell membranes can 
significantly increase within two weeks supplementation and the levels of 
eicosapentaenoic acid could reach peak accumulation after six weeks of 
supplementation (Mickleborough et al. 2009; Wong 2005). Dietary fat intake may 
change the membrane composition of fatty acids and modulate the types of 
eicosanoids produced in the pathway, thus influencing the inflammatory response of 
the cells. N-6 is metabolized into arachidonic acid through a process of desaturation 
and elongation (Wong 2005) (Figure 7). 
 
The delta-5 desaturase is an enzyme that catalyzes the last step of the conversion of 
dihomo-γ-linolenate. The presence of eicosapentaenoic acid acts as a negative 
allosteric effector of delta-5 desaturase, which is the rate-limiting enzyme of 
arachidonic acid metabolism. Hence, eicosapentaenoic acid limits the direct 
precursors of the leukotrienes (Schmitz & Ecker 2008). 
 
In this research along with the individual fatty acids (α-linolenic acid, parinaric acid, 
eicosapentaenoic acid, docosapentaenoic acid, docosahexaenoic acid, linoleic acid, 
arachidonic acid and docosatetraenoic acid), total n-3 and total n-6, the effects of the 
ratio of n-6:n-3 on asthma and asthmatic symptoms were investigated.
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Figure 6- Proposed effects of n-3 and n-6 fatty acids on IgE synthesis. 
(Compiled by the candidate) 
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Figure 7- Effect of n-6 and n-3 fatty acids on prostaglandin thromboxane metabolism 
(Adapted from Wong 2005). 
 
1.8  TREATMENTS OF ASTHMA 
 
Asthma medications include the use of corticosteroids, anti-inflammatory drugs 
(mast cell stabilizers), long acting beta-agonists (bronchodilators often used along 
with an anti-inflammatory drug) (Woisetschlager, Stutz & Ettmayer 2002). Other 
asthma medications include leukotriene modifiers. These are alternatives to steroids 
and mast cell stabilizers. New potential therapeutics would ideally minimize the 
“direct” functionality of IgE by neutralizing IgE (Larche, Robinson & Kay 2003). An 
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example of this new treatment is Xolair, which blocks IgE. Xolair is used when 
inhaled steroids for asthma have failed to control asthma symptoms in people with 
moderate to severe asthma who also have allergies. 
 
Several studies have showed that steroids reduce T-cell activity (Cornejo-Garcia et 
al. 2007; Duramad, Tager & Holland 2007; Park et al. 2007). However, prolonged 
use of steroids aggravates unwanted side effects such as slowing of normal growth, 
development of osteoporosis and affecting control of diabetes, therefore, it is 
suggested that altering the immune response to asthma by direct or indirect retraction 
of IgE is a more efficient way for treatment asthma (Bratke et al. 2007; Cornejo-
Garcia et al. 2007; Kuiper et al. 2006; Pole et al. 2008). Figure 8 outlines how 
reducing IgE concentration results in inhibition of mast cell and eosinophil 
degranulation and cytokine production and decreased mast cell counts.  
 
 
 
Figure 8- The effects of reduction of IgE on other immune cells 
(Compiled by the candidate) 
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This chapter highlighted the current knowledge on the immunological basis of 
respiratory diseases with focusing on asthma. It was noted that there are many 
different immunological components working in synchronization, and any 
imbalances in their activity may have severe consequences. Most treatment and 
prevention strategies of asthma are currently focused on allergic/eosinophilic asthma. 
As discussed earlier (section 1.5), a major proportion of asthma is based on 
neutrophilic (non-asthmatic) airway inflammation. Eosinophilic asthma is a 
consequence of the activation of T cells and mast cells in the airway and responds 
well to steroid treatment. Non-eosinophilic asthma however, is the product of cell 
mediated and innate immune responses. Therefore, use of steroids is not an effective 
way of treatment in non- eosinophilic asthmatics. A diet low in antioxidants and high 
in saturated fat intake may activate innate immune responses in asthma (Wood and 
Gibson 2009), therefore, there is potential for treatments that target the metabolic 
pathways. Use of cholesterol lowering drugs such as statins has been shown to 
reduce innate immune markers such as IL-6, IL-8, and TNFα. Use of antioxidant rich 
diets such as lycopene has also been shown to modify non-eosinophilic airway 
inflammation in asthma (Wood and Gibson 2009) .  
 
1.9  SUMMARY 
 
There is an increasing rise in the prevalence of asthma in Western societies over the 
last two decades compared to developing countries. There are also increasing   
inconsistencies in the literature over the role of diet in asthma. The aim of this 
project was to investigate possible associations between nutrients and asthmatic 
symptoms in 14 year old adolescents enrolled in the Western Australian Pregnancy 
Cohort (Raine) study. 
 
The hypothesis of this thesis was that consumption of specific antioxidants (vitamins 
A, C, and E, ß-carotene, zinc and fruits rich these nutrients) and n-3 fatty acids will 
reduce asthmatic symptoms in 14 year old adolescents. There is evidence in the 
literature suggesting a protective role for these nutrients against asthma (de Luis et 
al. 2005; Hatch 1995; McKeever & Britton 2004; Soutar, Seaton & Brown 1997,  
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Chavali, Zhong & Forse 1998,Hennig et al. 1999; Zalewski et al. 2005, Park et al. 
2007).            
 
On the other hand, some studies suggest that consumption of n-6 fatty acids will have 
a detrimental association with asthmatic symptoms (McKeever 2007). Therefore, the 
objective of this project was to investigate whether consumption of specific 
antioxidants, n-3 and n-6 fatty acids were associated with asthmatic symptoms in 
these adolescents.   
 
1.10  HYPOTHESES OF THE STUDY 
 
The hypotheses of the study were that: 
 
1. consumption of specific antioxidants i.e. vitamins A, C, and E, ß-carotene, 
zinc and fruits and vegetables containing these nutrients is lower in asthmatic 
compared with non-asthmatic 14 year old adolescents.  
 
2. consumption of n-3 fatty acids is lower in asthmatic 14 year old compared 
with non-asthmatic 14 year old adolescents.  
 
3. consumption of specific antioxidants i.e. vitamins A, C, and E, ß-carotene, 
zinc and fruits containing these nutrients is the lowest in adolescents with 
asthmatic symptoms at eight and 14 years compared to the non-asthmatic 
group and those with asthma at eight and 14 years only.  
 
4. consumption of n-3 fatty acids is lowest in adolescents with asthmatic 
symptoms at eight and 14 years compared to the other groups.  
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CHAPTER TWO 
STUDY METHODS 
2.1  INTRODUCTION 
 
This study was based on two longitudinal studies from the West Australian 
Pregnancy Cohort (Raine) study. The enrolment criteria for the Raine study were 
gestational age between 16 and 20 weeks, an expectation to deliver at King Edward 
Memorial Hospital, sufficient proficiency in English to understand the implication of 
participation and an intention to remain in Western Australia so that follow-up 
through childhood would be possible. Children have been followed up at birth, one, 
two, six, eight, ten and 14 years of age during the Raine study.  This thesis reports on 
data collected at eight and 14 years of age. 
 
2.2  THE RAINE STUDY 
 
The Raine study is an ongoing multidisciplinary health research project commenced 
between August 1989 and March 1992, when approximately 100 women per month 
were enrolled over a period of 30 months, 2900 women were enrolled (Newnham et 
al. 1993; Oddy  et al. 2004a; Oddy et al. 2000) during their second trimester of 
pregnancy. Mothers were recruited from the public antenatal clinic at King Edward 
Memorial Hospital in Perth Western Australia, or surrounding obstetric clinics. This 
project presents information that has been gathered over fourteen years in the Raine 
study. 
 
Study One 
 
Study One “the cross-sectional study” was a cross-sectional study of 1531 
adolescents at 14 years of age identified as having current asthma (n=167) or no 
asthma (n=1364). This study examined the first two hypotheses outlined in the 
previous chapter (section 1.10).  
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Study Two 
 
Study Two “the case-control study” was a longitudinal analysis from a subset of the 
overall cross-sectional study. Cases were defined as having current asthma and 
controls as not having asthma at eight (n=335) and 14 (n=242) years of age (Oddy et 
al. 2004a). The third and fourth hypotheses outlined in the previous chapter (section 
1.10) were examined by Study Two. 
 
The children were selected as cases and controls at eight years of age as follows in an 
earlier study (Oddy et al. 2004a): 
 
Case ascertainment 
 
During 1999 when the children were eight years of age, all cases of current asthma 
were identified at six years. The diagnosis of asthma was confirmed from the six year 
assessment by diagnosis of asthma by a doctor and wheeze in  the last year or using 
preventer or reliever medication (n=147). Mothers were telephoned, invited to 
participate and the child’s asthma status confirmed. Case children whose mother 
consented to participate by telephone were sent dietary questionnaires. During 
control ascertainment, parent reported current asthma at age eight but not at age six 
resulted in the child designated as a case (n=19). If a parent reported that an 
identified case from the six year follow-up no longer had asthma they were excluded 
from the study. 
 
Control ascertainment 
 
Controls were children with no asthma diagnosis, no current wheeze and not taking 
asthma medication at either six or at eight years of age. At the same time as case 
ascertainment, controls were selected (one per case) on gender and age (birth date 
within one month). One control was selected from the potential controls for each 
case (usually about 12) and the child’s absence of asthma was confirmed through 
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personal contact with parent. Controls whose parent consented to participate were 
sent dietary questionnaires. 
 
In this thesis, the role of risk factors for asthma and atopy in children was examined 
with specific attention given to the roles of antioxidant and n-3 fatty acids for both 
studies. 
 
Administration of the Raine study and the questionnaires was conducted by the 
project coordinator, research nurses and research assistants employed on the large 
overall cohort study. Dietary data were collected using the CSIRO food frequency 
questionnaire (Baghurst & Record 1983). The analytical methods for Study One and 
Two were developed by Dr Wendy Oddy, Professor Nick deKlerk, Peter Jacoby and 
the DrPH candidate during the period of this study (2006-2007). 
 
2.3  POPULATION GROUP FOR STUDY ONE AND STUDY 
TWO 
 
At birth 2868 infants from 2900 women were available for follow up.  Parents 
(n=2900) of the children completed a questionnaire about their own respiratory 
illnesses, smoking behaviour and general health conditions at the time of enrolment. 
Detailed data on each infant including gestational age, birth weight and gender were 
collected at birth; however, these data were not used in the analysis for this thesis. 
 
Informed consent from parents was also obtained at the birth of their children and at 
each subsequent follow up for their child’s participation in the study and follow-up 
assessments.  
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2.4  DATA COLLECTION FOR STUDY ONE: CROSS 
SECTIONAL STUDY OF 14 YEAR OLD ADOLESCENTS  
 
Study One investigated if there was an association between the current intake of 
antioxidants and n-3 fatty acids with asthmatic traits in 14 year olds using 
questionnaire data, physical assessment and red blood cell analysis. 
 
2.4.1 Food Frequency Questionnaire (FFQ) 
 
Dietary data were collected by the CSIRO food frequency questionnaire (Baghurst & 
Record 1983) (See Appendix 9). The FFQ was validated in adults (Yearsley, Last & 
Ward 1999) and has previously been validated and applied for fish intake against 
serum fatty acids samples in the eight year follow-up in children in the Raine study 
(Oddy et al. 2004a). These questionnaires were very comprehensive and contained 
questions on a variety of 212 foods and nutrients.  
 
The parents, in discussion with the children, were asked to complete the dietary 
questionnaire to describe their child’s usual eating patterns over the past year as well 
as seasonal variations. By using the number of times a food was eaten per day, week, 
or month, the best total estimate of the child’s usual diet was made. Seasonal 
differences were measured by asking how often foods were eaten during both 
summer and winter. (See Appendix 4) 
 
This questionnaire was posted to all the participants and completed questionaries 
were then reviewed by nurses to ensure that all the sections had been completed. 
Follow up calls were made by nurses when necessary for completion of 
questionnaires.  
 
Completed questionaries were posted to CSIRO for data entry by skilled data entry 
personnel. Completed data sets were returned to Dr Wendy Oddy as SPSS data files. 
 
 55 
2.4.2 Dietary and nutrient exposures  
 
The average daily intake of the dietary antioxidant nutrients were estimated from the 
fruit and vegetable consumption in FFQ. The antioxidants of interest were: vitamin A 
(µg/day), vitamin C (mg/day), vitamin E (mg/day), magnesium (mg/day) and zinc 
(mg/day). Foods high in antioxidant nutrients included fruits (berry, citrus, stone, 
pome [apples and pears] and tropical fruits) (g/day), vegetables (carrots, turnip, 
broad beans, green beans, capsicum, cabbages, green peas, Brussels sprouts, spinach, 
broccoli, cauliflower, pumpkins, sweet corn, and zucchini)(g/day). Average daily 
intake of the total n-3 and n-6 were also estimated from the FFQ (g/day). 
 
2.4.3 Red blood cell fatty acids 
 
The possible association of the red blood cell fatty acids (α-linolenic acid, parinaric 
acid, eicosapentaenoic acid, docosapentaenoic acid, docosahexaenoic acid, linoleic 
acid, arachidonic acid and docosatetraenoic acid) (mmol/L), total n-3 (mmol/L), total 
n-6 (mmol/L),  and the ratio of n6:n3 with the asthmatic outcome of interest were 
also investigated. 
 
A fasting red blood cell sample was collected from adolescents at the 14 year follow-
up (n=1329). A phlebotomist attended each study child first thing in the morning to 
collect fasting blood samples. Fatty acid analyses of red blood cells were carried out 
by Dr Trevor Mori of School of Medicine & Pharmacology Royal Perth Hospital, as 
previously described (Mori et al. 2000). Briefly, total lipids were extracted with 
chloroform: methanol  (2:1) and fatty acid methyl esters were prepared by treatment 
of extracts with 4% H2SO4 in methanol at 90
oC for 20 minutes and analysed by gas 
liquid chromatography using a Hewlett-Packard model 5980A gas chromatograph. 
The column was a BPX70 (25m x 0.32mm, 0.25um film thickness) (SGE, 
Ringwood, Victoria, Australia) with a temperature programmed from 150oC to 
210oC at 4oC/min and using N2 as the carrier gas at a split ratio of 30:1. Peaks were 
identified by comparison with a known standard mixture. The fatty acids were 
expressed as a percentage of the weight of the total fatty acids measured (C14 to C22) 
(Mori et al. 2000). Percentage of the weight of the total fatty acids was quantified 
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using an internal standard to provide the concentration (mmol/L). This facilitated the 
comparison between the mean level of fatty acids in the cohort and that of the 
healthy population.  
 
Fatty acids of interest for this study were: n-3: α-linolenic acid (18:3n3), parinaric 
acid (18:4n3), eicosapentaenoic acid (20:5n3), docosapentaenoic acid (22:5n3), 
docosahexaenoic acid (22:6n3) and n-6: linoleic acid (18:2n6), arachidonic acid 
(20:4n6) and docosatetraenoic acid (22:4n6). 
 
The red blood cell fatty acid data were used to investigate the possible association of 
individual fatty acids, total n-6, total n-3 and the ratio of n6:n3 fatty acids on the 
outcome of interest (described below) at 14 years of age in Study One. The 
phlebotomist was employed on the study to increase the fasting blood collection 
response rate. 
 
2.4.4 Physical assessment: 
 
Physical assessments included Skin Prick Test (SPT) and test for bronchial 
hyperresponsiveness (BHR). These tests are described in sections 2.5.4 and 2.5.5.   
 
2.4.5 Respiratory questionnaire 
 
Asthmatic outcomes were measured at 14 years of age using a respiratory 
questionnaire (See Appendix 3). The questions asked in the respiratory 
questionnaires were based on the American Thoracic Society questionnaire and 
published elsewhere (Oddy et al. 2004a). This questionnaire included questions that 
captured the outcomes of wheeze frequency and asthma severity and other asthmatic 
symptoms. The respiratory questionnaire was based on the International Study of 
Asthma and Allergies in Childhood (ISSAC) study questionnaire (Tabak et al. 2005) 
and other related respiratory questionnaires (Parrish et al. 2003). 
 
The definitions of the asthmatic outcomes used in this study are described in 
following sections. 
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2.5  ASTHMATIC SYMPTOMS: OUTCOMES FOR STUDY ONE 
(THE CROSS-SECTIONAL STUDY AT 14 YEARS)  
 
The outcomes of interest for Study One included current asthma, current wheeze, 
bronchial hyperresponsiveness (BHR), asthma severity and atopy.  
 
2.5.1 Current asthma 
 
Current asthma was defined by a positive response to the following question: 
Was asthma diagnosed by a doctor within the past 12 months?  
 
2.5.2 Current wheeze and number of wheezing attacks 
 
Current wheeze was defined as having any wheezing episodes reported in the 
questionnaire in the past 12 months (Joseph-Bowen et al. 2004). The adolescents 
were also divided according to The International Study of Asthma and Allergies in 
Childhood (ISAAC), into the following 4 groups based on the number of wheezing 
episodes within the last 12 months: none, 1-2, 3-12 and more than 12 (Pearce et al. 
2007). 
 
2.5.3 Asthma severity 
 
Severity of asthma was defined as mild, moderate, or severe on the basis of the main 
symptoms of episodes of wheezing per year (Joseph-Bowen et al. 2004). If 1 to 2 
episodes of wheeze were reported in the past 12 months, then asthma was considered 
to be mild. Asthma was considered to be moderate, if 3 to 12 wheezing episodes and 
on average not more than one occasion of nocturnal wakening per week caused by 
wheeze had been reported during the past 12 months. Severe asthma was defined as 
having at least one of the following symptoms: more than 12 episodes of wheeze, 
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one or more episodes of acute asthma limiting speech, or more than one occasion of 
nocturnal wakening per week (on average) throughout the past 12 months. 
 
2.5.4 Atopy 
 
The skin-prick test (SPT) was performed to determine the presence of atopic 
dermatitis in 14 year old children. This test was carried out by pricking through a 
drop of allergen extract (house dust mite, grasses, cat, dog, moulds, egg protein and 
peanut) placed on the surface of the arm (Clausen et al. 2008). The test showed that a 
level of anti-bodies were/or were not present which may be causing allergic 
symptoms. If the test was positive it resulted in the appearance of a small, itchy 
swelling and a reddening of the skin one or more positive SPT of equal or more than 
3 mm in diameter was recorded as atopy positive (Clausen et al. 2008).  
 
2.5.5 BHR 
 
The degree of bronchial hyperresponsiveness (BHR) was tested according to the 
American Thoracic Society (ATS) using the challenge as described below (Joseph-
Bowen et al. 2004).  
 
Inhalations of saline and methacholine were delivered using a dosimeter to ensure 
controlled doses were delivered.  The children who completed this protocol (n= 
1479) initially received an inhalation of normal saline, followed by increasing doses 
of methacholine.  Lung function Forced Expiratory Volume (FEV1) was measured by 
the research nurse 30 seconds and 90 seconds after each inhalation.  
 
The next dose of methacholine was delivered provided the FEV1 had not fallen by 
20% of the post-saline value. Doubling doses of Methacholine from 0.03 to 7.8 M 
were delivered. The test was finished when the FEV1 had fallen by 20% of the post 
saline value or the highest dose was delivered. A dose-response curve was 
constructed and the dose that caused a 20% fall in FEV1 (PD20< 7.8 M) was 
recorded as a positive BHR (Joseph-Bowen et al. 2004). 
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2.6  DATA COLLECTION FOR STUDY TWO: THE CASE-
CONTROL STUDY 
 
Study Two was a longitudinal analysis from a subset of the overall prospective 
cohort study. Data were used from both the eight and 14 year follow-up of the 
cohort. Doctor diagnosed asthma cases were selected from eight-year-old children in 
a previous study (Oddy et al. 2004b). These cases, identified at eight years were 
combined with cases of current asthma at 14 years of age.  
 
A new variable of history of asthma was created with four sub-groups (please see 
Table 24). Group 1: had no asthma at either ages of eight or 14, group 2: had asthma 
only at the age of eight, group 3: had asthma only at the age of 14 and group 4 had 
asthma at both ages of eight and 14 years.  
 
The data from the food frequency questionnaire (FFQ) at 14 years of age was used to 
investigate the intake of the nutrient of interest for each group.  
 
The number of adolescents participating at 14 year follow-up was reduced compared 
with participation at eight years, due to several factors including loss to follow-up, 
withdrawal from the study or non-participation in this phase of the study. 
 
Dietary intake of fatty acids (n-3: α-linolenic acid, parinaric acid, eicosapentaenoic 
acid, docosapentaenoic acid, docosahexaenoic acid, n-6: linoleic acid, arachidonic 
acid, docosatetraenoic acid,  total n-3, total n-6 and the ratio of n6:n3) intake was 
estimated through CSIRO data bases for fatty acids in these foods, as described in 
section 2.3.2 (fish, cereals, legumes, red meat and chicken).  
 
The information gathered from the FFQ (fatty acids, fruits, vegetables and 
antioxidants) data were used for analyses of the previously selected cases and 
controls at eight years of age (Oddy et al. 2004a) and for assessing their dietary 
status six years later at 14 years of age. 
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2.6.1 Observer bias 
 
The nurses conducting the physical assessments (as described in 2.3.4) were blinded 
to the information contained in the questionnaires when performing these 
assessments to eliminate observer bias. 
 
2.7  ASTHMATIC OUTCOMES FOR STUDY TWO: THE CASE-
CONTROL STUDY 
 
The outcome of interest for the case-control study was asthma history which was 
based on doctor diagnosed asthma. Combining doctor diagnosed asthma at the age of 
eight as one variable with current asthma (at 14 years of age) or not as another 
variable, a new variable of history of asthma was created with 4 sub-groups. Group 
1: had no asthma at either ages of eight or 14, group 2: had asthma only at the age of 
eight, group 3: had asthma only at the age of 14 and group 4 had asthma at both ages 
of eight and 14 years.  
 
2.8  STATISTICAL ANALYSIS  
2.8.1 Study One 
 
Consumption estimates of various antioxidants (listed in section 2.4.2), were 
obtained from the food frequency questionnaires from all participants.  
 
The average daily intake of dietary antioxidant, fruits, vegetables and the mean red 
blood cells fatty acid content of total n-3, total n-6, n6:n3 ratio and mean of 
individual n-3 fatty acids; [α-linolenic acid (18:3n3), parinaric acid (18:4n3), 
eicosapentaenoic acid (20:5n3), docosapentaenoic acid (22:5n3), docosahexaenoic 
acid (22:6n3)] and n-6 [linoleic acid (18:2n6), arachidonic acid (20:4n6), 
docosatetraenoic acid (22:4n6)] fatty acids were compared in association with 
asthma severity and the number of times wheezed over the last 12 months by using 
one way ANOVA. The Fisher’s Least Significance Difference (LSD) test was 
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applied to compare fatty acid content between the two groups’ means after ANOVA 
was performed. 
 
All the children in Study One were divided into five groups (quintiles) according to 
the fatty acids content in their red blood cells (RBC). Quintiles were used to make 
the results comparable to groupings already identified in the literature (Farchi et al. 
2003; McKeever 2007; Varraso et al. 2007). The groups spanned from the lowest to 
the highest fatty acid content of interest. It was then determined if there were any 
significant differences between the respective fatty acid content between individual 
groups (Pearson chi square) as well as any trends across all groups (trend p-value) 
with any of the outcomes of interest (current asthma, current wheeze, BHR and 
atopy) for the individual fatty acids. Two-tailed tests of significance were used with 
α=0.05. Depending on the outcome of interest, multinominal or binary logistic 
regression was performed to control for potential confounding effects of age, sex, 
BMI and total daily energy intake. Odds Ratio (OR) and 95% confidence interval 
(95% CI) were computed to estimate the degree of association.  
 
2.8.2 Study Two 
 
As in Study One, dietary antioxidant data were collected using FFQ and fatty acid 
intake was estimated as there was no RBC data available for eight year old children. 
This method has previously been shown to be valid (Oddy et al. 2004b). Dietary 
antioxidants and fatty acid data were assessed for normality and log-transformed if 
necessary.  ANOVA was performed for different antioxidants and fruits and different 
fatty acid intake with a history of asthma to make comparisons between the means of 
these nutrients and presence or absence of asthma history. The mean for each 
nutrient intake was compared between the entire four groups (group 1: no history of 
asthma, group 2: asthma at eight, group 3: asthma at 14 and group 4: asthma at eight 
and 14). The Fisher’s Least Significance Difference (LSD) test as a post hoc 
comparison procedure was also performed when ANOVA resulted in a significant F 
test. One way analysis of variance (ANOVA) allowed comparisons of food and 
nutrient intakes between the groups. Fatty acids that were significant in these 
analyses (p<0.05) were included in analysis of covariance (ANCOVA) to determine 
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whether they made an independent contribution on the outcome of interest (history of 
asthma) after adjustment for age, sex, BMI and total energy intake. Bonferroni post 
hoc tests were applied to control for false positive results.  
 
2.8.2.1 Statistical power for Study Two 
 
Subjects were divided into groups based on presence or absence of asthma. Power 
calculations were performed based on the actual size in each group. The power 
calculation showed that a sample size of n=123 achieves 91.4% power to detect a 
difference of 0.3 between the means with a significance level of 0.05 using a 2-sided 
paired samples. When n=68 statistical power =69.6%, n=6 power=11.4% and when 
n=45 power=52.1%. 
 
2.9  ETHICS APPROVAL FOR STUDY ONE AND TWO 
 
Ethics approval to conduct the analysis for the studies One and Two that form this 
thesis were obtained at candidacy from Curtin University Human Ethics Committee 
(Protocol Approval Number: SP-019-2007) (See Appendix 1). 
 
Parents were informed prior to agreeing to participate, that the study would be 
ongoing over a number of years and would involve the investigation of child health 
outcomes. The Human Ethics Committee at King Edward Memorial Hospital for 
Children, Perth, Western Australia had approved the protocol for the Western 
Australian Pregnancy Cohort Study (See Appendix 2). At the time of enrolment and 
at each follow-up mothers consented to participate in the study (See Appendix 6).  
 
The work of this thesis represents a collaboration between the School of Public 
Health at Curtin University and the Telethon Institute for Child Health Research. 
 
Ethics approval was obtained from parents for the eight year follow-up and also from 
the teenage study participants for the 14 year follow-up. Information sheets were 
provided for parents and teens and a consent form was signed by each participant for 
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clinical assessments. Parents and teens were informed that their refusal to participate 
in any aspect of the study would not affect future care in the health system. Parents 
were advised that any tests could be abandoned if the adolescent declined to co-
operate. 
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CHAPTER THREE 
STUDY ONE RESULTS 
 
Results from Study One are reported in this chapter. The results for Study Two are 
reported in Chapter Four. Study One was conducted to investigate if there was a 
significant association between the intake of antioxidants and n-3 fatty acids with 
asthma manifestations (wheeze, asthma, atopy and bronchial hyperresponsiveness) 
by using data from food frequency questionnaires (FFQ). Also, for this study, red 
blood cell fatty acid data were used to investigate the possible association of 
individual fatty acids, total n-3, total n-6 and the ratio of n6:n3 fatty acids on the 
asthma manifestation.  
 
3.1  THE RESULTS OF STUDY ONE: 
 
Study One was a cross-sectional study that included adolescents at age 14 
participating in the follow-up identified as having current asthma (n=167) or no 
asthma (n=1364) in this cohort.  
 
3.1.1 Cohort characteristics 
 
Characteristics of the cohort under investigation are summarized in Table 1. The 
participants were 50.8% male and 49.2% female. The main outcomes of the study, 
separate measurements of wheeze, asthma, atopy and bronchial hyperresponsiveness, 
were found to be positive in between 10.9% to 44.5% of adolescents. One hundred 
and sixty seven adolescents (10.9%) of the cohort had asthma. Among those with 
current asthma, different levels of severity were observed (mild, moderate and 
severe) with moderate asthma being most prevalent (4.4%) followed by mild (4.0%) 
and severe asthma (2.5%).  Two hundred and eighteen adolescents of the total cohort 
(14.2%) were reported to have current wheeze. Different allergy outcomes were 
observed; bronchial hyperresponsiveness (17.9%), allergic conjunctivitis (27.3%), 
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itchy eyes (25.4%), eczema (10.7%), hay fever (37.3%), and atopy (44.5%) for this 
population. The most common allergy outcome was atopy. The least common allergy 
outcome was eczema (Table 1)  
 
Table 1: Characteristics of subjects in Study One 
Outcome at 14 
years 
Frequency 
N=1531 
Percentage 
Current wheeze 218 14.2 
*Number of wheeze attacks in the last 12 months 
0 1314 85.9 
1-2 129 8.4 
3-12 67 4.4 
>12 20 1.3 
Current asthma 167 10.9 
Asthma severity 
None 1364 89.1 
Mild 62 4.0 
Moderate 67 4.4 
Severe 38 2.5 
Bronchial 
Hyperresponsiveness 
274 17.9 
Allergic conjunctivitis 418 27.3 
Itchy eyes 389 25.4 
Eczema 164 10.7 
Hayfever 572 37.3 
Atopy 682 44.5 
Child characteristics  
Gender  
Male 778 50.8 
Female 773 49.2 
*Total number of participants who answered the number of wheeze attacks was 216 as 2 participants 
did not complete this section in the questionnaire.  
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3.1.2 Red blood cell membrane fatty acid content. 
 
Red blood cell (RBC) membrane fatty acid content was analysed from 1304 
participants, Table 2 describes mean and range of the RBC membrane fatty acid 
content.  Individual mean RBC membrane fatty acid content was diverse among 
individuals. The highest range was observed for arachidonic acid (20:4n6) with a 
range of (2.93-20.17 mmol/L) and the lowest range was observed in 
eicosapentaenoic acid (20:5n3) with a range of (0.0-1.91 mmol/L).   
 
The level of parinaric acid (18:4n3), docosapentaenoic acid (22:5n3) and linoleic 
acid (18:2n6) were above the levels of the healthy population, while the level of α-
linolenic acid (18:3n3), arachidonic acid (20:4n6) and docosatetraenoic acid (22:4n6) 
were below the average of the healthy population range. Eicosapentaenoic acid 
(20:5n3) and docosahexaenoic acid (22:6n3) levels were very similar to the healthy 
population levels (Table 2).  
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Table 2: Red blood cell fatty acid content for the cohort (n=1304) and a healthy population. 
Nutrient 
 
Cohort mean  
(mmol/L) ± SD 
 
Cohort range 
(mmol/L) 
*Healthy 
population 
mean  (mmol/L) 
± SD 
18:3n3  
Alpha-linolenic acid 
(ALA) 
0.22 ± 0.25 0.0-3.36 0.30 ± 0.02 
18:4n3 
Parinaric acid 
0.54 ± 0.45 0.0-8.54 0.31 ± 0.001 
20:5n3  
Eicosapentaenoic acid 
(EPA) 
0.71 ± 0.21 0.0-1.91 0.66 ± 0.04 
22:5n3 
Docosapentaenoic acid 
(DPA) 
4.33 ± 2.15 0.29-11.17 2.93 ± 0.08 
22:6n3 
Docosahexaenoic acid 
(DHA) 
4.29 ± 1.07 
 
0.69-9.91 4.70  ± 0.18 
18:2n6 
Linoleic acid 
10.06 ± 1.21 3.12-14.61 5.94 ± 0.10 
20:4n6 
Arachidonic acid (AA) 
13.46 ± 2.17 2.93-20.17 19.77 ± 0.29 
22:4n6 
Docosatetraenoic acid 
1.61 ± 2.02 0.0-8.21 6.45 ± 0.12 
*(Harris et al. 2005). 
3.1.3 Daily nutrient/antioxidant and energy intake  
 
Daily nutrient/antioxidant intake for Study One subjects who responded to the food 
frequency questionnaire (n=1531) is shown in Table 3.  The level of recommended 
daily intake for this population group is also described in Table 4 (Baghurst et al. 
2005; Bhagavan 2002). 
 
The smallest range of daily nutrients consumed among this population was observed 
for n-3 fatty acids ranging from 0.27-6.03 g/day (Table 3).  
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The daily intake of vitamin C was very diverse among the cohort (191.8 ± 116.39 
mg/day) and was considerably higher than the recommended daily intake of 45 
mg/day. The mean daily intake of vitamin E was 8.78 ± 4.61 mg/day which was 
below the recommended daily intake of 11 mg/day. The recorded average daily 
intake for zinc was 12.88 ± 4.42 mg/day and this was very similar to the 
recommended daily intake of 10-15 mg/day.  
 
The mean daily intake of n-3 was within the recommended daily intake. However, 
the average daily intake of n-6 was nearly 5 times more than the recommended daily 
amount of 2.4-5.6 g/day. The ratio of n6:n3 was consequently higher (9.45 ± 4.24) 
compared with the average recommended ratio of 2-4 (Katrine Baghurst et al. 2005; 
Bhagavan 2002). 
 
Table 3: Daily nutrient/antioxidant intake for the cohort who responded to the food frequency 
questionnaire (n=1531). Recommended daily intake (RDI) is also described for this population 
group. 
Food/Nutrient 
 
Mean ± SD 
 
Range *Recommended 
daily intake 
(RDI)   
Vitamin A (µg/day) 
 
1240.05  ± 656.99 199.89- 8904.26 600-900 
Vitamin C (mg/day) 
 
191.8  ± 116.39 6.79- 1047.2 45 
Vitamin E  (mg/day) 
 
8.78  ± 4.61 1.26-41.01 11 
β-carotene (µg/day) 
 
4324.84  ± 2220.97 315.38-20588.47 6000-15000 
Zinc (mg/day) 
 
12.88  ± 4.42 2.85-36.87 10-15 
Magnesium (mg/day) 
 
319.49  ± 113.57 89.2-914.07 240 
n-3  (g/day) 
 
1.30 ± 0.66 0.27-6.03 1.2-1.4 
n-6 (g/day) 
 
11.67 ± 6.42 1.56-77.9 2.4-5.6 
n6:n3 
 
9.45 ± 4.24 1.84-101.2 2-4 
(Katrine Baghurst et al. 2005; Bhagavan 2002). 
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The average daily energy intake for girls in our study was 2327.78 Kcal ± 736.78 SD 
with a mean weight of 57.4 kg ± 13.67 SD and an average height of 1.63 m ± 0.10 
SD. This is significantly (p<0.05) more than the average recommended daily energy 
intake of 2192 Kcal for a reference weight of 49.4 kg and reference height of 1.60 m 
for 14 year girls (Nutrient Reference Values for Australia and New Zealand 
(Baghurst et al. 2005; Bhagavan 2002). The average daily energy intake for boys in 
our study was 2378.33 Kcal ± 836.46 SD with a mean weight of 57.93kg ± 12.89 SD 
and an average height of 1.64 m ± 0.09 SD. This was significantly (p<0.05) less than 
the 2531 Kcal for a reference weight of 51 kg and reference height of 1.64 m average 
recommended daily energy intake for 14 year boys (Table 4).  
 
There was no significant difference in total energy intake between genders in our 
study (p=0.209). 
 
The average daily total fat intake for our cohort was 92.79g ± 38.89 SD which is 
43% higher than the recommended daily intake of 65 g/day. The average intake of 
saturated fat was 40.91 g ± 17.72 SD that is twice the amount of RDI (20 g/day) 
(Katrine Baghurst et al. 2005; Bhagavan 2002). There was a significant difference in 
total fat intake between males (94.03 g/day ± 38.09 SD) and females (92.25 g/day ± 
33.82 SD) (p=0.004).  
 
Table 4: Daily fat/energy intake for the cohort who responded to the food frequency 
questionnaire (n=1531). Recommended daily intake (RDI) is also described for this population 
group. 
Food/Nutrient 
 
Mean ± SD 
 
Range **Recommended 
daily intake 
(RDI)   
Energy (Kcal/day) 
Girls 
2327.78 ± 736.78 645.75-5718.92 2192 
Energy (Kcal/day) 
Boys 
2378.33 ± 836.46 790.08-6682.45 2531 
*Total fat (g/day) 
 
92.79 ± 38.89 17.63 ± 267.65 65 
*Saturated fat (g/day) 
 
40.91 ± 17.72 7.89 ± 138.28 20 
* Average for cohort **(Baghurst et al. 2005; Bhagavan 2002). 
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3.1.4 Association between daily nutrient/antioxidant and food 
intake and allergy outcomes  
 
Differences among average daily nutrients and antioxidant intake were analysed 
using independent samples T-test for different allergic outcomes of wheeze, asthma, 
atopy and bronchial hyperresponsiveness (BHR) (Tables 5-12). 
 
3.1.4.1 Association between daily nutrient/antioxidant and food 
intake and wheezing  
 
The association between daily nutrient/antioxidant and food intake and wheezing is 
described in Table 5. There was no significant difference between mean dietary 
intakes of vitamin E between wheezers (those adolescents with more than one 
wheeze attack in the last 12 months) and non-wheezers. After adjusting for 
confounders (age, sex, BMI and total energy intake), none of the foods and nutrients 
of interest were shown to be a significant risk for wheezing (Table 6). 
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Table 5: Daily nutrient/antioxidant intake for wheezers and non-wheezers, mean ± SEM using 
independent samples T-test (n=1531).  
(*logarithmic value of nutrients). 
 
Food/Nutrient 
 
Wheezers 
Mean (SEM) 
N=218 
Non-wheezers  
Mean (SEM) 
N=1313 
P-value 
Vitamin A (µg/day) 
 
1304.92 (63.79) 1228.97 (18.10) 0.253 
*Vitamin C (mg/day) 
 
2.19 (0.02) 2.20 (0.007) 0.425 
*Vitamin E (mg/day) 
 
0.91 (0.016) 0.88 (0.006) 0.096 
Zinc (mg/day) 
 
13.17 (0.34) 12.80 (0.12) 0.280 
Magnesium (mg/day) 
 
320.56 (8.55) 317.26 (3.24) 0.707 
β-carotene (µg/day) 
 
2694.12 (255.31) 2519.59 (98.52) 0.498 
*N-3  (g/day) 0.08 (0.014) 0.06 (0.006) 0.296 
*N-6 (g/day) 
 
1.04 (0.016) 1.01 (0.007) 0.086 
n6:n3 
 
9.91 (0.29) 9.44 (0.11) 0.094 
*Steamed /grilled fish 
(g/day) 
1.71 (0.032) 1.68 (0.013) 0.418 
*Sea food (g/day) 
 
0.71 (0.04) 0.69 (0.02) 0.647 
Pome fruits 
 
1.81 (0.03) 1.79 (0.01) 0.529 
Berry fruits 
 
7.55 (1.46) 7.99 (0.4) 0.696 
*Citrus fruits 
 
1.43 (0.04) 1.40 (0.02) 0.499 
*Stone fruits 
 
1.24 (0.05) 1.29 (0.02) 0.269 
Tropical fruits 
 
51.88 (3.99) 58.52 (2.03) 0.213 
Dried/preserved fruit 
 
4.27 (0.81) 4.75 ( 0.39) 0.645 
*Fresh vegetables 
(g/day) 
1.88 (0.017) 1.85 (0.009) 0.242 
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Table 6: Adjusted and unadjusted odds ratio (OR) for the risk of current wheeze for different 
foods/nutrients. 
Food/Nutrient 
 
Crude OR 95% CI *Adjusted OR 95% CI 
Vitamin A  
 
1.000 1.000,1.000 1.000 1.000,1.000 
Vitamin C  
 
1.000 0.998,1.001 0.998 0.996,1.000  
Vitamin E  
 
1.027 0.994,1.060 1.024 0.969,1.083 
Zinc  
 
1.019 0.985,1.054 1.025 0.939,1.118 
Magnesium  
 
1.000 0.999,1.002 1.000 0.997,1.002 
β-carotene  
 
1.000 1.000,1.000 1.000 1.000,1.000 
N-3   
 
1.051 0.989,1.117 1.031 0.942,1.129 
N-6  
 
0.975 0.935,1.016 0.988 0.931,1.048 
n6:n3 
 
0.876 0.752,1.020 0.930 0.749,1.156 
Steamed 
/grilled fish  
 
1.000 0.997,1.004 0.998 0.994,1.003 
Sea food  
 
1.004 0.962,1.048 0.985 0.922,1.053 
Pome fruits 
 
1.000 0.998,1.002 0.999 0.996,1.001 
Berry fruits 
 
0.998 0.987,1.009 0.999 0.986,1.012 
Citrus fruits 
 
1.000 0.997,1.003 0.995 0.990,1.000 
Stone fruits 
 
0.998 0.994,1.003 0.997 0.991,1.003 
Tropical fruits 
 
0.998 0.996,1.001 0.998 0.995,1.002 
Dried/preserved 
fruit 
 
0.997 0.985,1.010 0.996 0.981,1.012 
Fresh 
vegetables  
 
1.000 0.997,1.002 0.998 0.994,1.002 
*Odds ratio adjusted for age, sex, BMI and total energy intake. 
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3.1.4.2 Association between daily nutrient/antioxidant and food 
intake and asthma 
 
The association between daily nutrient/antioxidant and food intake and asthma is 
described in Table 7. There were no significant differences between mean dietary 
intakes of vitamins A,E,C, magnesium, zinc β-carotene, n-3, n-6 fatty acids, 
steamed/grilled fish, sea foods and different fruits and vegetables between those who 
have doctor diagnosed asthma and those who didn’t have asthma.  
 
The mean intake of vitamin C was slightly lower for asthmatic compared with non-
asthmatic adolescents (2.17 compared with 2.20); however this difference was not 
statistically significant. 
 
After adjusting for confounders (age, sex, BMI and total energy intake), increased 
intake of vitamin C showed a protective effect on asthma (adjusted OR= 0.997, 95% 
CI= 0.994–0.999). For every 1 mg/day increase in intake of vitamin C there was a 
0.3% reduction in the risk of developing asthma (Table 8). 
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Table 7: Daily nutrient/antioxidant intake for asthma and non-asthma cases, mean ±SEM using 
independent samples T-test (n=1531)  
Food/Nutrient 
 
Asthma 
Mean (SEM) 
N=167 
Non-Asthma 
Mean (SEM) 
N=1364 
P-value 
Vitamin A (μg/day) 
 
1274.00 (74.84) 1235.34 (17.97) 0.507 
*Vitamin C (mg/day) 
 
2.17 (0.023) 2.20 (0.007) 0.174 
Vitamin E 
(mg/day) 
9.16 (0.405) 8.74 (0.126) 0.284 
Zinc (mg/day) 
 
12.93 (0.386) 12.84 (0.123) 0.826 
*Magnesium(mg/day) 
 
2.47 (0.013) 2.48 (0.004) 0.575 
*β-carotene (μg/day) 
 
3.26 (0.049) 3.24 (0.018) 0.642 
N-3  (g/day) 
 
1.32 (0.018) 1.29 (0.057) 0.640 
*N-6 (g/day) 
 
1.03 (0.018) 1.01 (0.006) 0.451 
n6:n3 
 
9.85 (0.345) 9.46 (0.099) 0.208 
*Steamed /grilled fish (g/day) 
 
1.71 (0.037) 1.68 (0.013) 0.555 
*Sea food (g/day) 
 
0.73 (0.046) 0.69 (0.015) 0.356 
*Pome fruits 
 
1.83 (0.039) 1.79 (0.013) 0.339 
Berry fruits 
 
6.81 (1.167) 8.07 (0.425) 0.334 
*Citrus fruits 
 
1.44 (0.042) 1.40 (0.015) 0.449 
*Stone fruits 
 
1.24 (0.052) 1.29 (0.017) 0.335 
Tropical fruits 
 
52.67 (4.79) 58.19 (1.97) 0.356 
*Fruits combined (Pome, berry, 
citrus, stone)  
2.03 (0.039) 2.02 (0.013) 0.791 
Mixture of 2 or more group of 
fruits 
18.89 (2.33) 20.31 (0.789) 0.557 
Dried/preserved fruit 
 
3.88 (0.899) 4.78 (0.386) 0.439 
Fresh vegetables  
(g/day) 
83.80 (4.388) 87.33 (1.608) 0.473 
(*logarithmic value of nutrients). 
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Table 8: Adjusted and unadjusted odds ratio (OR) for the risk of current asthma for different 
foods/nutrients. 
Food/Nutrient 
 
Crude OR 95% CI *Adjusted 
OR 
95% CI 
Vitamin A  
 
1.000 1.000,1.000 1.000 1.000,1.001 
Vitamin C  
 
0.999 0.998,1.001 **0.997 0.994,0.999 
Vitamin E  
 
1.020 0.984,1.058 1.044 0.981,1.112 
Zinc  
 
1.004 0.966,1.044 1.025 0.928,1.132 
Magnesium  
 
1.000 0.998,1.002 1.000 0.998,1.003 
β-carotene  
 
1.000 1.000,1.000 1.000 1.000,1.000 
N-3   
 
1.064 0.995,1.139 1.041 0.944,1.149 
N-6  
 
0.973 0.929,1.018 0.974 0.916,1.037 
n6:n3 
 
0.856 0.721,1.017 0.915 0.719,1.165 
Steamed /grilled 
fish  
 
1.000 0.997,1.004 0.998 0.992,1.003 
Sea food  
 
1.010 0.965,1.058 0.983 0.913,1.060 
Pome fruits 
 
1.000 0.999,1.002 0.999 0.997,1.002 
Berry fruits 
 
0.993 0.979,1007 0.984 0.963,1.007 
Citrus fruits 
 
1.000 0.996,1003 0.995 0.989,1.001 
Stone fruits 
 
0.998 0.993,1.003 0.995 0.988,1.003 
Tropical fruits 
 
0.999 0.996,1.002 0.999 0.996,1.003 
Dried/preserved 
fruit 
 
0.994 0.978,1.010 0.997 0.975,1.014 
Fresh vegetables  
 
0.999 0.996,1.002 0.997 0.993,1.002 
*Odds ratio adjusted for age, sex, BMI and total energy intake.** Statistically significant (p<0.05). 
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3.1.4.3 Association between daily nutrient/antioxidant and food 
intake and atopy 
 
The association between daily nutrient/antioxidant and food intake and atopy is 
described in Table 9. There were significant differences between mean dietary 
intakes of zinc and the ratio of n6:n3 between those who had atopy and those who 
didn’t have atopy (Table 9). 
 
Atopy positive adolescents had a significantly higher daily intake of zinc than atopy 
negative adolescents (p=0.02) (Table 9). Atopy positive adolescents also had a higher 
n6:n3 ratio than their atopy negative counterparts (p=0.04).  
 
The unadjusted level of zinc was shown to have detrimental effects against atopy 
(OR= 1.029, 95% CI= 1.004–1.055). However after adjusting for confounders (age, 
sex, BMI and total energy intake) this association was proved to be insignificant 
(OR= 1.019, 95% CI= 0.957–1.085) (Table 10). 
 
Increased intake of berry fruits showed protective effects against atopy (adjusted 
OR= 0.988, 95% CI= 0.976–0.999). Therefore, when we controlled for potential 
confounders, for every 1 g/day increased intake of these fruits there was a 1.2% 
reduction in the risk of having atopy. 
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Table 9: Daily nutrient/antioxidant intake for atopy positive and atopy negative, mean ±SEM 
using independent samples T-test (n=1518).  
Food/Nutrient 
 
Atopy Positive  
Mean (SEM) 
N=676 
Atopy Negative  
Mean (SEM) 
N=842 
P-value 
*Vitamin A (μg/day) 
 
3.06 (0.008) 3.04 (0.007) 0.21 
*Vitamin C (mg/day) 
 
2.19 ( 0.011) 2.20 (0.009) 0.81 
*Vitamin E 
(mg/day) 
0.89 (0.009) 0.88 (0.008) 0.93 
*Zinc (mg/day) 
 
1.09 (0.006) 1.07 (0.005) 0.02 
*Magnesium (mg/day) 
 
2.48 (0.006) 2.47 (0.005) 0.44 
*β-carotene (μg/day) 
 
3.24 (0.025) 3.25 (0.024) 0.64 
*N-3  (g/day) 
 
0.07 ( 0.196) 0.06 (0.167) 0.23 
*N-6 (g/day) 
 
1.00 (0.009) 1.01 (0.008) 0.59 
*n6:n3 
 
0.95 (0.006) 0.93 (0.007) 0.04 
Steamed /grilled fish (g/day) 
 
27.82 (1.90) 25.35 (1.66) 0.33 
Sea food (g/day) 
 
1.51 (0.15) 1.44 (0.13) 0.71 
*Pome fruits 
 
1.79 (0.02) 1.80 (0.01) 0.56 
Berry fruits 
 
7.02 (0.45) 8.33 (0.59) 0.09 
*Citrus fruits 
 
1.41 (0.022) 1.40 (0.019) 0.86 
*Stone fruits 
 
1.27 (0.025) 1.29 (0.021) 0.84 
*Tropical fruits 
 
1.57 (0.022) 1.62 (0.017) 0.098 
*Fruits combined (Pome, berry, 
citrus, stone)  
2.02 (0.019) 2.03 (0.016) 0.709 
*Mixture of 2 or more group of 
fruits 
1.25 (0.021) 1.27 (0.018) 0.457 
Dried/preserved fruit 
 
5.04 (0.61) 4.52 (0.46) 0.488 
*Fresh vegetables (g/day) 
 
1.86 (0.013) 1.85 (0.012) 0.754 
(*logarithmic value of nutrients). 
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Table 10: Adjusted and unadjusted odds ratio (OR) for the risk of atopy for different 
foods/nutrients. 
Food/Nutrient 
 
Crude OR 95% CI *Adjusted 
OR 
95% CI 
Vitamin A  
 
1.000 1.000,1.000 1.000 1.000,1.000 
Vitamin C  
 
1.000 0.999,1.001 0.999 0.998,1.001 
Vitamin E  
 
1.000 0.977,1.024 0.984 0.944,1.026 
Zinc  
 
**1.029 1.004,1.055 1.019 0.957,1.085 
Magnesium  
 
1.000 0.999,1.001 1.001 0.999,1.003 
β-carotene  
 
1.000 1.000,1.000 1.000 1.000,1.000 
N-3   
 
1.030 0.988,1.075 1.010 0.949,1.076 
N-6  
 
0.978 0.949,1.007 1.000 0.958,1.043 
n6:n3 
 
0.935 0.848,1.032 1.002 0.867,1.158 
Steamed /grilled 
fish  
 
1.001 0.999,1.003 1.001 0.998,1.004 
Sea food  
 
1.006 0.976,1.037 1.000 0.956,1.045 
Pome fruits 
 
1.000 0.999,1.001 0.999 0.997,1.000 
Berry fruits 
 
0.993 0.985,1.001 **0.988 0.976,0.999 
Citrus fruits 
 
1.000 0.998,1.002 0.999 0.996,1.001 
Stone fruits 
 
1.000 0.997,1.003 0.999 0.994,1.003 
Tropical fruits 
 
1.000 0.998,1.002 0.999 0.997,1.001 
Dried/preserved 
fruit 
 
1.003 0.995,1.011 0.999 0.989,1.009 
Fresh vegetables  
 
1.000 0.998,1.002 0.999 0.996,1.001 
*Odds ratio adjusted for age, sex, BMI and total energy intake. ** Statistically significant (p<0.05). 
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3.1.4.4 Association between daily nutrient/antioxidant and food 
intake and bronchial hyperresponsiveness. 
 
The association between daily nutrient/antioxidant and food intake and bronchial 
hyperresponsiveness is described in Table 11. There were no significant differences 
between mean dietary intakes of vitamins A, E, C, magnesium, zinc β-carotene, n-3, 
n-6 fatty acids, steamed/grilled fish, sea foods and different fruits and vegetables 
between those who were BHR positive compared to those who were BHR negative. 
 
The unadjusted level of n-3 fatty acid intake was showed protective effects against 
BHR (OR= 0.920, 95% CI= 0.868–0.974). However after adjusting for confounders 
(age, sex, BMI and total energy intake) this association was proved to be 
insignificant (OR= 0.933, 95% CI= 0.856–1.016) (Table 12). 
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Table 11: Daily nutrient/antioxidant intake for BHR positive and BHR negative, mean ±SEM 
(n=1479)  
Food/Nutrient 
 
BHR positive 
Mean (SEM) 
N=265 
BHR negative 
Mean (SEM) 
N=1214 
P-value 
*Vitamin A (µg/day) 3.04 (0.013) 3.05 (0.005) 0.714 
 
Vitamin C (mg/day) 191.78 (7.68) 187.27 (3.43) 0.585 
 
Vitamin E 
(mg/day) 
8.84 (0.315) 8.77 (0.135) 0.834 
Zinc (mg/day) 
 
12.53 (0.272) 12.94 (0.134) 0.200 
Magnesium (mg/day) 307.46 (7.139) 319.99 (3.469) 0.128 
 
β-carotene (μg/day) 
 
2419.11 (187.04) 2626.89 (107.50) 0.384 
N-3 (g/day) 
 
1.25 (0.036) 1.30 (0.02) 0.271 
N-6 (g/day) 
 
11.85 (0.457) 11.71 (0.184) 0.756 
n6:n3 
 
9.70 (0.260) 9.47 (0.106) 0.429 
Steamed /grilled fish (g/day) 
 
24.68 (2.64) 26.47 (1.42) 0.591 
Sea food (g/day) 
 
1.20 (0.19) 1.52 (0.11) 0.143 
*Pome fruit 
(g/day) 
1.78 (0.03) 1.79 (0.01) 0.632 
Berry fruit 
(g/day) 
7.13 (0.738) 8.19 (0.476) 0.333 
Citrus fruit 
(g/day) 
34.26 (3.54) 32.92 (1.69) 0.740 
Stone fruit 
(g/day) 
22.32 (1.98) 26.15 (1.12) 0.093 
*Tropical fruit 
(g/day) 
1.61 (0.03) 1.59 (0.01) 0.581 
Fruits combined  
(Pome, berry, citrus, stone) 
(g/day) 
149.93 (9.07) 150.82 (4.47) 0.933 
*Mixture of 2 or more group of 
fruits (g/day) 
1.24 (0.03) 1.27 (0.01) 0.391 
Dried/preserved fruit (g/day) 
 
3.95 (0.76) 4.99 (0.43) 0.297 
Fresh vegetables (g/day) 84.09 (3.47) 87.81 (1.75) 0.338 
 
(*logarithmic value of nutrients). 
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Table 12: Adjusted and unadjusted odds ratio (OR) for the risk of BHR for different 
foods/nutrients. 
Food/Nutrient 
 
Crude OR 95% CI *Adjusted 
OR 
95% CI 
Vitamin A  
 
1.000 1.000,1.000 1.000 0.999,1.000 
Vitamin C  
 
1.000 0.999,1.002 1.001 0.999,1.002 
Vitamin E  
 
1.003 0.973,1.035 1.037 0.983,1.093 
Zinc  
 
0.979 0.947,1.012 0.931 0.857,1.012 
Magnesium  
 
1.000 0.999,1.001 1.001 0.998,1.003 
β-carotene  
 
1.000 1.000,1.000 1.000 1.000,1.000 
N-3   
 
0.920 **0.868,0.974 0.933 0.856,1.016 
N-6  
 
0.999 0.961,1.039 0.973 0.922,1.028 
n6:n3 
 
1.133 1.000,1.283 1.035 0.852,1.257 
Steamed /grilled 
fish  
 
0.999 0.96,1.002 0.998 0.994,1.003 
Sea food  
 
0.970 0.926,1.017 0.951 0.887,1.021 
Pome fruits 
 
1.000 0.999,1.002 1.001 0.999,1.003 
Berry fruits 
 
0.995 0.984,1.006 0.994 0.979,1008 
Citrus fruits 
 
1.000 0.98,1.003 1.000 0.997,1.003 
Stone fruits 
 
0.997 0.992,1.001 0.995 0.989,1.001 
Tropical fruits 
 
1.000 0.998,1.002 1.000 0.998,1.003 
Dried/preserved 
fruit 
 
0.993 0.981,1.006 1.000 0.987,1.013 
Fresh vegetables  
 
0.999 0.996,1.001 1.001 0.997,1.004 
*Odds ratio adjusted for age, sex, BMI and total energy intake. ** Statistically significant (p<0.05). 
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3.1.5 The effects of antioxidants on number of times wheezed  
 
The effects of antioxidant intake on the number of times wheezed in the last 12 
months were investigated in the study adolescents (Table 13).  With the exception of 
berry fruits, there was no significant effect of fruit, vegetable and antioxidant intake 
on the number of times the child wheezed. 
 
The mean intake of berry fruits for adolescents who had wheezed between 3 to 12 
times within the last year was higher (10.08 g/day) compared to those who had 
wheezed more than 12 times in the last year (1.69 g/day) (p=0.025) (Table 13). This 
suggests that those adolescents who had wheezed the most in the last year had 
consumed 8.39 g/day less berry fruits compared with those who wheezed between 3 
to 12 times within the last year. 
 
The mean intake of berry fruits was higher (8.10 g/day) for adolescents who had not 
wheezed in the last 12 months compared to those who had wheezed more than 12 
times in the last year (p=0.053). This result was approaching significance. 
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Table 13: Analysis of variance of different antioxidants for number of times wheezed over the last 12 months (n=1531).  
Number of 
times 
wheezed in 
the last 12 
months 
N 
%(n) 
Mean 
vitamin A 
intake  
µg /day 
(±SEM) 
 
 
Mean 
vitamin C 
intake 
mg/day 
(±SEM) 
 
 
Mean 
magnesium 
intake  
mg/day 
(±SEM) 
 
 
Mean 
zinc 
intake 
mg/day 
(±SEM) 
 
 
Mean of 
berry fruits 
intake 
g/day 
(±SEM) 
 
Mean of 
citrus 
fruits 
intake 
g/day 
(±SEM) 
 
Mean of  
pome fruits 
intake 
g/day 
(±SEM) 
 
Mean of  
stone fruits 
intake 
g/day 
(±SEM) 
 
Mean of  
tropical 
fruits 
intake 
g/day 
(±SEM) 
 
Mean of  
combined 
fruits g/day 
(±SEM) 
 
 
Mean of 
combined 
vegetables 
fruits g/day 
(±SEM) 
 
Mean  
β – 
carotene 
intake 
µg/day 
(±SEM) 
 
A 
None 
1315 
(85.9%) 
 
1232.78 
 
(16.71) 
 
192.86 
 
(3.10) 
 
319.63 
 
(3.03) 
 
12.86 
 
(0.12) 
 
8.10 
 
(0.38) 
 
34.72 
 
(1.51) 
 
84.01 
 
(2.45) 
 
26.38 
 
(1.06) 
 
59.11 
 
(1.87) 
 
153.21 
 
(3.96) 
 
88.18 
 
(1.57) 
 
2556.85 
 
(94.06) 
 
B 
1-2 
129   
 
 (8.5%) 
 
1284.97 
 
(64.19) 
 
186.40 
 
(11.53) 
 
315.45 
 
(10.04) 
 
12.85 
 
(0.38) 
 
6.69 
 
(1.81) 
 
30.46 
 
(4.48) 
 
84.75 
 
(7.75) 
 
22.41 
 
(2.89) 
 
52.23 
 
(5.09) 
 
144.31 
 
(11.15) 
 
87.72 
 
(4.11) 
 
2647.37 
 
(307.91) 
 
C 
3-12 
67  
(4.4%)  
 
1344.16 
 
(125.95) 
 
190.59 
 
(13.85) 
 
331.78 
 
(15.37) 
 
13.58 
 
(0.62) 
 
10.08 
 
(2.26) 
 
29.79 
 
(6.06) 
 
83.41 
 
(11.04) 
 
27.79 
 
(4.31) 
 
58.39 
 
(6.91) 
 
151.06 
 
(17.63) 
 
91.02 
 
(7.78) 
 
2438.04 
 
(375.52) 
 
 
D 
>12 
20 
(1.3%)  
 
1156.62 
 
(143.05) 
 
169.20 
 
(18.84) 
 
305.23 
 
(19.05) 
 
12.76 
 
(0.84) 
 
1.69 
 
(0.66) 
 
48.47 
 
(13.27) 
 
80.24 
 
(15.25) 
 
23.07 
 
(7.53) 
 
43.28 
 
(9.01) 
 
153.47 
 
(24.89) 
 
87.87 
 
(12.45) 
 
3143.33 
 
(931.45) 
 
 
 
 
 
p-value 
 
 
0.387 (A,B) 
0.164 (A,C) 
0.599 (A,D) 
0.542 (B,C) 
0.407 (B,D) 
0.252 (C,D) 
 
0.547 (A,B)  
0.873 (A,C) 
0.357 (A,D) 
0.808 (B,C) 
0.531 (B,D) 
0.461 (C,D) 
 
 
0.689 (A,B)  
0.380 (A,C) 
0.565 (A,D) 
0.331(B,C) 
0.703 (B,D) 
0.348 (C,D) 
 
 
 
0.996 (A,B)  
0.176 (A,C) 
0.924 (A,D) 
0.264 (B,C) 
0.930 (B,D) 
0.455 (C,D) 
 
 
0.305 (A,B)  
0.280 (A,C) 
0.053 (A,D) 
0.127 (B,C) 
0.158 (B,D) 
0.025 (C,D) 
 
0.409 (A,B)  
0.471 (A,C) 
0.266 (A,D) 
0.933 (B,C) 
0.173 (B,D) 
0.181 (C,D) 
 
0.930 (A,B) 
0.956 (A,C) 
0.850 (A,D) 
0.921 (B,C) 
0.833 (B,D) 
0.889 (C,D) 
 
0.266 (A,B) 
0.766 (A,C) 
0.699 (A,D) 
0.349 (B,C) 
0.943 (B,D) 
0.625 (C,D) 
 
0.272 (A,B) 
0.931 (A,C) 
0.291 (A,D) 
0.541 (B,C) 
0.576 (B,D) 
0.372 (C,D) 
 
 
0.505 (A,B) 
0.904 (A,C) 
0.994 (A,D) 
0.754 (B,C) 
0.789 (B,D) 
0.947 (C,D) 
 
0.931 (A,B) 
0.687 (A,C) 
0.980 (A,D) 
0.700 (B,C) 
0.991 (B,D) 
0.827 (C,D) 
 
0.774 (A,B) 
0.781 (A,C) 
0.362 (A,D) 
0.684 (B,C) 
0.481 (B,D) 
0.354 (C,D) 
 
 
Fisher’s LSD p-value was used to compare between the two groups means after ANOVA was performed 
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3.1.6 The relationship of RBC membrane fatty acids with the 
incidence of wheezing 
 
The effects of RBC membrane fatty acids on number of times wheezed is shown in 
Table 14. 
 
Analysing the effects of RBC fatty acids: linoleic acid, alpha-linolenic acid, parinaric 
acid, arachidonic acid, eicosapentaenoic acid, docosatetraenoic acid, 
docosapentaenoic acid, docosahexaenoic acid, total n-3, total n-6 and the ratio of 
n6:n3, on the number of times wheezed in the last 12 months showed that none of the 
n-6 fatty acids were associated with wheeze. However, significant associations 
between total n-3 fatty acids and wheezing were observed.  
 
The mean level of α-linolenic acid (18:3n3) was equal for adolescents who had 1-2 
episodes of wheezing and those who had 3-12 episodes within the last 12 months 
(0.21 mmol/L). This level was also very similar for with those with no wheeze (0.22 
mmol/L). However, α-linolenic acid was approximately twice as much in those who 
had more than 12 wheezing episodes of wheezing in the last 12 months (0.41 
mmol/L). Therefore, there were significant differences in the α-linolenic acid levels 
in the group with more than 12 wheezing episodes compared with the other 3 groups 
(Table 14).  
 
The level of docosapentaenoic acid (22:5n3) was significantly higher for those 
adolescents with highest episodes of wheezing compared to those who did not 
wheeze in the last year (p=0.035) 
 
The mean level of total n-3 fatty acids was overall significantly higher for those with 
the highest number of wheeze episodes compared to those with no wheeze (Table 
14). 
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After performing regression analysis and adjusting for potential confounders (BMI, 
age, gender and total daily energy intake) none of the fatty acids were shown to be a 
predictor for wheezing (data not shown). 
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Table 14: Analysis of variance of the mean red blood cell membrane fatty acids for the number of times wheezed over the last 12 months (n=1531). 
Number of 
times 
wheezed in 
the last 12 
months 
N 
%(n) 
18:3n3 
Alpha-
linolenic acid   
mmol/L 
(ALA) 
(±SEM) 
18:4n3 
Parinaric 
acid mmol/L 
 (±SEM) 
20:5n3 
Eicosapentae
noic acid 
mmol/L 
  (EPA) 
(±SEM) 
22:5n3 
Docosapent
aenoic acid 
mmol/L 
 (DPA) 
(±SEM) 
22:6n3 
Docosahexa
enoic acid 
mmol/L 
  (DHA) 
(±SEM) 
18:2n6 
Linoleic acid 
mmol/L 
(±SEM) 
20:4n6 
Arachidonic 
acid (AA) 
mmol/L 
 (±SEM) 
22:4n6 
Docosatetra
enoic acid 
mmol/L 
 (±SEM) 
Total n-3 
fatty 
acids 
mmol/L 
(±SEM) 
Total n-6 
fatty 
acids 
mmol/L 
(±SEM) 
 
 
Ratio n6:n3 
fatty 
acids 
(±SEM) 
A 
None 
1315 
(85.9%) 
 
0.22 
 
(0.007) 
 
0.53 
 
(0.01) 
 
0.71 
 
(0.006) 
 
4.29 
 
(0.06) 
 
4.31 
 
(0.03) 
 
10.08 
 
(0.04) 
 
13.48 
 
(0.06) 
 
1.59 
 
(0.06) 
 
10.07 
 
(0.08) 
 
30.03 
 
(0.11) 
 
3.23 
 
(0.03) 
B 
1-2 
129   
 
 (8.5%) 
 
0.21 
 
(0.19) 
 
0.54 
 
(0.03) 
 
0.71 
 
(0.019) 
 
4.61 
 
(0.20) 
 
4.14 
 
(0.09) 
 
10.12 
 
(0.11) 
 
13.53 
 
(0.21) 
 
1.49 
 
(0.19) 
 
10.21 
 
(0.22) 
 
30.00 
 
(0.36) 
 
3.12 
 
(0.09) 
C 
3-12 
67  
(4.4%)  
 
0.21 
 
(0.02) 
 
0.53 
 
(0.03) 
 
0.69 
 
(0.02) 
 
4.77 
 
(0.31) 
 
4.28 
 
(0.15) 
 
9.91 
 
(0.18) 
 
13.00 
 
(0.27) 
 
1.84 
 
(0.28) 
 
10.49 
 
(0.39) 
 
29.45 
 
(0.47) 
 
3.11 
 
(0.15) 
D 
>12 
20 
(1.3%)  
 
0.41 
 
(0.007) 
 
0.63 
 
(0.40) 
 
0.69 
 
(0.04) 
 
5.37 
 
(0.58) 
 
4.26 
 
(0.25) 
 
9.63 
 
(0.45) 
 
13.14 
 
(0.57) 
 
1.05 
 
(0.30) 
 
11.36 
 
(0.73) 
 
28.57 
 
(1.13) 
 
2.74 
 
(0.25) 
 
 
p-value 
 
 
0.545 (A,B) 
0.778 (A,C) 
0.002 (A,D) 
0.879 (B,C) 
0.001 (B,D) 
0.003 (C,D) 
 
0851 (A,B) 
0.898 (A,C) 
0.316 (A,D) 
0.823 (B,C) 
0.392 (B,D) 
0.343 (C,D) 
 
 
0.807 (A,B) 
0.470 (A,C) 
0.666 (A,D) 
0.663 (B,C) 
0.762 (B,D) 
0.982 (C,D) 
 
0.154 (A,B) 
0.097 (A,C) 
0.035 (A,D) 
0.649 (B,C) 
0.167 (B,D) 
0.300 (C,D) 
 
0.127 (A,B) 
0.853 (A,C) 
0.834 (A,D) 
0.416 (B,C) 
0.416 (B,D) 
0.926 (C,D) 
 
0.749 (A,B) 
0.296 (A,C) 
0.111(A,D) 
0.292 (B,C) 
0.107 (B,D) 
0.352 (C,D) 
 
 
0.812 (A,B) 
0.099 (A,C) 
0.506 (A,D) 
0.135 (B,C) 
0.475 (B,D) 
0.817 (C,D) 
 
0.665 (A,B) 
0.349 (A,C) 
0.259 (A,D) 
0.299 (B,C) 
0.382 (B,D) 
0.144 (C,D) 
 
0.617 (A,B) 
0.230 (A,C) 
0.036 (A,D) 
0506 (B,C) 
0.080 (B,D) 
0.209 (C,D) 
 
0.947 (A,B) 
0.235 (A,C) 
0.093 (A,D) 
0.354 (B,C) 
0.125 (B,D) 
0.370 (C,D) 
 
0.319 (A,B) 
0.415 (A,C) 
0.060 (A,D) 
0.971 (B,C) 
0.178 (B,D) 
0.208 (C,D) 
 
Fisher’s LSD p-value was used to compare between the two groups means after ANOVA was performed 
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3.1.7 The effects of RBC fatty acids on asthmatic and atopic 
outcomes 
 
A skin-prick test (SPT) was performed to determine the presence of atopic dermatitis 
in 1518 fourteen year old adolescents. The effects of different RBC fatty acids 
(linoleic, α-linolenic, parinaric, arachidonic, eicosapentaenoic acids and 
docosatetraenoic) were examined on asthmatic and atopic outcomes. These effects 
are described below and demonstrated in Tables 15-22. The graph within these 
Tables depicts the relationship between the cut points (mmol/L) and the quintiles for 
the corresponding fatty acid. 
 
3.1.7.1 The effects of RBC α-linolenic acid (18:3n3) on asthmatic 
and atopic outcomes 
 
The effects of RBC α -linolenic acid on asthmatic and atopic outcomes are described 
in Table 10.  In the atopy positive group (n=584) there was a significant difference 
between each quintile as indicated by the Pearson chi (p=0.043) and there were more 
atopy positive adolescents in the fourth highest α –linolenic acid quintile. No 
associations were found between the other outcomes (current asthma, current 
wheeze, BHR) and the level of α -linolenic acid in RBC.  
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Table 15: Asthmatic and atopic outcome by quintile of alpha-linolenic acid (ALA) 18:3 n3 as 
measured in red blood cells. 
Alpha-linolenic acid (ALA) 18:3 n3 
  Lowest  Middle  Highest 
0
0.5
1
1.5
2
2.5
3
3.5
4
1 2 3 4 5
ALA Quintiles
C
u
t 
p
o
in
ts
 m
m
o
l/
L
 
Quintile Total 
number 
1 2 3 4 5 
Cut-points 
Range 
mmol/L 
 
 0.00 
0.1300 
0.1301 
0.1600 
0.1601 
0.1900 
0.1901 
0.2300 
0.2301 
3.360 
Outcome 
 
Current asthma 
n 140 37 28 17 27 31 Pearson chi 
square 
Trend 
p-value 
Outcome 
within 
quintile (as 
%) 
 
10.6 
 
12.3 
 
9.5 
 
6.9 
 
12.8 
 
11.7 
 
0.181 
 
0.821 
Outcome 
 
Current wheeze 
n 179 42 40 22 36 39  
Outcome 
within 
quintile (as 
%) 
 
13.6 
 
14.0 
 
13.5 
 
8.9 
 
17.1 
 
14.7 
 
0.135 
 
0.529 
Outcome Atopy 
n 584 130 137 94 111 112  
Outcome 
within 
quintile (as 
%) 
 
44.00 
 
41.9 
 
46.4 
 
38.5 
 
51.9 
 
42.4 
 
0.043 
 
0.589 
Outcome BHR 
n 226 58 51 41 39 37  
Outcome 
within 
quintile (as 
%) 
 
17.8 
 
19.9 
 
18.1 
 
17.6 
 
19.0 
 
14.2 
 
0.488 
 
0.137 
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3.1.7.2 The effects of RBC parinaric acid (18:4n3) on asthmatic 
and atopic outcomes  
 
The effects of RBC parinaric acid on asthmatic and atopic outcomes are described in 
Table 16. In the atopy positive group (n=584) there was a significant difference 
between each quintile (p= 0.016) and there were more atopy positive adolescents in 
the third and fourth parinaric acid intake groups.  There were no associations 
between current asthma, current wheeze, and BHR outcomes and the level of 
parinaric acid in RBC. 
 
Table 16: Asthmatic and atopic outcome by quintile of parinaric acid 18:4 n3 as measured in 
red blood cells. 
Parinaric acid 18:4 n3 
  Lowest  Middle  Highest 
0
1
2
3
4
5
6
7
8
9
1 2 3 4 5
Quintiles
C
u
tp
o
in
ts
 m
m
o
l/
L
 
Quintile Total 
number 
1 2 3 4 5 
Cut-points 
Range 
mmol/L 
 0.00 
0.2000 
0.2001 
0.5300 
0.5301 
0.6000 
0.6001 
0.6700 
0.6701 
8.5400 
Outcome Current asthma 
n 140 25 26 27 33 29 Pearson chi square Trend 
p-value 
Outcome 
within 
quintile (as 
%) 
 
10.6 
 
9.9 
 
8.8 
 
10.3 
 
13.0 
 
11.3 
 
0.568 
 
0.229 
Outcome Current wheeze 
n 179 32 35 34 40 38  
Outcome 
within 
quintile (as 
%) 
 
13.6 
 
12.7 
 
11.8 
 
13.0 
 
15.8 
 
14.8 
 
0.650 
 
0.209 
Outcome Atopy 
n 584 105 139 124 123 93  
Outcome 
within 
quintile (as 
%) 
 
44.0 
 
40.4 
 
47.0 
 
48.1 
 
48.0 
 
36.2 
 
0.016 
 
0.437 
Outcome BHR 
n 226 40 49 40 52 45  
Outcome 
within 
quintile (as 
%) 
 
17.8 
 
16.4 
 
17.5 
 
16.1 
 
20.9 
 
17.9 
 
0.655 
 
0.403 
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3.1.7.3 The effects of RBC eicosapentaenoic acid (20:5n3) on 
asthmatic and atopic outcomes  
 
The effects of RBC eicosapentaenoic acid on asthmatic and atopic outcomes are 
described in Table 17. BHR was shown to be strongly associated with the level of 
eicosapentaenoic acid in RBC p=0.007. Eicosapentaenoic acid levels in RBC did not 
show any effects on current asthma, current wheeze and atopy. 
 
Table 17: Asthmatic and atopic outcome by quintile of eicosapentaenoic acid 20:5 n3 as 
measured in red blood cells. 
Eicosapentaenoic acid 20:5 n3 
  Lowest  Middle  Highest 
0
0.5
1
1.5
2
2.5
1 2 3 4 5
Quintiles
Cu
tp
oi
nt
s 
m
m
ol
/L
 
Quintile Total 
number 
1 2 3 4 5 
Cut-points 
Range 
mmol/L 
0.00 
0.56 
 
0.57 
0.67 
0.68 
0.75 
 
0.76 
0.85 
0.86 
1.91 
Outcome Current asthma 
n 140 33 32 21 32 22 Pearson chi square Trend 
p-value 
Outcome 
within 
quintile (as 
%) 
 
10.6 
 
12.00 
 
11.9 
 
8.2 
 
12.1 
 
8.7 
 
0.388 
 
0.289 
Outcome Current wheeze 
n 179 38 43 29 41 28  
Outcome 
within 
quintile (as 
%) 
 
13.6 
 
13.8 
 
15.9 
 
11.3 
 
15.5 
 
11.1 
 
0.336 
 
0.384 
Outcome Atopy 
n 584 126 121 112 117 108  
Outcome 
within 
quintile (as 
%) 
 
44.0 
 
44.8 
 
45.0 
 
44.1 
 
44.3 
 
41.7 
 
0.945 
 
0.474 
Outcome BHR 
n 226 55 29 38 50 54  
Outcome 
within 
quintile (as 
%) 
 
17.8 
 
22.2 
 
11.1 
 
15.5 
 
19.5 
 
20.6 
 
0.007 
 
0.141 
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3.1.7.4 The effects of RBC docosapentaenoic acid (22:5n3) on 
asthmatic and atopic outcomes  
 
The effects of RBC docosapentaenoic acid on asthmatic and atopic outcomes are 
shown in Table 18. There were significant differences between current asthma, 
current wheeze and BHR and the lowest and the highest of the quintiles of red blood 
cell levels of docosapentaenoic acid. For adolescents with current asthma, the lowest 
quintile of docosapentaenoic acid had 8.2% of the sample population while the 
highest quintile consisted of 12.7% of the group (p=0.106, trend p-value 0.013) 
(Table 18). For current wheeze positive cases, the lowest quintile of 
docosapentaenoic acid had 10.9% while the highest quintile consisted of 17.2% of 
the cases (p=0.166, trend p-value 0.014).  
 
Within the bronchial hyperresponsiveness (BHR) positive cases 19.2%  were in the 
lowest quintile of  RBC docosapentaenoic acid levels, while the highest quintile 
included only 15.2% of the cases (p=0.90, trend p-value 0.029).  
 
92 
Table 18: Asthmatic and atopic outcome by quintile of docosapentaenoic acid (DPA) 22:5 n3 as 
measured in red blood cells. 
Docosapentaenoic acid (DPA) 22:5 n3 
  Lowest  Middle  Highest 
0
2
4
6
8
10
12
1 2 3 4 5
Quintiles
C
u
tp
o
in
ts
 m
m
o
l/
L
 
Quintile Total 
number 
1 2 3 4 5 
Cut-points 
Range 
mmol/L 
 
 0.29 
2.48 
2.49 
2.81 
2.82 
4.73 
4.74 
6.81 
6.82 
11.17 
Outcome 
 
Current asthma 
n 140 21 20 29 36 34 Pearson chi square Trend 
p-value 
Outcome 
within 
quintile (as 
%) 
 
10.6 
 
8.2 
 
7.5 
 
11.1 
 
13.3 
 
12.7 
 
0.106 
 
0.013 
Outcome 
 
Current wheeze 
n 179 28 29 36 40 46  
Outcome 
within 
quintile (as 
%) 
 
13.6 
 
10.9 
 
10.9 
 
13.8 
 
14.8 
 
17.2 
 
0.166 
 
0.014 
Outcome Atopy 
n 584 113 112 109 128 122  
Outcome 
within 
quintile (as 
%) 
 
44.0 
 
43.5 
 
42.3 
 
40.8 
 
47.4 
 
46.0 
 
0.530 
 
0.282 
Outcome BHR 
n 226 46 59 44 38 39  
Outcome 
within 
quintile (as 
%) 
 
17.8 
 
19.2 
 
22.8 
 
17.5 
 
17.4 
 
15.2 
 
0.900 
 
0.029 
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3.1.7.5 The effects of RBC docosahexaenoic acid (22:6n3) on 
asthmatic and atopic outcomes  
 
The effects of RBC docosahexaenoic acid on asthmatic and atopic outcomes are 
shown in Table 19. RBC docosahexaenoic acid level showed significant differences 
between BHR positive and the lowest and the highest of the quintiles. For 
adolescents who were BHR positive, the lowest quintile of RBC docosahexaenoic 
acid level contained 20.9% of the group, while the highest quintile consisted of only 
14.8% of the BHR positive group (p=0.242, trend p-value 0.036).  
 
Table 19: Asthmatic and atopic outcome by quintile of docosahexaenoic acid (DHA) 22:6 n3 as 
measured in red blood cells. 
Docosahexaenoic acid (DHA) 22:6 n3 
  Lowest  Middle  Highest 
0
2
4
6
8
10
12
1 2 3 4 5
Quintiles
C
u
tp
o
in
ts
 m
m
o
l/L
 
Quintile Total 
number 
1 2 3 4 5 
Cut-
points 
Range 
mmol/L 
 
 0.69 
3.53 
3.54 
4.06 
4.07 
4.47 
4.48 
5.05 
5.06 
9.91 
Outcome Current asthma 
n 140 30 30 26 27 27 Pearson chi square Trend 
p-value 
Outcome 
within 
quintile 
(as %) 
 
10.6 
 
11.3 
 
11.5 
 
9.8 
 
10.3 
 
10.2 
 
0.963 
 
0.584 
Outcome Current wheeze 
n 179 37 39 39 34 30  
Outcome 
within 
quintile 
(as %) 
 
13.6 
 
20.7 
 
21.8 
 
21.8 
 
19.0 
 
16.8 
 
0.756 
 
0.291 
Outcome Atopy 
n 584 123 115 98 119 129  
Outcome 
within 
quintile 
(as %) 
 
44 
 
45.6 
 
43.4 
 
37.3 
 
45.4 
 
48.3 
 
0.117 
 
0.437 
Outcome BHR 
n 226 55 51 40 42 38  
Outcome 
within 
quintile 
(as %) 
 
17.8 
 
20.9 
 
20.5 
 
15.7 
 
16.9 
 
14.8 
 
0.242 
 
0.036 
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3.1.7.6 The effects of RBC linoleic acid on asthmatic (18:2n6) and 
atopic outcomes 
 
The effects of RBC linoleic acid in quintiles, on asthmatic and atopic outcomes are 
shown in Table 20. The RBC level of linoleic acid was divided into quintiles and the 
proportion of the sample which showed the outcome of interest was recorded for 
each quintile. No significant trend was found between the lowest and the highest 
quintiles of linoleic acid levels and any of the asthmatic and allergic outcomes. 
Interestingly if the lowest quintile was ignored there was a weak trend in the 
increasing of the proportion of each quintile with increasing the level of linoleic acid 
for atopy (Table 15). 
Table 20: Asthmatic and atopic outcome by quintile of linoleic acid (LA) 18:2 n6 as measured in 
red blood cells. 
Linoleic acid (LA) 18:2 n6 
  Lowest  Middle  Highest 
0
2
4
6
8
10
12
14
16
1 2 3 4 5
Quintiles
C
u
tp
o
in
t 
m
m
o
l/
L
 
Quintile Total 
number 
1 2 3 4 5 
Cut-points 
Range 
mmol/L 
 
 0.00 
9.2100 
9.2101 
9.8500 
9.8501 
10.3500 
10.3501 
11.0020 
11.0021 
14.6100 
Outcome Current asthma 
n 140 32 26 27 25 30 Pearson chi 
square 
Trend 
p-value 
Outcome 
within 
quintile (as 
%) 
 
10.6 
 
12.0 
 
9.7 
 
10.7 
 
9.5 
 
11.2 
 
0.872 
 
0.774 
Outcome Current wheeze 
n 179 44 34 32 32 37  
Outcome 
within 
quintile (as 
%) 
 
13.6 
 
16.5 
 
12.7 
 
12.6 
 
12.1 
 
13.9 
 
0.595 
 
0.382 
Outcome Atopy 
n 584 117 103 118 122 124  
Outcome 
within 
quintile (as 
%) 
 
44.0 
 
42.4 
 
38.9 
 
45.9 
 
46.4 
 
46.6 
 
0.303 
 
0.098 
Outcome BHR 
n 226 48 40 39 44 55  
Outcome 
within 
quintile (as 
%) 
 
17.8 
 
18.1 
 
15.8 
 
15.9 
 
17.2 
 
21.7 
 
0.399 
 
0.263 
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3.1.7.7 The effects of RBC arachidonic acid (20:4n6) on asthmatic 
and atopic outcomes  
 
The effects of RBC arachidonic acid on asthmatic and atopic outcomes are described 
in Table 21. There was no evidence to suggest any associations between the level of 
arachidonic acid in RBC and any of the outcomes of interest.  
 
Table 21: Asthmatic and atopic outcome by quintile of arachidonic acid (AA) 20:4n6 as 
measured in red blood cells. 
Arachidonic acid (AA) 20:4n6 
  Lowest  Middle  Highest 
0
0.5
1
1.5
2
2.5
1 2 3 4 5
Quintile
A
ra
ch
id
on
ic
 a
ci
d 
cu
t-
po
in
ts
 
Quintile Total 
number 
1 2 3 4 5 
Cut-
points 
Range 
mmol/L 
 0.00 
0.56 
0.57 
0.67 
0.68 
0.75 
0.76 
0.85 
0.86 
1.91 
Outcome Current asthma 
n 140 36 25 30 24 25 Pearson chi square Trend 
p-value 
Outcome 
within 
quintile 
(as %) 
 
10.6 
 
13.6 
 
9.5 
 
11.5 
 
9.1 
 
9.4 
 
0.383 
 
0.138 
Outcome Current wheeze 
n 179 44 34 33 34 34  
Outcome 
within 
quintile 
(as %) 
 
13.6 
 
16.7 
 
12.9 
 
12.6 
 
12.9 
 
12.7 
 
0.608 
 
0.241 
Outcome Atopy 
n 584 127 118 117 111 111  
Outcome 
within 
quintile 
(as %) 
 
44.0 
 
47.4 
 
44.4 
 
45.0 
 
41.3 
 
42.0 
 
0.628 
 
0.151 
Outcome BHR 
n 226 48 52 43 34 49  
Outcome 
within 
quintile 
(as %) 
 
17.8 
 
18.3 
 
20.2 
 
17.3 
 
13.41 
 
19.6 
 
0.295 
 
0.575 
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3.1.7.8 The effects of RBC docosatetraenoic acid (22:4n6) on 
asthmatic and atopic outcomes 
 
The effects of RBC docosatetraenoic acid on asthmatic and atopic outcomes are 
shown in Table 22. There was no evidence to suggest any associations between the 
level of docosatetraenoic acid in RBC and any of the outcomes of interest. 
 
Table 22: Asthmatic and atopic outcome by quintile of docosatetraenoic acid 22:4 n6 as 
measured in red blood cells. 
Docosatetraenoic acid 22:4 n6 
  Lowest  Middle  Highest 
0
1
2
3
4
5
6
7
8
9
1 2 3 4 5
Quintiles
C
u
tp
o
in
ts
 m
m
o
l/L
 
Quintile Total 
number 
1 2 3 4 5 
Cut-points 
Range 
mmol/L 
 0.00 
0.51 
0.52 
0.63 
0.64 
0.72 
0.73 
3.28 
3.29 
8.21 
Outcome Current asthma 
n 140 26 32 35 22 25 Pearson chi square Trend 
p-value 
Outcome 
within 
quintile 
(as %) 
 
10.6 
 
9.8 
 
11.2 
 
13.7 
 
8.6 
 
9.8 
 
0.373 
 
0.662 
Outcome Current wheeze 
n 179 33 42 42 29 33  
Outcome 
within 
quintile 
(as %) 
 
13.6 
 
12.4 
 
14.7 
 
16.5 
 
11.3 
 
12.9 
 
0.446 
 
0.712 
Outcome Atopy 
n 584 113 133 121 120 97  
Outcome 
within 
quintile 
(as %) 
 
44.0 
 
42.8 
 
46.5 
 
47.1 
 
46.9 
 
36.7 
 
0.079 
 
0.214 
Outcome BHR 
n 226 52 45 47 34 48  
Outcome 
within 
quintile 
(as %) 
 
17.8 
 
20.2 
 
16.4 
 
19.3 
 
13.5 
 
19.5 
 
0.253 
 
0.568 
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3.1.8 Comparison of RBC membrane fatty acid content in 
wheezers and non-wheezers 
 
The level of different fatty acids in RBC for wheezers versus non-wheezers was 
compared in adolescents (Table 23). It was found that the concentration of 
docosatetraenoic acid (22:4n6) was significantly lower for wheezers (4.987 mmol/L) 
compared with non-wheezers (5.056 mmol/L) (p=0.047). No other fatty acids, total 
n-3 fatty acids, total n-6 fatty acids and the ratio of n6:n3 showed significant effects 
on wheezing.  
 
The unadjusted level of docosapentaenoic acid (22:5n3) was shown to have 
detrimental effects against wheezing (OR= 1.096, 95% CI= 1.020–1.178). However 
after adjusting for confounders (age, sex, BMI and total energy intake) this 
association was proved to be insignificant (OR= 1.077, 95% CI= 0.966–1.200) 
(Table 24). 
 
The adjusted ratio of n6:n3 was shown to have detrimental association on wheezing 
episodes (OR= 1.064, 95% CI= 1.007–1.124). Therefore, while controlling for 
potential confounders, for every 1 unit increased in the ratio of n6:n3 there was a 
6.4% increase in the risk of having wheezing episodes. 
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Table 23: Red blood cell Fatty acids levels for wheezers and non-wheezers mean (SEM) using T-
tests.  
Red blood cell 
fatty acids 
Wheezers  
(Mean ±SEM) 
(mmol/L) 
Non-wheezers 
(Mean ±SEM) 
(mmol/L) 
P-value 
18:2n6 
Linoleic acid  
9.928 (0.806) 9.965 (0.032) 0.661 
18:3n3  
Alpha-linolenic 
acid (ALA)   
0.224 (0.019) 0.206 (0.005) 0.137 
18:4n3 
Parinaric acid  
0.618 (0.015) 0.617 (0.006) 0.507 
20:4n6 
Arachidonic acid 
(AA) 
13.274 (0.142)  13.313 (0.062) 0.911 
20:5n3  
Eicosapentaenoic 
acid (EPA) 
0.697 (0.013) 0.696 (0.006) 0.248 
22:4n6 
Docosatetraenoic 
acid 
4.987 (0.083) 5.056 (0.030) 0.047 
22:5n3 
Docosapentaenoic 
acid (DPA) 
2.370 (0.031) 2.389  (0.013) 0.439 
22:6n3 
Docosahexaenoic 
acid (DHA) 
4.143  (0.071) 4.206(0.029) 0.759 
n-3 8.053 (0.093) 8.113 (0.038) 0.993 
n-6 32.923 (0.186) 33.084 (0.081) 0.772 
n6:n3 4.147 (0.059) 4.150 (0.025) 0.738 
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Table 24: Odds ratio (OR) for the risk of current wheeze in red blood cell Fatty acids 
Red blood cell 
fatty acids 
Crude OR 95% CI *Adjusted 
OR 
95% CI 
18:2n6 
Linoleic acid  
0.947 0.832,1.076 1.006 0.836,1.211 
18:3n3  
Alpha-
linolenic acid 
(ALA)   
1.118 0.617,2.024 1.377 0.607,3.121 
18:4n3 
Parinaric acid  
1.047 0.719,1.524 0.852 0.387,1.877 
20:4n6 
Arachidonic 
acid (AA) 
0.968 0.902,1.038 0.990 0.895,1.095 
20:5n3  
Eicosapentaen
oic acid (EPA) 
0.768 0.359,1.639 0.695 0.226,2.134 
22:4n6 
Docosatetraen
oic acid 
0.993 0.917,1.075 0.980 0.870,1.105 
22:5n3 
Docosapentaen
oic acid (DPA) 
**1.096 1.020,1.178 1.077 0.966,1.200 
22:6n3 
Docosahexaen
oic acid 
(DHA) 
0.910 0.784,1.055 0.908 0.738,1.116 
n-3 1.092 0.874,1.364 0.987 0.672,1.451 
n-6 1.018 0.994,1.041 1.030 0.992,1.069 
n6:n3 1.036 0.994,1.080 **1.064 1.007,1.124 
*Data are presented as odds ratio (OR) (95% confidence interval). OR are adjusted for the following 
confounders: Age, sex, BMI and total energy intake. **Statistically significant (p< 0.05). 
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3.1.9 Comparison of RBC membrane fatty acid content in 
asthmatic and non-asthmatic adolescents 
 
The mean level of RBC fatty acid was compared between asthmatic and non-
asthmatic adolescents (Table 25). No significant differences in the concentration of 
fatty acids between the asthmatic and non-asthmatic adolescents were found.  
 
The unadjusted level of docosapentaenoic acid (22:5n3) was shown to have 
detrimental effects on asthma (OR= 1.112, 95% CI= 1.027–1.204) (Table 25). 
However after adjusting for confounders (age, sex, BMI and total energy intake) this 
association was proved to be insignificant (OR= 1.103, 95% CI= 0.980–1.241) 
(Table 26). 
 
The adjusted ratio of n6:n3 was shown to have a detrimental association with asthma 
(OR= 1.072, 95% CI= 1.009–1.139). Therefore, while controlling for potential 
confounders, for every 1 level increased in the ratio of n6:n3 there was a 7.2% 
increase in risk of developing asthma. 
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Table 25: Red blood cell fatty acids levels for asthma and non-asthma cases mean (SEM) using 
T-tests.  
Red blood cell 
fatty acid 
Current asthma 
(Mean ± SEM) 
(mmol/L) 
Non-asthma 
(Mean ± SEM) 
(mmol/L) 
P-value 
18:3n3  
Alpha-linolenic 
acid (ALA) 
0.216 (0.025) 0.199 (0.069) 0.446 
18:4n3 
Parinaric acid  
0.601 (0.017) 0.622 (0.009) 0.669 
20:5n3  
Eicosapentaenoic 
acid (EPA) 
0.721 (0.023) 0.689 (0.007) 0.904 
22:5n3 
Docosapentaenoic 
acid (DPA) 
2.333 (0.042) 2.385 (0.016) 0.190 
22:6n3 
Docosahexaenoic 
acid (DHA) 
4.178 (0.112) 4.218 (0.038) 0.926 
18:2n6 
Linoleic acid  
9.857 (0.128) 9.970 (0.040) 0.326 
20:4n6 
Arachidonic acid 
(AA) 
13.575 (0.246) 13.289 (0.085) 0.735 
22:4n6 
Docosatetraenoic 
acid 
4.975 (0.143) 5.045 (0.042) 0.128 
n-3 8.049 (0.137) 8.114 (0.050) 0.829 
n-6 33.151 (0.295) 33.012 (0.113) 0.639 
n6:n3 4.189 (0.065) 4.145 (0.024) 0.651 
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Table 26: Odds ratio (OR) for the risk of current asthma in red blood cell Fatty acids 
Red blood cell 
fatty acids 
Crude OR 95% CI *Adjusted 
OR 
95% CI 
18:2n6 
Linoleic acid  
0.976 0.845,1.128 1.018 0.831,1.246 
18:3n3  
Alpha-
linolenic acid 
(ALA)   
1.197 0.637,2.248 1.393 0.583,3.329 
18:4n3 
Parinaric acid  
1.019 0.63,1.566 0.862 0.363,2.044 
20:4n6 
Arachidonic 
acid (AA) 
0.961 0.890,1.038 0.950 0.855,1.054 
20:5n3  
Eicosapentaen
oic acid (EPA) 
0.645 0.276,1.508 0.501 0.147,1.710 
22:4n6 
Docosatetraen
oic acid 
0.987 0.902,1.078 0.987 0.868,1.123 
22:5n3 
Docosapentaen
oic acid (DPA) 
**1.112 1.027,1.204 1.103 0.980,1.241 
22:6n3 
Docosahexaen
oic acid 
(DHA) 
0.930 0.789,1.096 0.883 0.706,1.105 
n-3 1.062 0.825,1.367 1.076 0.707,1.638 
n-6 1.009 0.983,1.036 1.033 0.992,1.077 
n6:n3 1.030 0.983,1.079 **1.072 1.009,1.139 
*Data are presented as odds ratio (OR) (95% confidence interval). OR are adjusted for the following 
confounders: Age, sex, BMI and total energy intake. **Statistically significant (p < 0.05). 
 
 
103 
3.2 Comparison of RBC membrane fatty acid content in atopy 
and non-atopy adolescents 
 
The mean level of RBC fatty acid was compared between atopic and non-atopic 
adolescents (Table 27). The mean level of α-linolenic acid (18:3n3) was higher 
(p=0.016) and docosapentaenoic acid (22:5n3) was lower (p=0.039) in red blood cell 
membrane in atopic compared with non-atopic adolescents. None of the other 
differences between atopic and non-atopic cases were shown to be significant. 
 
 
The unadjusted level of docosatetraenoic acid (22:4n6) was shown to be protective 
against atopy (OR= 0.946, 95% CI= 0.895–0.999) (Table 27). However after 
adjusting for confounders (age, sex, BMI and total energy intake) this protection was 
proved to be insignificant (OR= 0.968, 95% CI= 0.892–1.050) (Table 28). 
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Table 27: Red blood cell fatty acids levels for atopy and non-atopy cases mean (SEM) using T-
tests.  
Red blood cell 
fatty acids 
Atopy 
Mean (SEM) 
(mmol/L) 
Non-atopy 
Mean (SEM) 
(mmol/L) 
P-value 
18:3n3  
Alpha-linolenic 
acid (ALA) 
0.219 (0.013) 0.190 (0.006) 0.016 
18:4n3 
Parinaric acid 
0.619 (0.013) 0.621 (0.012) 0.733 
20:5n3  
Eicosapentaenoic 
acid (EPA) 
0.699 (0.012) 0.694 (0.009)   0.946 
22:5n3 
Docosapentaenoic 
acid (DPA) 
2.374 (0.027) 2.377 ( 0.019) 0.039 
22:6n3 
Docosahexaenoic 
acid (DHA) 
4.247 (0.059) 4.185 (0.046) 0.155 
18:2n6 
Linoleic acid 
9.932 (0.061) 9.993 (0.051) 0.798 
20:4n6 
Arachidonic acid 
(AA) 
13.328 (0.129) 13.297 (0.105) 0.874 
22:4n6 
Docosatetraenoic 
acid 
5.042 (0.065) 5.013 (0.054) 0.459 
n-3 8.158 (0.077) 8.067 (0.059) 0.159 
n-6 32.990 (0.163) 33.010 (0.139) 0.779 
n6:n3 4.129 (0.037) 4.162 (0.029) 0.251 
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Table 28: Odds ratio (OR) for the risk of atopy in red blood cell Fatty acids 
Red blood cell 
fatty acids 
Crude OR 95% CI *Adjusted 
OR 
95% CI 
18:2n6 
Linoleic acid  
1.057 0.966,1.157 1.068 0.938,1.216 
18:3n3  
Alpha-
linolenic acid 
(ALA)   
0.965 0.623,1.495 0.907 0.463,1.777 
18:4n3 
Parinaric acid  
0.818 0.620,1.080 0.906 0.532,1.544 
20:4n6 
Arachidonic 
acid (AA) 
0.980 0.932,1.029 1.012 0.942,1.088 
20:5n3  
Eicosapentaen
oic acid (EPA) 
0.835 0.500,1.394 1.056    0.486,2.296 
22:4n6 
Docosatetraen
oic acid 
**0.946 0.895,0.999 0.968 0.892,1.050 
22:5n3 
Docosapentaen
oic acid (DPA) 
1.041 0.990,1.095 0.985 0.913,1.063 
22:6n3 
Docosahexaen
oic acid 
(DHA) 
1.055 0.954,1.166 1.120 0.972,1.291 
n-3 1.085 0.922,1.277 1.134 0.862,1.491 
n-6 0.995 0.978,1.012 0.987 0.959,1.016 
n6:n3 0.975 0.976,1.004 0.979 0.940,1.019 
*Data are presented as odds ratio (OR) (95% confidence interval). OR are adjusted for the following 
confounders: Age, sex, BMI and total energy intake. **Statistically significant (p < 0.05). 
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3.2.1 Comparison of red blood cell fatty acid content in BHR 
positive and BHR negative adolescents. 
 
The mean level of RBC fatty acids was compared between BHR positive and BHR 
negative adolescents (Table 29). The only n-6 fatty acid which had a higher level in 
BHR positive compared with BHR negative adolescents was docosatetraenoic acid 
(22:4n6). The other n-6 fatty acids (linoleic 18:2n6 and arachidonic 20:4n6) and total 
n-6 level were lower in BHR positive compared with BHR negative individuals. The 
level of the majority of the individual n-3 fatty acids (parinaric 18:4n3, 
eicosapentaenoic 20:5n3 and docosapentaenoic 22:5n3) and total n-3 fatty acids was 
higher in BHR positive compared with BHR negative cases except for α-linolenic 
acid (18:3n3) and docosahexaenoic acid (22:6n3 ) which had lower levels in BHR 
positive  adolescents  although none of these differences reached significance. 
 
The unadjusted level of docosapentaenoic acid (22:5n3) was shown to be protective 
against BHR (OR= 0.928, 95% CI= 0.866–0.995). However after adjusting for 
confounders (age, sex, BMI and total energy intake) this association was not 
significant (OR= 0.965, 95% CI= 0.871–1.070) (Table 30). 
 
Increased level of docosahexaenoic acid (22:6n3) in RBC membrane showed 
protective effects against BHR (adjusted OR= 0.814, 95% CI= 0.669–0.989). 
Therefore, when controlled for potential confounders, for every 1 mmol/L increased 
level of docosahexaenoic acid in RBC membrane there was an 18.6% reduction in 
risk of having BHR. 
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Table 29: Red blood cell fatty acids levels for BHR positive and negative cases mean (SEM) 
using T-tests.  
Red blood cell fatty acids BHR+ 
Mean (SEM) 
(mmol/L) 
BHR- 
Mean (SEM) 
(mmol/L) 
P-value 
18:3n3  
Alpha-linolenic acid (ALA)  
0.186 (0.008) 0.209 (0.008) 0.070 
18:4n3 
Parinaric acid 
0.637 (0.022) 0.617  (0.098) 0.710 
20:5n3  
Eicosapentaenoic acid (EPA) 
0.701 (0.022) 0.695 (0.078) 0.248 
22:5n3 
Docosapentaenoic acid (DPA)  
2.403 (0.035) 2.379 (0.017) 0.629 
22:6n3 
Docosahexaenoic acid (DHA)  
4.209 (0.089) 4.213 (0.039) 0.525 
18:2n6 
Linoleic acid 
9.832 (0.090) 10.001 (0.043) 0.874 
20:4n6 
Arachidonic acid (AA) 
13.043 (0.192) 13.405 (0.086) 0.949 
22:4n6 
Docosatetraenoic acid 
5.140 (0.096) 5.002 (0.047) 0.525 
n-3 
 
8.135 (0.018) 8.114 (0.051) 0.513 
n-6 
 
32.656 (0.253) 33.134 (0.116) 0.816 
n6:n3 
 
4.098 (0.058) 4.153 (0.024) 0.952 
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Table 30: Odds ratio (OR) for the risk of BHR in red blood cell Fatty acids 
Red blood cell 
fatty acids 
Crude OR 95% CI *Adjusted 
OR 
95% CI 
18:2n6 
Linoleic acid  
1.038 0.921,1.171 1.001 0.842,1.190 
18:3n3  
Alpha-
linolenic acid 
(ALA)   
0.455 0.193,1.071 0.529 0.155,1.809 
18:4n3 
Parinaric acid  
0.756 0.486,1.177 1.182 0.597,2.341 
20:4n6 
Arachidonic 
acid (AA) 
1.017 0.948,1.092 0.973 0.886,1.070 
20:5n3  
Eicosapentaen
oic acid (EPA) 
1.243 0.632,2.444 0.648 0.228,1.839 
22:4n6 
Docosatetraen
oic acid 
1.017 0.948,1.092 0.929 0.822,1.050 
22:5n3 
Docosapentaen
oic acid (DPA) 
**0.928 0.866,0.995 0.965 0.871,1.070 
22:6n3 
Docosahexaen
oic acid 
(DHA) 
0.883 0.771,1.012 **0.814 0.669,0.989 
n-3 0.879 0.698,1.106 0.885 0.601,1.303 
n-6 1.004 0.981,1.026 1.024 0.988,1.062 
n6:n3 1.017 0.978,1.058 1.027 0.975,1.082 
*Data are presented as odds ratio (OR) (95% confidence interval). OR are adjusted for the following 
confounders: Age, sex, BMI and total energy intake. **Statistically significant (p < 0.05). 
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3.2.2 Asthma severity; antioxidants and fatty acids intake 
 
The asthma severity outcomes (described in section 2.5.3) were divided into four 
groups: severe asthma (2.5%), moderate asthma (4.4%), mild asthma (4.0%) and no 
asthma (89.1%). The effects of different antioxidants and fatty acids on the severity 
of asthma were investigated.  
 
3.2.2.1 The effects of dietary antioxidant, fruits and vegetables 
and severity of asthma 
 
The individual intake of 13 fresh vegetables (carrots, turnip, broad beans, green 
beans, capsicum, cabbages, green peas, Brussels sprouts, spinach, broccoli, 
cauliflower, pumpkins, sweet corn, and zucchini) did not show a significant 
association with asthma severity in adolescents. However, when the intake of the 
combination of these vegetables was examined against asthma severity a significant 
non protective association was shown (Table 31). The mean intake of combined 
vegetables in individuals with severe asthma was higher at 102.45 g/day compared 
with that for moderate asthma (73.64 g/day). The difference between the mean intake 
of these combined vegetables was 28.81g/day higher (p=0.044) for severe asthma 
(n=38) compared with moderate asthma (n=67) (Figure 8). The mean intake of 
combined vegetables for mild asthma was 84.96 g/day and for moderate asthma was 
73.64 g/day. Therefore, the difference between the mean intake of these combined 
vegetables was 11.32 g/day higher for mild asthma (n=62) compared with moderate 
asthma (n=67), although this difference was not statistically significant (p= 0.359). 
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Table 31: Analysis of variance of the effect of dietary antioxidant, fruits and vegetables on severity of asthma (n=1531). 
Asthma 
severity 
 
N 
%(n) 
Mean 
vitamin A 
intake  
µg /day 
(±SEM) 
Mean 
vitamin C 
intake 
mg/day 
(±SEM) 
 
Mean 
vitamin E 
intake 
mg/day 
(±SEM 
Mean 
magnesium 
intake  
mg/day 
(±SEM) 
 
Mean 
zinc 
intake 
mg/day 
(±SEM) 
 
Mean of 
berry 
fruits 
intake 
g/day 
(±SEM) 
Mean of 
citrus 
fruits 
intake 
g/day 
(±SEM) 
Mean of  
pome 
fruits 
intake 
g/day 
(±SEM) 
Mean of  
stone 
fruits 
intake 
g/day 
(±SEM) 
Mean of  
tropical 
fruits 
intake 
g/day 
(±SEM) 
Mean of  
combined 
fruits 
g/day 
(±SEM) 
 
*Mean  
β – 
carotene 
intake 
µg/day 
(±SEM) 
Mean of 
combined 
vegetables 
fruits 
g/day 
(±SEM) 
A 
No 
asthma 
1364 
(89.1%) 
 
1235.34 
(17.97) 
 
 
 
190.54 
(3.26) 
 
8.74 
(0.13) 
 
318.16 
(3.20) 
 
 
 
12.84 
(0.12) 
 
8.07 
(0.42) 
 
 
 
32.85 
(1.55) 
 
 
 
84.17 
(2.64) 
 
 
 
25.86 
(1.03) 
 
 
 
58.19 
(1.97) 
 
 
 
160.77 
(5.40) 
 
 
 
2629.68 
(79.62) 
 
 
 
88.79 
(1.97) 
 
 
B 
Mild 
asthma 
62 
(4.0%) 
 
1251.98 
(84.96) 
 
 
 
179.56 
(17.74) 
 
9.20 
(0.65) 
 
300.70 
(14.66) 
 
 
 
12.61 
(0.59) 
 
5.02 
(1.12) 
 
 
 
36.80 
(10.16) 
 
 
 
96.54 
(11.11) 
 
 
 
22.35 
(4.46) 
 
 
 
51.61 
(8.69) 
 
 
 
175.24 
(24.87) 
 
 
 
2599.41 
(333.38) 
 
 
 
84.96 
(8.85) 
 
 
C 
Moderate 
asthma 
67 
(4.4%) 
 
1111.58 
(62.31) 
 
 
 
180.62 
(14.99) 
 
9.31 
(0.69) 
 
318.62 
(15.71) 
 
 
 
12.93 
(0.63) 
 
 
7.72 
(1.54) 
 
 
 
25.29 
(4.22) 
 
 
 
79.75 
(12.49) 
 
 
 
22.98 
(4.09) 
 
 
 
56.54 
(7.78) 
 
 
 
130.32 
(14.28) 
 
 
 
2000.6 
(278.89) 
 
 
 
73.64 
(5.42) 
 
 
D 
Severe 
asthma 
38 
 (2.5%) 
 
1285.79 
(264.60) 
 
 
 
17.80 
(15.01) 
 
8.86 
(0.76) 
 
325.6 
(20.45) 
 
 
 
13.41 
(0.85) 
 
7.98  
(3.84) 
 
 
 
36.29 
(6.71) 
 
 
 
85.46 
(14.40) 
 
 
 
25.85 
(6.67) 
 
 
 
47.65 
(7.93) 
 
 
 
152.38 
(23.19) 
 
 
 
2035.97 
(366.84) 
 
 
 
102.45 
(16.19) 
 
 
None, Mild  
None, Mod 
None, 
Severe 
Mild, Mod 
Mild, 
Severe 
Mod, 
Severe 
p-value 
0.859 (A,B) 
0.161 (A,C) 
0.002 (A,D) 
0.265(B,C) 
0.022 (B,D) 
0.001 (C,D) 
0.498 (A,B) 
0.516 (A,C) 
0.520 (A,D) 
0.961 (B,C) 
0.944 (B,D) 
0.908 (C,D) 
0.469 (A,B) 
0.345 (A,C) 
0.881 (A,D) 
0.902 (B,C) 
0.728 (B,D) 
0.641 (C,D) 
0.273 (A,B) 
0.976 (A,C) 
0.700 (A,D) 
0.402  (B,C) 
0.313 (B,D) 
0.770 (C,D) 
 
0.704 (A,B) 
0.885 (A,C) 
0.452 (A,D) 
0.700 (B,C) 
0.403 (B,D) 
0.606 (C,D) 
 
0.146 (A,B) 
0.860(A,C) 
0..971(A,D) 
0..337 (B,C) 
0..364(B,D) 
0..936(C,D) 
0.605 (A,B) 
0.295 (A,C) 
0.713 (A,D) 
0.263 (B,C) 
0.966 (B,D) 
0.343 (C,D) 
 
0.343 (A,B) 
0.719 (A,C) 
0.936 (A,D) 
0.338 (B,C) 
0.584 (B,D) 
0.773 (C,D) 
 
0.489(A,B) 
0.546 (A,C) 
0.998 (A,D) 
0.927 (B,C) 
0.657 (B,D) 
0.709 (C,D) 
 
0.495(A,B) 
0.856 (A,C) 
0.372 (A,D) 
0.704 (B,C) 
0.792 (B,D) 
0..544(C,D) 
 
0.562 (A,B) 
0.189 (A,C) 
0.791 (A,D) 
0.176 (B,C) 
0.564 (B,D) 
0.567 (C,D) 
0.934 (A,B) 
0.083 (A,C) 
0.219 (A,D) 
0.235 (B,C) 
0.344 (B,D) 
0.953 (C,D) 
 
0.680 (A,B) 
0.078 (A,C) 
0..246(A,D) 
0..359 (B,C) 
0..235(B,D) 
0.044 (C,D) 
Fisher’s LSD p-value was used to compare between the two groups means after ANOVA was performed.  
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Figure 9 - The mean intake of combined vegetables (+/- 95% confidence intervals) and asthma 
severity at 14 years of age. 
Fisher’s LSD p-value was used to compare between the two groups means after ANOVA was 
performed. Significant differences between mild and moderate asthma (p=0.044).  
 
A: No asthma, B: Mild asthma, C: Moderate asthma, D: Severe asthma 
P-value between groups: 
A, B 0.680  
A, C    0.078  
A, D   0.246  
B, C 0.359  
B, D  0.235  
C, D   0.044 
 
There was a significant difference (p=0.044) in combined vegetables intake between 
the severe asthma group (n=38) compared with moderate asthma group (n=67) 
(Figure 9). The severe asthma group had a higher mean intake of combined 
vegetables compared with moderate asthma group. In Figures 8 to11, despite 
observing overlaps between the Confidence Interval (CI) bars, significant differences 
were observed in the intake of foods and nutrients in groups with varying levels of 
asthma severity. This is because the Standard Error (SE) of a difference between two 
estimates is not simply the sum of the individual SE but a smaller value given by the 
square root of the sum of the squares of the individual values. Therefore, if 95% CI 
bars do not overlap, we can be sure that the difference is statistically significant  
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(P < 0.05). However, the converse is not true, i.e. we may or may not have statistical 
significance when the 95% CI overlaps. This is different for SE bars, as when SE 
bars overlap, we can be sure the difference between the two means is not statistically 
significant (P>0.05).  
 
There was a significant difference (p=0.001) in vitamin A intake between the severe 
asthma group compared with no asthma, mild asthma and moderate asthma groups 
(Figure 10). The severe asthma group (n=38) had a higher mean intake of vitamin A 
compared with all the other groups. This difference in intake of vitamin A was 
especially high between severe and moderate asthma (n=67) with a mean difference 
of 474.21 µg/day.  
 
 
 
Figure 10 - The mean intake of vitamin A (+/- 95% confidence intervals) and severity of asthma 
at 14 years of age.  
Fisher’s LSD p-value was used to compare between the two groups means after ANOVA was 
performed. Significant differences between no asthma and severe asthma (p=0.002), mild and severe 
asthma (p= 0.022) and moderate and severe asthma (p= 0.001).    
A: No asthma, B: Mild asthma, C: Moderate asthma, D: Severe asthma 
P-value between groups: 
A, B 0.859  
A, C    0.161  
A, D   0.002 
B, C 0.265  
B, D  0.022  
C, D   0.001 
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There was also a significant difference in vitamin A consumption between severe 
asthma and the no asthma group (n=1364) as the severe asthma group had a 350.45 
µg/day (p=0.002) higher mean intake of vitamin A compared with the no asthma 
group (Figure 10). The difference in intake of vitamin A in the severe asthma 
compared with the mild asthma group (n=62) was not as high or as significant as in 
the other groups. The severe asthma group had a 333.81 µg/day (p=0.022) higher 
mean intake of vitamin A compared to the moderate asthma group. 
 
3.2.2.2 The effects of fish consumption and fatty acid intake on 
asthma severity 
 
The effect of fish consumption and asthma severity is shown in Figure 10. 
 
Consumption of fish had a significant association with the severity of asthma. The 
average consumption of steamed/grilled fish intake for the group with severe asthma 
was 40.58 g/day; while for the group with moderate asthma was 20.50 g/day. 
Therefore, the severe asthma group (n=33) had 20.08 g/day, (p=0.039) higher mean 
intake of steamed/grilled fish intake compared with the group with moderate asthma 
(n=58) (Figure 11).  
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Figure 11 - The mean intake of grilled/steamed fish intake (+/- 95% confidence intervals) and 
severity of asthma at 14 years of age.  
Fisher’s LSD p-value was used to compare between the two groups means after ANOVA was 
performed. Significant differences between moderate and severe asthma (p=0.039).  
A: No asthma, B: Mild asthma, C: Moderate asthma, D: Severe asthma. 
P-value between groups: 
A, B 0.976  
A, C    0.338 
A, D 0.068 
B, C 0.516 
B, D  0.146  
C, D   0.039 
 
Red blood cell docosapentaenoic acid (22:5n3) level for the no asthma group (4.31 
mmol/L) was significantly lower compared with the severe asthma group (5.14 
mmol/L) (p=0.027) (Table 32). 
 
Whilst the α-linolenic acid (18:3n3) in the no asthma group (0.22 mmol/L) was lower 
than in the severe asthma group (0.29 mmol/L), this difference was not statistically 
significant (p=0.089). In contrast the arachidonic acid (20:4n6) levels in the no 
asthma (13.62 mmol/L) group were higher than in the moderate asthma group (12.94 
mmol/L) although this difference was also not statistically significant (p=0.077).  
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Table 32: Analysis of variance of different mean red blood cell membrane fatty acids (mmol/L) with severity of asthma (n=1319). 
Asthma 
severity 
 
N 
%(n) 
18:3n3  
Alpha-
linolenic 
acid (ALA) 
(±SEM) 
18:4n3 
Parinaric 
acid  
 
(±SEM) 
20:5n3  
Eicosapent
aenoic acid 
(EPA) 
(±SEM) 
22:5n3 
Docosapent
aenoic acid 
(DPA) 
(±SEM) 
22:6n3 
Docosahexa
enoic acid 
(DHA) 
(±SEM) 
18:2n6 
Linoleic 
acid 
 
(±SEM) 
20:4n6  
Arachidonic 
acid (AA)  
 
(±SEM) 
22:4n6 
Docosatetra
enoic acid  
 
(±SEM) 
Steam/grill
ed fish 
(g/day) 
 
(±SEM) 
*Total n-3 
 
 
 
(±SEM) 
*Total n-6 
 
 
 
(±SEM) 
 
*Ratio 
n6:n3 
 
 
(±SEM) 
A 
No asthma 
1175 
(89.1%) 
0.22 
(0.007) 
0.54 
(0.01) 
0.71 
(0.006) 
4.31 
(0.06) 
4.30 
(0.03) 
10.08 
(0.03) 
13.48 
(0.06) 
1.59 
(0.05) 
26.29 
(1.30) 
10.08 
(0.07) 
30.03 
(0.11) 
3.23 
(0.03) 
B 
Mild 
asthma 
53 
(4.0%) 
0.23 
(0.03) 
0.55 
(0.04) 
0.71 
(0.02) 
4.73 
(0.28) 
4.25 
(0.12) 
10.13 
(0.16) 
13.62 
(0.27) 
1.60 
(0.27) 
26.10 
(5.18) 
10.47 
(0.30) 
30.21 
(0.46) 
3.06 
(0.14) 
C 
Moderate 
asthma 
58 
(4.4%) 
0.19 
(0.02) 
 
0.52 
(0.03) 
0.68 
(0.03) 
4.69 
(0.31) 
4.24 
(0.17) 
9.99 
(0.17) 
12.94 
(0.30) 
1.65 
(0.28) 
20.50 
(4.17) 
10.32 
(0.38) 
29.29 
(0.50) 
3.11 
(0.15) 
D 
Severe 
asthma 
33 
(2.5%) 
0.29 
(0.45) 
0.57 
(0.05) 
0.69 
(0.02) 
5.14 
(0.38) 
4.14 
(0.19) 
9.98 
(0.29) 
13.30 
(0.40) 
1.27 
(0.28) 
40.58 
(11.05) 
10.83 
(0.49) 
29.33 
(0.75) 
2.95 
(0.19) 
None, Mild  
None, Mod 
None, Severe 
Mild, Mod 
Mild, Severe 
Mod, Severe 
p-value 
 
0.713 (A,B) 
0.443 (A,C) 
0.089 (A,D) 
0.414 (B,C) 
0.270 (B,D) 
0.066 (C,D) 
0.876 (A,B) 
0.729 (A,C) 
0.668  (A,D) 
0.717 (B,C) 
0.812 (B,D) 
0.575(C,D) 
0.952 (A,B) 
0.255 (A,C) 
0.539 (A,D) 
0.440 (B,C) 
0.656 (B,D) 
0.814 (C,D) 
0.167 (A,B) 
0.205 (A,C) 
0.027 (A,D) 
0.920 (B,C) 
0.390 (B,D) 
0.339 (C,D) 
 
0.731 (A,B) 
0.673 (A,C) 
0.386 (A,D) 
0.959 (B,C) 
0.644 (B,D) 
0.339 (C,D) 
0.755 (A,B) 
0.633 (A,C) 
0.639 (A,D) 
0.569 (B,C) 
0.569 (B,D) 
0.945 (C,D) 
0.651 (A,B) 
0.077 (A,C) 
0.643 (A,D) 
0.110 (B,C) 
0.511 (B,D) 
0.450 (C,D) 
0.983 (A,B) 
0.834 (A,C) 
0.356 (A,D) 
0.893 (B,C) 
0.458 (B,D) 
0.386 (C,D) 
0.976 (A,B) 
0.338 (A,C) 
0.068 (A,D) 
0.516 (B,C) 
0.146 (B,D) 
0.039 (C,D) 
0.287 (A,B) 
0.510 (A,C) 
0.096 (A,D) 
0.761 (B,C) 
0.528 (B,D) 
0.365 (C,D) 
0.727 (A,B) 
0.143 (A,C) 
0.275 (A,D) 
0.192 (B,C) 
0.277 (B,D) 
0.950 (C,D) 
0.293 (A,B) 
0.436 (A,C) 
0.150 (A,D) 
0.834 (B,C) 
0.646 (B,D) 
0.517 (C,D) 
Fisher’s LSD p-value was used to compare between two groups means after ANOVA was performed.  
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The mean red blood cell membrane content of docosapentaenoic acid (DPA) 
(22:5n3) was 0.83 mmol/L higher in group with severe asthma (n=33) compared with 
the group with no asthma (n=1175) (p=0.027) (Figure 12) 
 
 
Figure 12- The mean level of red blood cell docosapentaenoic acid (22:5:n3) (+/- 95% confidence 
intervals) and asthma severity at 14 years of age. 
Fisher’s LSD p-value was used to compare between the two groups means after ANOVA was 
performed. Significant difference between groups A, D (p=0.027) 
A: No asthma, B: Mild asthma, C: Moderate asthma, D: Severe asthma. 
P-value between groups: 
A, B 0.167  
A, C    0.205 
A, D 0.027 
B, C 0.920 
B, D  0.390  
C, D   0.339 
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3.2.3 The effects of dietary antioxidant, fruits and vegetables 
on wheeze. 
 
The effects of dietary antioxidant, fruits and vegetables on wheeze was summarised 
earlier in this chapter (section 3.1.4.1). Among the entire antioxidant nutrient and 
fruit intake, only the mean level of berry fruits intake showed significant associations 
with wheezing episodes within the last 12 months. 
 
The mean intake of vitamin C was not normally distributed, therefore logarithmic 
values of the mean intake of vitamin C (which had a very close to normal 
distribution) were used for analysis in association with the number of times the 
adolescent had wheezed in the last 12 months (Figures 13 & 14). Comparison of 
mean intake of vitamin C for different groups based on the number of times wheezed 
in last 12 months demonstrated that there was no difference in vitamin C intake in 
adolescents and the number of times wheezed in the last 12 months (group A, B, C, 
D).  
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The effect of vitamin C intake on wheeze 
 
 
Figure 13 - The mean intake of vitamin C (+/- 95% confidence intervals) at 14 years of age and 
the number of times wheezed in the last 12 months. 
The number of times wheezed in the last 12 months for each corresponding group: A; none, B; 1-2, C: 
3-12 and D >12. Fisher’s LSD p-value was used to compare between the two groups means after 
ANOVA was performed. 
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 The effect of vitamin C intake (log values) on wheeze 
 
 
 
Figure 14 - The log of mean intake of vitamin intake C (+/- 95% confidence intervals) at 14 
years of age and the number of times wheezed in the last 12 months. 
The number of times wheezed in the last 12 months for each corresponding group: A; none, B; 1-2, C: 
3-12 and D >12. Fisher’s LSD p-value was used to compare between the two groups means after 
ANOVA was performed. 
 
The mean intake of ß-carotene was not normally distributed; therefore logarithmic 
values of the mean intake of ß-carotene (which had a very close to normal 
distribution) were used for analysis in association with the number of times the 
adolescent had wheezed in the last 12 months (Figures 15 & 16). There was no 
difference in ß-carotene intake in adolescents and the number of times wheezed in 
the last 12 months (group A, B, C, D).  
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  The effect of ß-carotene intake on wheeze 
 
 
 
Figure 15 - The mean intake of ß-carotene (µg/day) (+/- 95% confidence intervals) at 14 years of 
age and the number of times wheezed in the last 12 months.  
The number of times wheezed in the last 12 months for each corresponding group: A; none, B; 1-2, C: 
3-12 and D >12. Fisher’s LSD p-value was used to compare between the two groups means after 
ANOVA was performed. 
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The effect of ß-carotene intake on wheeze (log values) 
 
Figure 16 - The mean intake of log of ß-carotene (µg/day) (+/- 95% confidence intervals) at 14 
years of age and the number of times wheezed in the last 12 months. 
The number of times wheezed in the last 12 months for each corresponding group: A: none, B: 1-2, C: 
3-12 and D: >12. Fisher’s LSD p-value was used to compare between the two groups means after 
ANOVA was performed. 
 
3.3  THE EFFECTS OF ANTIOXIDANTS AND FATTY ACIDS 
INTAKE ON ASTHMATIC SYMPTOMS (FFQ DATA)-STUDY 
ONE  
 
In the first part of Study One using the data collected in FFQ, the effects of 
antioxidants and fatty acids intake on asthmatic symptoms were investigated. One of 
the main conclusions that can be drawn from the first part of this study is that most of 
the dietary antioxidants did not show a protective effect on asthma in 14 year old 
adolescents. One of the significant effects was observed in zinc consumption with 
average zinc intake higher for the atopy positive (1.09 mg/day) compared with the 
atopy negative group (1.07 mg/day) (p=0.02) (Table 9) suggesting that a higher zinc 
intake may be related to atopy.  However, after controlling for confounders (age, sex, 
BMI and total energy intake) this effect was shown as non-significant (Table 10). 
This finding contradicts the proposed role of zinc as an antioxidant by inhibiting 
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oxidative stress-responsive events in endothelial cells (Hennig et al. 1999; Zalewski 
et al. 2005).  
 
Daily consumption of berry fruits was negatively correlated with asthma severity 
based on wheezing frequency. The average daily intake of berry fruits for 
adolescents who had between 3-12 wheezing episodes within the last 12 months was 
significantly higher (10.08 g/day) than for those who had more than 12 wheezing 
episodes (1.69 g/day) (Table 13). The adjusted odds ratio for the risk of atopy also 
showed a protective role for berry fruits consumption (adjusted OR= 0.988, 95% CI= 
0.976–0.999) (Table 10). Therefore, for every 1 g/day increased intake of berry fruits 
there was a 1.2% reduction in the risk of developing atopy (1-0.988 (OR) = 0.012 X 
100= 1.2%). 
 
Asthma severity (defined as mild, moderate, or severe) was another asthmatic 
symptom that was investigated in relation to adolescents’ diet. The group with severe 
asthma had the highest vitamin A intake which was significantly higher compared to 
those with no asthma and also in comparison with those who had mild and moderate 
asthma (Table 31). Therefore, our crude analysis suggested that vitamin A does not 
protect against severity of asthma. After controlling for confounders we did not find 
any associations between the level of vitamin A daily intake and asthmatic 
symptoms. Hence, our findings on Vitamin A consumption and its effect on asthma 
severity contradicts the hypothesis that vitamin A, as a part of the antioxidant system, 
has a protective role against asthma (de Luis et al. 2005; Hatch 1995; McKeever & 
Britton 2004; Soutar, Seaton & Brown 1997). There are however other studies that 
associate high serum levels of vitamin A with increased risk of IgE sensitization 
(Kull et al. 2006) suggesting the need for further work in this area. In the absence of 
certain types of childhood infection, vitamin A and other retinoids accumulate in the 
lung. Later on, after exposure to known triggers for asthma, retinoid metabolites may 
be produced in high concentration and they produce an acute, localized form of 
retinoid intoxication, recognized as status asthmaticus (Mawson 2001). The 
underlying mechanism for this is yet to be known.  In one study it has been 
demonstrated that in young adult mice excessive supplementary amounts of vitamin 
A (above dietary requirements) would enhance inflammatory responses accompanied 
by decreased TH1 and increased mucosal responses (Albers et al. 2003). However, 
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supplementation of the same amount of vitamin A if combined with vitamins C and 
E, selenium, or zinc has no effects on immune function (Albers et al. 2003). 
 
In analysing the role of different antioxidants on bronchial hyperresponsiveness 
(BHR) outcome, no significant differences were observed between BHR positive and 
BHR negative and the amount of intake of these nutrients. Our finding on the role of 
antioxidants on BHR supports other studies in which no association of manganese 
and vitamin C on BHR was observed (Soutar, Seaton & Brown 1997). However, we 
observed a mild protective association between the consumption of vitamin C on 
current asthma (adjusted OR= 0.997, 95% CI= 0.994–0.999). This means that when 
controlled for potential confounders, for every 1 mg/day increased intake of vitamin 
C there was a 0.3% reduction in the risk of developing asthma (1-0.997 (OR)= 0.003 
X 100= 0.3%) (Table 8).  
 
One of the major findings in relation to dietary fatty acid intake in Study One was 
observed in the ratio of n6:n3 fatty acids between the atopy positive and the atopy 
negative group. The ratio of n6:n3 fatty acids intake was higher for the atopy positive 
(0.95), compared with the atopy negative group (0.93) (p=0.04). The adjusted ratio of 
n6:n3 showed to have detrimental association with asthma (OR= 1.072, 95% CI= 
1.009–1.139) and wheezing episodes (OR= 1.064, 95% CI= 1.007–1.124). This 
means that for every 1 level increase in the ratio of n6:n3 there was a 7.2% and 6.4% 
increase in the risk of developing asthma and wheezing episodes (Tables 24 and 26).  
 
This is consistent with the literature where it is shown that an increase in the ratio of 
n6:n3 is associated with an increase in the risk of asthma and significant evidence is 
found for a modulatory effect of the dietary n-6: n-3 fatty acid ratio on the presence 
of asthma in adolescents (Oddy et al. 2004a; Simopoulos 2002; Strachan 1999).  
 
The next section explores more comprehensive analysis on the relationship between 
red blood cell membrane n-3, n-6 and total fatty acids contents and asthmatic 
symptoms. 
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3.4  THE RELATIONSHIP BETWEEN RED BLOOD CELL 
MEMBRANE FATTY ACIDS CONTENTS AND ASTHMATIC 
SYMPTOMS -STUDY ONE 
 
The second part of Study One was dedicated to studying the relationship between red 
blood cell membrane fatty acids content and asthmatic symptoms.  
 
Analysing the effects of mean red blood cell fatty acids content on the number of 
times wheezed in the last 12 months revealed that none of the n-6 fatty acids had any 
effects on wheeze frequency. However, significant associations were found between 
wheeze and total n-3 fatty acids. The highest level of α-linolenic (18:3n3) acid was 
observed in adolescents who had the highest number of times wheezed in the last 12 
months. The mean level of α-linolenic acid for adolescents with no wheeze (n=1315) 
was 0.22 mmol/L while for those wheezing more than 12 times within the last year 
(n=20) was 1.86 times higher at 0.41 mmol/L (p=0.002) (Table 14). Therefore, those 
adolescents who had the highest number of wheezing episodes in the last year had 
0.19 mmol/L more α-linolenic acid in their red blood cells compared with those who 
had no wheezing episodes in the last year (p=0.002), 0.20 mmol/L more α-linolenic 
acid than those with 1 to 2 episodes of wheezing in the last year (0.21 mmol/L)  
(p=0.001) and 0.20 mmol/L  more α-linolenic acid in their RBC compared to those 
who had 3 to 12 wheezing episodes in the last year (p=0.003). Those adolescents 
who had the highest levels of α-linolenic acid in their red blood cells also had the 
highest number of wheezing episodes compared to the other groups.   
 
It has been shown that in infants who were born to mothers with no allergy (low-risk 
infants), a higher intake of α-linolenic acid (18:3n3) may increase the risk of 
sensitization (defined as a titer of IgE higher than 0.35 IU/mL to an allergen) (Wijga 
et al. 2006). Therefore, the highest level of α-linolenic acid may have resulted in a 
higher titer of IgE and hence the highest number of wheezing episodes was observed 
in this group. 
 
There was also a significant difference between red blood cell docosapentaenoic acid 
(22:5n3) levels for the group that had more than 12 wheezing episodes in the last 
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year compared with the group with no wheezing episodes in the last year (Table 14). 
The highest level of docosapentaenoic acid was observed in those who had the 
highest number of times wheezed in the last 12 months (5.37 mmol/L) compared 
with 4.29 mmol/L for those with no wheeze (p=0.035). Therefore, adolescents who 
had the highest number of wheezes in the last year had 1.07 mmol/L more 
docosapentaenoic acid in their red blood cell membrane compared to those who had 
no episodes of wheezing in the last year (p=0.035).  
 
There were also significant differences between current asthma, current wheeze and 
BHR and the lowest and the highest of the quintiles of red blood cell levels of 
docosapentaenoic acid. For adolescents with current asthma, current wheeze and 
BHR the lowest quintile of docosapentaenoic acid had the lowest of the sample 
population while the highest quintile consisted of highest percentage of the group 
(Table 14). 
 
The mean level of red blood cell total n-3 was also significantly higher for those with 
the highest wheeze number compared with those with no wheeze. The mean level of 
total n-3 for cases with more than 12 wheezing episodes was 11.36 mmol/L 
compared with 10.07 mmol/L for those with no wheeze (p=0.036). Therefore, our 
findings suggest that n-3 fatty acids do not protect against wheeze severity. This 
contradicts some findings in the literature (Haby et al. 2001; Mickleborough et al. 
2006; Peat et al. 2004) which propose a protective role for n-3 fatty acids against 
asthma and asthmatic symptoms.  However these findings do support those which 
suggest that n-3 fatty acids are not associated with a reduced risk of asthma 
(Almqvist et al. 2007; Woods et al. 2004). 
 
The level of red blood cell α-linolenic acid (18:3n3) was shown to be significantly 
higher in atopy positive (0.219 mmol/L) compared with atopy negative adolescents 
(0.190 mmol/L) (Table 27). When Pearson chi square of association in univariate 
analysis was performed to assess the differences in individual fatty acid content and 
the prevalence of asthmatic outcomes we found that for α-linolenic acid in atopy 
positive individuals (n=584), there was a significant difference between the lowest 
and the highest quintile groups. There were more atopy positive adolescents in the 
highest compared with the lowest α-linolenic acid quintile (p=0.043) (Table 15). 
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Therefore, we concluded that the levels of α-linolenic acid in red blood cell may be 
associated with atopy. No associations were found between the other outcomes 
(current asthma, current wheeze, BHR) and the level of α-linolenic acid in red blood 
cells.  
 
In one study in mice it was shown that α-linolenic rich oils lower serum lipids and 
ovalbumin-specific IgG1, but increases total IgE levels (Chang, Chen & Lin 2009). 
This agrees with our finding in humans that the highest level of red blood cell α-
linolenic acid (18:3n3) was observed in the adolescents who had the highest number 
of times (>12) wheezing episodes in the last 12 months. The mechanism by which α-
linolenic acid increases total IgE levels is not fully understood. It is suggested 
however, that the modulation of TH1/TH2 antibody levels via isotype switching of B 
cells does not occur during the process of elevation of IgE by α-linolenic (Chang, 
Chen & Lin 2009). 
 
Atopy also was associated with the level of parinaric acid (18:4n3) (p=0.016) (Table 
11) but no associations were found between the other outcomes (current asthma, 
current wheeze, and BHR) and the level of parinaric acid in red blood cell.  
 
BHR was shown to be strongly associated with the level of eicosapentaenoic acid 
(20:5n3) in red blood cell, as p=0.007 (Table 17). The lowest number of BHR 
positive adolescents was observed in the second quintile. This could indicate a direct 
association between the level of RBC eicosapentaenoic acid and the incidence of 
BHR but there was no significant trend found in rising quintiles. Therefore our 
finding on eicosapentaenoic acid does not confirm the hypothesis that 
polyunsaturated fatty acids such as eicosapentaenoic acid may be beneficial to the 
asthmatic condition (Nauta et al. 2008). 
 
In crude analysis we observed that, with the exception of docosapentaenoic acid 
(22:5n3) in red blood cell no other fatty acids (linoleic acid, α-linolenic acid, 
parinaric acid, arachidonic acid, eicosapentaenoic acid, docosatetraenoic acid and 
docosahexaenoic acid) had a significant impact on the severity of asthma (Table 32). 
We showed a mean level of docosapentaenoic acid in red blood cells of adolescents 
with no asthma to be significantly lower compared to severe asthma (p=0.027). 
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These findings are in contradiction with the literature as there is much evidence 
proposing a protective role for n-3 fatty acids on asthma (Haby et al. 2001; 
Mickleborough et al. 2006; Oddy et al. 2004b; Peat et al. 2004). Although our crude 
analysis suggested that the higher level of docosapentaenoic acid (DPA) the higher 
the risk of having severe asthma (Figure 12) after controlling for potential 
confounders (age, sex, BMI and total energy intake) no significant roles between the 
concentration of DPA and asthmatic symptoms was observed (Tables: 24, 26, 28 and 
30).  
  
After adjusting for confounders, the only fatty acid that showed a significant 
association on one of the asthmatic symptoms (BHR) was docosahexaenoic acid 
(22:6n3) (DHA). Higher levels of DHA in RBC membrane showed protective effects 
on BHR (adjusted OR= 0.814, 95% CI= 0.669–0.989) (Table 30). Therefore, for 
every 1 mmol/L increased level of docosahexaenoic acid in RBC membrane there 
was an 18.6% reduction in the risk of having BHR (1- 0.814 (OR) = 0.186 X 100= 
18.6%). 
 
There is evidence which suggests that cells may become more susceptible to 
oxidative injury when they are exposed to elevated amounts of polyunsaturated fatty 
acids due to the peroxidation of fatty acids (North et al. 1994). The peroxidation rate 
of the polyunsaturated fatty acids can be lowered in the presence of an optimum 
concentration of antioxidant vitamins (Van den Berg et al. 1990). The effect of 
vitamin C on the peroxidation of parinaric acid in red blood cell membranes was 
shown to be highly dependent on the concentration of the vitamin (Drummen et al. 
2004). Vitamin E is shown to have a concentration-dependent protection of parinaric 
acid against peroxidation, while the protective effect of the combination of vitamins 
E plus C exceeds the sum of their individual effects (Van den Berg et al. 1990).  
 
No evidence was observed for docosapentaenoic acid to be a risk factor for mild or 
moderate asthma. There are a few studies which suggest that n-3 fatty acids are not 
associated with a reduced risk of asthma (Almqvist et al. 2007; Woods et al. 2004) 
and our findings support this. 
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There was no evidence to suggest any associations between the level of arachidonic 
acid (20:4n6) in red blood cells and any of the outcomes of interest (current asthma, 
current wheeze, atopy and BHR). 
 
Our data suggest that consumption of fish did not protect against asthma severity. 
The severe asthma group (n=33) had 20.08 g/day higher mean intake of 
steamed/grilled fish intake compared with the group with moderate asthma (n=58) 
(Figure 11).  After controlling for confounders, we found no associations between 
consumption of fish and asthmatic symptoms (Tables 6-12). 
 
3.5  DISCUSSION ON STUDY ONE RESULTS 
 
Our data demonstrated a small protective association (0.3%) between vitamin C 
consumption and asthma. No protective association was found between the other 
antioxidants and asthmatic symptoms. The only fruit that showed a protective 
association (1.2%) on atopy was berry. Berry fruits are rich sources of vitamin C and 
their effect on atopy could be attributed to their high vitamin C content. However, 
other fruits (such as citrus fruits), which are also known to have high vitamin C 
content were shown to have no effects on the asthmatic symptoms. Berry fruits are a 
rich source of anthocyanins which are natural pigments that belong to the flavonoid 
family and are widely distributed in the human diet in foods such as beans, fruits, 
vegetables, and red wines (Park et al. 2007).  
 
There are 27 known anthocyanidins (anthocyanins without sugar groups) present in 
nature, however, only six (cyanidin, pelargonidin, peonidin, delphinidin, petunidin, 
and malvidin) are commonly found in berries (Duan et al. 2007). The major 
anthocyanins found in berries are identified as cyanidin 3-O-glucoside, delphinidin 
3-O-glucoside and cyanidin 3-O-arabinoside. Antioxidative properties of 
anthocyanins in berries arise from their high reactivity as hydrogen or electron 
donors, and from the ability of the polyphenol-derived radicals to stabilize and 
delocalize the unpaired electron, and also from their ability to chelate transition metal 
ions (Duan et al. 2007).  
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Anthocyanins have been shown previously to reduce the levels of inflammatory 
mediators in a lung inflammatory disease model in rats (Rossi et al. 2003). A recent 
study suggests that anthocyanins inhibit airway inflammation and 
hyperresponsiveness in asthma (Park et al. 2007). It is proposed that anthocyanins 
may undermine the development of asthma by down-regulating T-helper type 2 
(TH2) cytokines, and cyclooxygenase COX-2 mRNA (Jeon et al. 2007; Park et al. 
2007). Therefore, the protective role of berry fruits on wheezing episodes observed 
here could be due to the presence of anthocyanins. 
 
Therefore, the reduction in the risk of developing atopy associated with higher 
consumptions of berry fruits could be due to a higher intake of anthocyanins in this 
group. None of the other antioxidants (vitamins A, E, magnesium, zinc and β-
carotene) in our study demonstrated a protective association with asthmatic 
symptoms. Our preliminary results showed that adolescents with the most severe 
asthma had the highest intake of combined vegetables and fruits and vitamin A. 
Further investigations however, revealed that the association between the 
consumptions of these nutrients was due to the interference of confounders and 
therefore after introduction of the confounders the effect was not significant.   
 
In animal and in-vitro models many studies have implicated mast cells in the full 
expression of asthma (Matsubara et al. 2006; Metz, Siebenhaar & Maurer 2008); 
although other studies have shown that clinical features of asthma can develop in the 
absence of mast cells or IgE (Hamelmann & Gelfand 1999; Kraneveld et al. 2005). 
In asthmatic people, mast cells migrate into the airway epithelium, the airway 
mucous and smooth muscle glands (Nauta et al. 2008). The number of mast cells 
infiltrated in the airway smooth muscle bundles has been shown to correlate 
significantly with BHR in asthmatics, implicating their importance for the 
pathophysiology of asthma while virtually no mast cells were found in these regions 
in non-asthmatics (Bradding & Brightling 2007). It is proposed that foods and 
nutrients such as antioxidants (by inhibiting TNF-α) and n-3 fatty acids (by inhibiting 
APC function) can interrupt the infiltration of mast cells in the airway smooth muscle 
(van de Laar & van der Korst 1992). 
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While the average daily intake of n-3 fatty acid in our cohort was within the RDI 
level (1.2-2.4 g/day), the average daily intake for n-6 and the ratio of n6:n3 were 
between 4 to 5 times higher than the RDI level (Table 4). The ratio of n6:n3 was 
higher in atopy positive teenagers compared to atopy negative individuals. This 
finding is in accordance with the literature, as it is proposed that increases in intake 
of foods containing n-6 fatty acids can increase the synthesis of prostaglandin E2, 
therefore increasing the risk of inflammation, which may increase the risk of asthma 
(Black & Sharpe 1997; Bolte et al. 2006; Gold et al. 2006; Haby et al. 2001; 
Marangoni et al. 2007). 
 
Our initial investigations indicated that higher levels of docosapentaenoic acid 
(DPA) (22:5n3) in red blood cells were positively associated with severe asthma, 
atopy, wheeze and increasing number of wheezing episodes. However, after further 
analyses and controlling for confounders it was revealed that DPA did not have a 
significant association with the asthmatic symptoms of interest. These findings 
contradict those of Reichardt et al (2004) who proposed that a lower level of 
docosapentaenoic acid (22:5n3) is associated with elevated total serum IgE (p< 0.05) 
in one year old children although our participants were older.  
 
Preliminary results also indicated that higher levels of α-linolenic acid (18:3n3) and 
parinaric acid (18:4n3) in red blood cells were positively associated with atopy. 
Alpha-linolenic acid was also positively associated with increasing number of 
wheezing episodes. After adjusting for confounders and performing further analyses 
it was revealed that α-linolenic acid and parinaric acid did not play a significant role 
in manifestation of the asthmatic symptoms. 
 
Our initial results showed that an increase in the total level of red blood cell n-3 fatty 
acids was associated with an increase in the number of the wheezing episodes and 
thus asthma severity. There is one study which demonstrates that frequency of fish 
intake is positively related to the prevalence of asthma during childhood (Takemura 
et al. 2002). There are however other studies which propose that increased 
consumption of fish is associated with a reduced risk of asthma (Peat, Salome & 
Woolcock 1992). Other studies suggest that using fish oil supplements makes no 
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clinical improvement in patients with asthma and that despite reduced TNF-α 
production; no effects on the clinical severity of asthma have been observed 
(Anticevich et al. 1995; Hodge et al. 1998). After performing further analyses and 
controlling for the effects of confounders it was revealed that total level of n-3 fatty 
acids did not have a significant role on asthmatic symptoms. 
 
A decrease in docosatetraenoic acid (22:4 n6) may be associated with an increase in 
the amount of docosahexaenoic acid (22:6n3) (Chavali, Zhong & Forse 1998). 
Increased level of docosahexaenoic acid subsequently results in more binding of this 
fatty acid to cyclo-oxygenase molecules and, consequently, reduces the formation of 
pro-inflammatory prostaglandin E2 and increases formation of less inflammatory 
prostaglandin E1 and E3.  This agrees with our findings that docosahexaenoic acid 
might play a protective role against BHR.  
 
3.6  SUMMARY OF DISCUSSION OF STUDY ONE RESULTS 
 
We found a protective association between the consumption berry of fruits and 
atopy. We propose that this is due to the high content of anthocyanins in these fruits 
as the role of this antioxidant against asthmatic inflammation has been documented 
(Park et al. 2007). We also found a protective association between vitamin C 
consumption and asthma. This may be due to the suppression of NF-κB activity by 
vitamin C (Sackesen et al. 2008). No other associations were found between the 
other antioxidants and asthmatic symptoms.   
 
We observed a protective association for docosahexaenoic acid (22:6n3) on BHR. 
This could be due to the proposed role of this fatty acid for binding cyclo-oxygenase 
molecules and, consequently, reducing the formation of pro-inflammatory 
prostaglandin E2 and increase formation of less inflammatory prostaglandin E1 and 
E3 (Chavali, Zhong & Forse 1998).  
 
We showed that the ratio of n-6:n-3 was higher in asthmatics and wheezers compared 
with non-asthmatics and non-wheezing individuals. This may be due to an increase 
in the synthesis of prostaglandin E2 as a result of the higher intake of foods rich in n-
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6 fatty acids (Black & Sharpe 1997; Bolte et al. 2006; Gold et al. 2006; Haby et al. 
2001; Marangoni et al. 2007). 
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CHAPTER FOUR 
STUDY TWO RESULTS 
 
Results from Study Two are reported in this chapter. This study was conducted to 
assess the current asthmatic symptoms and dietary intake (fatty acid and antioxidant 
nutrients) of previously selected cases and controls (Oddy et al. 2004a) and re-assess 
their asthmatic and dietary status six years later.  
 
4.1  THE RESULTS OF STUDY TWO: 
 
Study Two was a longitudinal analysis from a subset of the overall cross-sectional 
Study One. In this study participants of the previous nested case control study at the 
age of eight (n=335), were followed up six years later at 14 years of age (n=242) 
(Oddy et al. 2004a). Cases of asthma and controls were identified from the six year 
follow-up of the nested case-control study. The diagnosis of current asthma was 
confirmed by diagnosis of asthma by a doctor and wheeze in the last year. 
 
4.1.1 The population 
 
The reporting of asthma in children at both eight and 14 years were combined into 
one categorical variable and a new variable was created with four groups. Group 1: 
no asthma at either ages of eight and 14, group 2: asthma only at the age of eight but 
not at 14, group 3: asthma only at the age of 14 but not at eight and group 4: asthma 
at both ages of eight and 14 years (summarised in Table 33). One way analysis of 
variance was performed for these variables and the different nutrients of interest 
(Tables 34 & 35).  
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Table 33: Occurrence or reporting of asthma at eight and 14 years 
Groups n Asthma at 8 years of 
age 
Asthma at 14 years 
of age 
1 123 No No 
2  68 Yes No 
3  6* No Yes 
4  45 Yes Yes 
Total 242  
* Very small “n” in this group is acknowledged therefore, results related to this group may be limited. 
 
4.1.2 The effects of antioxidant and fruit intake on asthma 
history  
 
In crude analyses we found that there were significant differences (p <0.05) in the 
mean intake of vitamin A between those who had asthma at eight years only (n=68) 
and those who did not have asthma at that age but developed asthma later at the age 
of 14 (n=6). The mean intake of vitamin A was 772.77 µg/day higher for those who 
developed asthma at the age of 14 compared to those who had asthma at the age of 
eight years only (1246.41 µg/day) (p=0.019) (Figure 17) and also higher (789.49 
µg/day) than the group who did not have asthma at either eight or 14 (1229.68 
µg/day) (p=0.014) (n=123).  
 
As stated in section 3.2.2.1, CI for the means of two factor levels can overlap, but the 
difference between them can be significant at the p<0.05. Hence, figures 17-23 
demonstrate significant differences in the intake of a variety of foods and nutrients in 
asthmatic groups despite the presence of overlaps between the CI.  
 
The highest mean intake of vitamin C was 234.76 mg/day in adolescents with asthma 
only at 14 years (n=6) whereas the lowest mean intake of vitamin C was 192.42 
mg/day in those who had asthma at eight years only (n=68). Similarly, the highest 
intake of β-carotene was 3876.65 µg/day in adolescents who had asthma at 14 and 
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the lowest intake was 2166.02 µg/day in those who had asthma at the age of eight 
(n=68) although this difference was not significant. 
 
The lowest intake of vitamin E was 8.35 mg/day in those who never had asthma 
(n=123) and the highest intake was in the group who had asthma at both eight and 14 
(9.55 µg/day) (n=45) although, this difference was not statistically significant (Table 
25). 
 
The lowest intake of magnesium was 304.02 mg/day and was recorded for the group 
who had asthma at the age of eight years (n=68). The highest intake of magnesium 
was 339.88 mg/day and was seen in adolescents with asthma at 14 only (n=6). This 
difference was not statistically significant. 
 
The lowest mean intake of zinc was 12.91 mg/day and was observed in the group 
with no asthma at eight or 14 (n=123). The highest mean intake of zinc was 14.08 
mg/day and was observed in the adolescents with asthma at 14 only (n=6). The latter 
also showed the highest variation in their zinc intake, although none of these 
differences recorded significance. 
 
The association between dietary fruits and vegetables with asthma was assessed in 
detail using subgroups of fruit: citrus fruits, berry fruits, pome fruits such as apples 
and pears, stone fruits and a combination of all these fruits. 
 
There was a large difference in the mean intake of berry fruits across the four groups 
(Table 34). The lowest intake of berry fruit intake was 5.31 g/day in adolescents with 
asthma at 14 years only (n=6) compared with the highest intake of 12.40 g/day in 
those reporting asthma at eight years only (n=68). However, the differences in the 
intake of berry fruits were not significant. There were also large variations in the 
intake of citrus fruits. The highest intake of citrus fruits was 61.02 g/day and was 
recorded for those with asthma at 14 only and the lowest was 25.73 g/day recorded 
for those with no asthma. 
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Those participants who had asthma at eight years of age only, had the highest mean 
intake of pome fruit with 120.16 g/day. The pome fruit intake was considerably 
higher than the group who had an asthma history at the age of 14 only with 33.43 
g/day. Despite the large magnitude of difference in pome fruits intake between these 
two groups, the difference was not significant due to the small sample size in the 
group with asthma at 14 only (n=6). 
 
The mean intake of tropical fruit was very similar for the group who had asthma at 
the age of eight only (n=68) with a mean intake of 76.79 g/day and those with asthma 
at 14 years of age only (n=6) with 71.81 g/day. The former also had the highest mean 
intake of tropical fruits compared with the other groups. Those who had asthma at 
both ages of eight and 14 had the lowest intake of tropical fruits with 46.23 g/day. 
 
The average daily consumption of stone fruit was significantly higher for those 
children who had asthma at eight years only (n=68) with 44.76 g/day compared with 
those who did not have asthma at either age with an average daily consumption of 
28.90 g/day (n=123). Therefore, the mean difference in stone fruit intake was 15.86 
g/day more for those with asthma at the age of only eight compared with those who 
did not have asthma at either ages (p=0.025) (Figure 18).  The mean intake of stone 
fruit was also higher for the children with asthma at eight years only (n=68) with 
44.76 g/day compared with adolescents who had asthma at both ages of eight and 14, 
(n=45) with an average intake of 20.27 g/day (Figure 18 and Table 34). 
 
Intake of all four different fruit groups (pome, berry, citrus and stone fruits) were 
combined to produce a new variable called combined fruits. There were significant 
differences in the mean intake of combined fruits for children with asthma at the age 
of eight (n=68) as they had 68.26 g/day higher intake than those with no asthma 
(n=123) (p=0.012) (Figure 18). The mean daily intake of combined fruits was 
significantly lower (p=0.035) in adolescents who had asthma at both ages of eight 
and 14 (n=45) with an average daily intake of 143.84 g/day compared with those 
who only had asthma at eight years of age (n=68) with 216.48 g/day (Figure 19 and 
Table 34). 
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The intake of 14 different vegetables (carrots, turnip, broad beans, green beans, 
capsicum, cabbages, green peas, Brussels sprouts, spinach, broccoli, cauliflower, 
pumpkins, sweet corn, and zucchini) were also combined to make a unique 
combination of vegetables ingested during both summer and winter. Analysis of 
variance showed no significant differences between the average daily intakes of 
vegetables with asthma outcome for any of the groups (data not shown).
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Table 34: Analysis of variance of different antioxidants and fruits intake with history of asthma.  
History of 
asthma 
 
 
 
 
N 
Mean 
vitamin A 
intake  
µg /day 
(±SEM) 
 
 
Mean 
vitamin C 
intake 
mg/day 
(±SEM) 
 
 
Mean 
vitamin E 
intake 
mg/day 
(±SEM) 
 
 
Mean  
β – 
carotene 
intake 
µg/day 
(±SEM) 
 
Mean 
magnesium 
intake 
mg/day 
(±SEM) 
 
Mean 
zinc 
intake 
mg/day 
(±SEM) 
 
 
Mean of 
berry 
fruits 
intake 
g/day 
(±SEM) 
 
Mean of 
citrus 
fruits 
intake 
g/day 
(±SEM) 
 
Mean of  
pome 
fruits 
intake 
g/day 
(±SEM) 
 
Mean of  
stone 
fruits 
intake 
g/day 
(±SEM) 
 
Mean of  
tropical 
fruits 
intake 
g/day 
(±SEM) 
 
Mean of  
combined 
fruits 
g/day 
(±SEM) 
 
 
A 
Never 
 
 123 
1229.68 
(40.27) 
 
 
197.56 
(9.66) 
 
 
8.35 
(0.39) 
 
 
2735.10 
(226.95) 
 
 
314.88  
(9.05) 
 
 
12.91 
(0.37) 
 
 
8.68  
(1.41) 
 
 
 
25.73 
(3.24) 
 
 
 
84.91  
(7.65) 
 
 
28.90 
(3.47) 
 
 
54.51 
(5.33) 
 
 
148.22 
(10.62) 
 
 
B 
Asthma At 
8 years 
only 
68 
1246.41 
(69.72) 
 
 
192.42 
(16.29) 
 
 
9.15 
(0.56) 
 
 
2166.02 
(346.84) 
 
 
304.02  
(12.83) 
 
 
12.28 
(0.52) 
 
 
12.40 
(3.03) 
 
 
39.16 
(9.00) 
 
 
 
120.16 
(23.04) 
 
 
44.76 
(7.93) 
 
 
76.79 
(14.58) 
 
 
216.48 
(33.29) 
 
 
C 
Asthma At 
14 years 
only 
6 
2019.18 
(730.99) 
 
 
234.76 
(58.76) 
 
 
9.41 
(1.44) 
 
 
3878.65 
(1646.97) 
 
 
339.88  
(55.10) 
 
 
14.08 
(2.41) 
 
 
5.31  
(5.30) 
 
 
 
61.02 
(37.86) 
 
 
33.43 
(24.92) 
 
 
16.07 
(7.62) 
 
 
71.81 
(28.70) 
 
 
115.83 
(52.62) 
 
 
D 
Asthma At 
8 & 14 
years 
45 
1326.40 
(197.73) 
 
 
173.47 
(15.13) 
 
 
9.55 
(0.64) 
 
 
2270.09 
(288.84) 
 
 
332.24 
(17.92) 
 
 
13.31 
(0.68) 
 
 
8.98  
(2.07) 
 
 
 
 
33.19 
(14.96) 
 
 
 
81.40 
(11.17) 
 
 
20.27 
(5.26) 
 
 
46.23 
(10.15) 
 
 
 
143.84 
(21.34) 
 
 
 
p-value 
 
0.885 (A,B) 
0.014 (A,C) 
0.079 (A,D) 
0.019 (B,C) 
0.138 (B,D) 
0.098 (C,D) 
 
0.769 (A,B) 
0.441 (A,C) 
0.232 (A,D) 
0.390 (B,C) 
0.393 (B,D) 
0.223 (C,D) 
0.229 (A,B) 
0.561 (A,C) 
0.116 (A,D) 
0.886 (B,C) 
0.631 (B,D) 
0.942 (C,D) 
0.662 (A,B) 
0.229(A,C) 
0.298 (A,D) 
0.179 (B,C) 
0.567 (B,D) 
0.108 (C,D) 
 
0.501 (A,B) 
0.575 (A,C) 
0.351 (A,D) 
0.431 (B,C) 
0.170 (B,D) 
0.869 (C,D) 
0.324 (A,B) 
0.516 (A,C) 
0.595 (A,D) 
0.324 (B,C) 
0.209 (B,D) 
0.680 (C,D) 
 
0.183 (A,B) 
0.612 (A,C) 
0.925 (A,D) 
0.301 (B,C) 
0.333 (B,D) 
0.600 (C,D) 
 
0.181 (A,B) 
0.142 (A,C) 
0.512 (A,D) 
0.375 (B,C) 
0.638 (B,D) 
0.270 (C,D) 
0.055 (A,B) 
0.239 (A,C) 
0.865 (A,D) 
0.054 (B,C) 
0.095 (B,D) 
0.297 (C,D) 
0.025 (A,B) 
0.447 (A,C) 
0.282 (A,D) 
0.099 (B,C) 
0.007(B,D) 
0.813 (C,D) 
 
 
0.074 (A,B) 
0.560 (A,C) 
0.558 (A,D) 
0.870 (B,C) 
0.054 (B,D) 
0.413 (C,D) 
 
0.012 (A,B) 
0.616 (A,C) 
0.886 (A,D) 
0.130 (B,C) 
0.035 (B,D) 
0.680 (C,D) 
Fisher’s LSD p-value was used to compare between two groups means after ANOVA was performed.  
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Figure 17 - Mean intake of vitamin A (µg/day) (+/- 95% confidence intervals) and asthma at 
eight and 14 years of age.  
Fisher’s LSD p-value was used to compare between the two groups means after ANOVA was 
performed. Significant differences between groups A & C (α=0.014) and groups 1 & 2 (α=0.019). 
P-value between groups: 
A, B 0.885  
A, C    0.014 
A, D 0.079 
B, C 0.019 
B, D  0.138  
C, D   0.098 
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Figure 18 – Mean intake of stone fruits (g/day) (+/- 95% confidence intervals) and asthma at 
eight and 14 years of age.  
Fisher’s LSD p-value was used to compare between the two groups means after ANOVA was 
performed. Significant differences between groups A, B (α=0.025) and groups B, D (α=0.007). 
P-value between groups: 
A, B 0.025  
A, C    0.447 
A, D 0.282 
B, C 0.099 
B, D  0.007  
C, D   0.813 
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Figure 19 – Mean intake of combined fruits (g/day) (mean +/- 95% confidence intervals) and 
asthma at eight and 14 years of age for asthma. 
Fisher’s LSD p-value was used to compare between the two groups means after ANOVA was 
performed. Significant differences between groups A, B (α=0.012) and groups B, D (α=0.035). 
P-value between groups: 
A, B 0.012  
A, C    0.616 
A, D 0.886 
B, C 0.130 
B, D  0.035  
C, D   0.680 
 
In summary, in crude analysis, the only antioxidant nutrients and foods which 
showed significant associations with asthma history were vitamin A, stone fruits and 
combined fruits. The mean intake of vitamin A was higher in adolescents who had 
asthma at the age of 14 compared to those who did not have any history of asthma 
earlier at the age of eight. Lowest consumption of stone fruits was observed in 
adolescents who had a history of asthma at the age of 14. The mean intake of 
combined fruits showed that a significant reduction in the average intake of these 
fruits in participants from eight to 14 years resulted in the persistence of a history of 
asthma. However, after controlling for potential confounders (age, sex, BMI and total 
energy) none of the antioxidants and fruits were shown to be associated with the 
history of asthma (data not shown). 
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4.1.3 Effect of fatty acids intake on asthma history  
 
Reported dietary intake of fatty acids obtained from the CSIRO FFQ was used for 
analysis in Study Two, because red blood cell fatty acid content was not available at 
the age of eight years and dietary fatty acid estimates were available. The dietary 
fatty acids that we considered for this study were five n3 fatty acids, α-linolenic acid 
(18:3n3), parinaric acid (18:4n3), eicosapentaenoic acid (20:5n3), docosapentaenoic 
acid (22:5n3) and docosahexaenoic acid (22:6n3) and three n6 fatty acids: linoleic 
acid (18:2n6), arachidonic acid (20:4n6) and, docosatetraenoic acid (22:4n6).   
 
The mean intake of arachidonic acid for the group with no asthma was 13.41 g/day 
while the intake for the group with asthma at 14 years was 10.75 g/day, although the 
numbers were small in the 14 only group (n=6) (Figure 20).  
 
There were differences (p<0.05) in the mean intake of arachidonic acid, total n-3, 
total n-6 and the ratio of n6:n3 fatty acids between the different groups.  The levels 
of all the individual n-3 fatty acids as well as total n-3 fatty acids were uniformly 
lower for the adolescents who had asthma at both ages of eight and 14 years 
compared to those who never had asthma (Table 35). The only significant difference 
in the intake of n-3 fatty acids among the four groups (never asthma, asthma at eight, 
asthma at 14 and asthma at eight and 14) was observed in intake of total n-3 fatty 
acids. The intake of total n-3 fatty acids was higher (p=0.009) for those with no 
asthma (11.13 ± 0.25 g/day) compared to 9.82 ± 0.46 g/day for those with asthma at 
both eight and 14 years. The intake of total n-3 fatty acids was also higher for those 
with asthma at eight years only (10.96 ± 0.30 g/day) compared to the group who had 
asthma at both eight and 14 years (Figure 21 and Table 35). 
 
The mean level of all the individual n-3 fatty acids was lower in the group who had 
asthma at both eight and 14 years but no significant differences were found (Table 
35). The levels of the individual n-6 fatty acids linoleic acid (18:2n6) and 
docosatetraenoic acid (22:4n6) were higher for adolescents who had asthma at eight 
and 14 years of age compared with those who did not report asthma at either age but 
not significantly so ( Table 35). In contrast to linoleic and docosatetraenoic acids, the 
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mean intake of arachidonic acid was lower for the adolescents with asthma at eight 
and 14 years (13.21 g/day) compared to those with no asthma (13.41 g/day) but this 
was not significant.  
 
The highest intake of total n-6 fatty acids was observed in adolescents who had 
asthma at eight and 14 years (29.32 g/day). This intake was significantly higher 
compared with the total n-6 fatty acids intake of the group who had asthma only at 
14 years of age (23.98 g/day). The latter had the lowest intake of the total n-6 fatty 
acids, and showed the most variations in the intake of the total n-6 fatty acids 
compared with the other groups (Figure 22). There were also significant differences 
in the intake of total n-6 fatty acids between the groups with no asthma at any age 
(29.79 g/day) compared to the group who had asthma at 14 years only (23.98 g/day) 
(Figure 22 and Table 35). 
 
The mean ratio of n6:n3 was higher for the adolescents who had asthma at eight and 
14 years (3.38) compared with the group who did not have asthma (2.78). The group 
with asthma at both ages also showed a higher ratio of n6:n3 compared with the 
group who had a history of asthma at 14 years only (2.14). The group with asthma at 
both ages also demonstrated a higher ratio of n6:n3 intake compared with those who 
had asthma at eight years only (2.78) (Figure 23 and Table 35).  
 
However, after controlling for potential confounders (age, sex, BMI and total 
energy), only n6:n3 ratio between the non-asthmatic and the asthmatics at eight and 
14 years remained significant (Table 36). 
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Table 35: Mean (± Standard Error) of dietary fatty acid intake (g/day) for different groups. 
History of 
asthma 
 
 
N 
18:3n3  
Alpha-
linolenic 
acid (ALA) 
(±SEM) 
18:4n3 
Parinaric 
acid  
 
(±SEM) 
20:5n3  
Eicosapent
aenoic acid 
(EPA) 
(±SEM) 
22:5n3 
Docosapent
aenoic acid 
(DPA) 
(±SEM) 
22:6n3 
Docosahexa
enoic acid 
(DHA) 
(±SEM) 
18:2n6 
Linoleic 
acid 
 
(±SEM) 
20:4n6 
Arachidonic 
acid (AA)  
 
(±SEM) 
22:4n6 
Docosatetra
enoic acid  
 
(±SEM) 
Total n-3 
 
 
 
(±SEM) 
Total n-6 
 
 
 
(±SEM) 
 
 
Ratio n6:n3 
 
 
 
(±SEM) 
A 
Never  
 
 
123 
0.28 
 (0.04) 
0.57  
(0.03) 
0.69 
 (0.02) 
5.18 
 (0.21) 
4.41  
(0.14) 
10.05 
 (0.15) 
 
13.41  
(0.27) 
1.00  
(0.14) 
11.13 
 (0.25) 
29.27  
(0.44) 
 
2.78  
(0.09) 
B 
Asthma At 8 
years only 
 
68 
0.20 
 (0.03) 
0.57  
(0.04) 
0.68 
 (0.04) 
5.28 
 (0.29) 
4.22  
(0.16 ) 
9.98 
 (0.17) 
13.07  
(0.32) 
1.16 
 (0.22) 
10.96  
(0.30) 
29.09 
 (0.54) 
 
2.78 
 (0.12) 
C 
Asthma At 
14 years 
only 
 
6 
0.31 
 (0.16) 
0.64  
(0.09) 
0.86 
 (0.26) 
5.30 
 (0.98) 
4.38 
 (1.22) 
9.29  
(0.31) 
10.75  
(2.29) 
0.51  
(0.13) 
11.50 
 (1.43) 
23.98 
 (2.80) 
2.14 
 (0.31) 
D 
Asthma At 8 
& 14 years 
 
45 
0.17 
 (0.02) 
0.52  
(0.04) 
0.64  
(0.05) 
4.46 
 (0.38) 
4.03 
 (0.18) 
10.19  
(0.23) 
13.21 
 (0.48) 
1.35 
 (0.39) 
9.82  
(0.46) 
29.32  
(0.66) 
3.38 
 (0.35) 
 
p-value 
0.180 (A,B) 
0.845 (A,C) 
0.105 (A,D) 
0.508 (B,C) 
0.661 (B,D) 
0.400 (C,D) 
0..980 (A,B) 
0.555 (A,C) 
0.324 (A,D) 
0.567 (B,C) 
0.364 (B,D) 
0.336 (C,D) 
0.760 (A,B) 
0.173 (A,C) 
0.339 (A,D) 
0.149 (B,C) 
0.528 (B,D) 
0.091 (C,D) 
0.771 (A,B) 
0.905 (A,C) 
0.088 (A,D) 
0.988 (B,C) 
0.078 (B,D) 
0.423 (C,D) 
0.040 (A,B) 
0.963 (A,C) 
0.165 (A,D) 
0.805 (B,C) 
0.518 (B,D) 
0.597 (C,D) 
0.758 (A,B) 
0.244 (A,C) 
0.621 (A,D) 
0.301 (B,C) 
0.494 (B,D) 
0.189 (C,D) 
 
 
0.458 (A,B) 
0.039 (A,C) 
0.722 (A,D) 
0.077 (B,C) 
0.803 (B,D) 
0.066 (C,D) 
0.576 (A,B) 
0.529 (A,C) 
0.289 (A,D) 
0.417 (B,C) 
0.597 (B,D) 
0.304 (C,D) 
0.682 (A,B) 
0.759 (A,C) 
0.009 (A,D) 
0.657 (B,C) 
0.040 (B,D) 
0.178 (C,D) 
 
0.802 (A,B) 
0.009 (A,C) 
0.947 (A,D) 
0.013 (B,C) 
0.800 (B,D) 
0.011(C,D) 
0.990 (A,B) 
0257 (A,C,) 
0.013(A,D) 
0.268 (B,C) 
0.025 (B,D) 
0.038(C,D) 
Fisher’s LSD p-value was used to compare between two groups means after ANOVA was performed.
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Table 36: Association between fatty acids intake (g/day) and history of asthma after adjusting for confounders (age, sex, BMI and total energy). 
History of asthma 
 
 
N 
20:4n6 
Arachidonic acid (AA)  
 
(±SEM) 
Total n-3 
 
 
 
(±SEM) 
Total n-6 
 
 
 
(±SEM) 
 
 
Ratio n6:n3 
 
 
 
(±SEM) 
A 
Never  
 
 
123 
13.41  
(0.27) 
11.13 
 (0.25) 
29.27  
(0.44) 
 
2.78  
(0.09) 
B 
Asthma At 8 years only 
 
68 
13.07  
(0.32) 
10.96  
(0.30) 
29.09 
 (0.54) 
 
2.78 
 (0.12) 
C 
Asthma At 14 years only 
 
6 
10.75  
(2.29) 
11.50 
 (1.43) 
23.98 
 (2.80) 
2.14 
 (0.31) 
D 
Asthma At 8 & 14 years 
 
45 
13.21 
 (0.48) 
9.82  
(0.46) 
29.32  
(0.66) 
3.38 
 (0.35) 
 
p-value 
1.000 (A,B) 
0.330 (A,C) 
1.000 (A,D) 
0.627 (B,C) 
1.000 (B,D) 
0.510 (C,D) 
1.000 (A,B) 
1.000 (A,C) 
0.094(A,D) 
1.000 (B,C) 
0.204 (B,D) 
1.000 (C,D) 
 
1.000 (A,B) 
0.907 (A,C) 
1.000 (A,D) 
0.136 (B,C) 
1.000 (B,D) 
0.112(C,D) 
1.000 (A,B) 
1.000 (A,C) 
0.030(A,D) 
1.000 (B,C) 
0.173 (B,D) 
0.823(C,D) 
Significance levels were adjusted for multiple comparisons by using the Bonferroni method. 
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Figure 20 – Mean intake of arachidonic acid (20:4n6) (mean +/- 95% confidence intervals) at 
eight and 14 years of age for asthma.  
Fisher’s LSD p-value was used to compare between the two groups means after ANOVA was 
performed. Significant differences between groups A, C (p=0.039). 
P-value between groups: 
A, B 0.458  
A, C       0.039 
A, D 0.722 
B, C 0.077 
B, D  0.803  
C, D   0.066 
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Figure 21 - Mean intake of total n3 fatty acids (mean +/- 95% confidence intervals) at eight and 
14 years of age for asthma. 
Fisher’s LSD p-value was used to compare between the two groups means after ANOVA was 
performed. Significant differences between groups A, D (p=0.009) and groups B, D (p= 0.04). 
P-value between groups: 
A, B 0.682  
A, C    0.759 
A, D 0.009 
B, C 0.657 
B, D  0.040  
C, D   0.178 
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Figure 22 – Mean intake of total n-6 fatty acids (mean +/- 95% confidence intervals) at eight and 
14 years of age for asthma. 
Fisher’s LSD p-value was used to compare between the two groups means after ANOVA was 
performed.  Significant differences between groups A, C (p=0.009), groups B, C (p=0.013) and 
groups C, D (p=0.011). 
P-value between groups: 
A, B 0.802  
A, C    0.009 
A, D 0.947 
B, C 0.013 
B, D  0.800  
C, D   0.011 
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Figure 23 – Mean intake of the ratio of n6:n3 fatty acids (mean +/- 95% confidence intervals) at 
eight and 14 years of age for asthma. 
 Fisher’s LSD p-value was used to compare between the two groups means after ANOVA was 
performed.  Significant differences between groups A, D (p=0.013), groups B, D (p=0.025) and 
groups C, D (p=0.038). 
P-value between groups: 
A, B 0.990  
A, C    0.257 
A, D 0.013 
B, C 0.268 
B, D  0.025  
C, D   0.038     
 
In summary in crude analysis significant associations were observed between the 
intake of total n-3, total n-6 and the ratio of n6:n3 fatty acids with asthma. The only 
individual fatty acid that demonstrated a significant role in the history of asthma was 
the n-6 fatty acid, arachidonic acid, where intake was lower in adolescents with 
asthma at only 14 years of age compared with those who did not have asthma at any 
age.  
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4.2  Effect of antioxidants intake on asthma history  
 
The first part of Study Two was devoted to investigating the effects of antioxidant 
intake on asthma history. After adjusting for potential confounders (age, sex, BMI 
and total energy) none of the antioxidant nutrients and foods showed significant 
effects on asthma history.  
 
4.2.1 Effect of fatty acids intake on asthma  
 
The second part of Study Two was dedicated to investigating the effects of fatty acid 
intake on asthma history. After controlling for potential confounders significant 
association in the ratio of n6:n3 fatty acids between the non-asthmatics and 
asthmatics at eight and 14 years was found. 
 
4.3  DISCUSSION  
 
The results of Study Two will be discussed in the following sections. 
 
4.3.1 Antioxidants and fruits 
 
Our results did not demonstrate a protective association between any of the 
antioxidants and asthma at either age of eight or 14.  
 
In crude analyses we found that, the mean intake of vitamin A was higher in 
adolescents who had asthma at the age of 14 compared to those who did not have any 
history of asthma earlier at the age of eight. This finding contradicts the hypothesis 
that vitamin A as a part of the antioxidant system, has a protective role against 
asthma (de Luis et al. 2005; Hatch 1995; McKeever & Britton 2004; Soutar, Seaton 
& Brown 1997), and those studies which associate high serum levels of vitamin A 
with an increased risk of IgE sensitization (Kull et al. 2006). After controlling for 
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confounders, we found no associations between the intake of vitamin A and the 
history of asthma.  
 
Important differences were observed in crude analyses in the mean intake of 
combined fruits and the history of asthma. Comparison of the mean intake of these 
fruits showed that a significant reduction in the average intake of fruits in 
participants from eight to 14 years resulted in the persistence of a history of asthma. 
However, after adjusting for confounders the associations between the intake of these 
fruits and asthma was shown as non-significant. 
 
Consumption of none of the fruit groups (berry, citrus, pome, stone, tropical and 
combination of all fruits) showed a protective association for asthma. We did not 
observe any significance associations between consumption of berry, citrus and 
pome fruits and asthma. However, in crude analysis, we found significant differences 
in the consumption of stone fruits and combined fruits and their associations with 
asthma in different groups. Our crude analysis suggests that a lower consumption of 
stone fruits could contribute to the persistence of asthmatic symptoms later in life. It 
showed that the lowest consumption of stone fruits was observed in adolescents who 
had a history of asthma at the age of 14 (16.07 g/day) followed by those who had 
asthma at both ages of eight and 14 (20.27 g/day). However, the conclusion that 
consumption of stone fruits can offer protective roles against asthmatic symptoms 
cannot be conclusive as when we controlled for confounders, none of these 
associations were shown to be significant.  
 
The average intake of vitamin C, vitamin E, ß-carotene, manganese, zinc, berry 
fruits, citrus, pome and tropical fruits did not show any significant effect on asthma 
history. Thus, our study does not agree with those that propose protective roles for 
these vitamins micronutrients or fruits against asthma (Soutar, Seaton & Brown 
1997; Zalewski et al. 2005). Since fresh fruits and vegetables are rich sources of 
antioxidants, these findings contradict the hypothesis that dietary antioxidant intakes 
may modify the risk of developing asthma (de Luis et al. 2005; Martindale et al. 
2005; Soutar, Seaton & Brown 1997) as no evidence of any association was found 
between micronutrient and antioxidant intake and asthma. Therefore, our study 
agrees with the study conducted on adults that suggests dietary intake of antioxidants 
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and their main food sources have no effect on asthma risk (Nagel & Linseisen 2005) 
and contradicts those that propose protective roles for antioxidants against asthma 
(de Luis et al. 2005; Hatch 1995; McKeever & Britton 2004; Soutar, Seaton & 
Brown 1997).  
 
4.3.2 Fatty acids 
 
The mean level of total n-3 fatty acid intake was 1.31 g/day higher in those with no 
asthma compared with those who had asthma at both ages of eight and 14 (p=0.009), 
and those who had asthma at the age of 14 (p=0.04). Hence, it may be possible that 
the reduced levels of n-3 fatty acids have resulted in sustaining asthma in the latter 
group a result that is consistent with the literature. (Haby et al. 2001; Mickleborough 
et al. 2006; Oddy et al. 2004b; Peat et al. 2004) although there are some studies 
which do not find evidence  that n-3 fatty acids are associated with a reduced risk of 
asthma (Almqvist et al. 2007; Woods et al. 2004).  
 
N-3 fatty acids are suggested have a role in decreasing the production of 
inflammatory cytokines. It is suggested that these fatty acids act both directly 
(inhibiting arachidonic acid metabolism) and indirectly (altering the expression of 
inflammatory genes through effects on transcription factor activation) (Calder 2006). 
Our findings are consistent with these proposed roles of total n-3 fatty acids. We 
found that the lowest intake of n-3 fatty acids was observed in those individuals who 
had asthmatic symptoms at both ages of eight and 14 compared to the intake of n-3 
fatty acids in non-asthmatics.  
 
The mean intake of total n-6 fatty acids was 5.29 g/day higher in those without 
asthma history compared with the cases who did not have asthma at the age of eight 
but developed asthma later at the age of 14 (p=0.009). The total n-6 value was also 
5.106 g/day higher for those who had asthma only at the age of eight compared to 
those who developed asthma at the age of 14 (p=0.013). The group who had asthma 
at both ages of eight and 14 had 5.340 g/day higher level of total n-6 fatty acids 
compared with those who had asthma only at the age of 14 (p=0.011). Only the latter 
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is in accordance with the proposed detrimental roles of n-6 fatty acids in asthma 
(McKeever 2007; Ogwok, Muyonga & Sserunjogi 2008). 
 
An adverse effect of n-6 fatty acids is suggested in asthma (McKeever 2007), 
however, our study does not decisively support this. Arachidonic acid (20:4n6) is 
proposed to have a pro-inflammatory role as it is known to act as a substrate for 5-
Lipoxygenase (5-LO) (Radmark et al. 2007). Therefore it was expected to observe a 
higher intake of this fatty acid in asthmatic individuals compared to non-asthmatics. 
However, our results showed that intake of arachidonic acid was significantly lower 
in asthmatic adolescents at 14 years compared to non-asthmatics (10.75 g/day vs. 
13.41 g/day). It must be acknowledged that the number of adolescents in the group 
who had asthma at 14 years only, was very small (n=6 for group C) compared to 
other groups and consequently the mean intake of this fatty acid for this group may 
not represent an accurate estimate of the intake of arachidonic acid.  
 
The lowest intake of n-6 fatty acids was observed in adolescents who had asthmatic 
symptoms at 14 years only. The intake of n-6 fatty acids was significantly higher for 
this group compared to non-asthmatic, asthmatics at eight years and asthmatic at both 
ages.  
 
The level of n6:n3 also showed significant effects on the history of asthma. The 
mean ratio of n6:n3 was 0.592 higher in those who had asthma at both ages of eight 
and 14 years compared with those who never had asthma (p=0.013). This ratio was 
also 0.595 higher in the same group (those who had asthma at both ages) compared 
with the group who only had asthma at the age of eight (p=0.025). The group that 
had asthma at both ages also had 1.24 g/day higher ratio of n-6 to n-3 compared with 
the group who did not have asthma at the age of eight but did develop asthma at the 
age of 14 (p=0.038). 
 
The ratio of n6:n3 was observed to be highest for the asthmatic individuals at both 
ages of eight and 14. This ratio was significantly higher compared to non-asthmatic, 
asthmatic at eight years and asthmatic at 14 years only. These findings are consistent 
with the literature as significant evidence was previously found in this cohort for a 
modulatory effect of the dietary n-6:n-3 fatty acid ratio on the presence of asthma in 
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children (Oddy et al. 2004a). Linoleic acid (18:2n6) and α-linolenic (18:3n3) and 
their long-chain derivatives are essential components of cell membranes both in 
animals and plants (Simopoulos 2002). These two classes of fatty acids are 
metabolically and functionally separate, often have important opposing physiological 
functions and are not interchangeable (Riediger et al. 2009; Simopoulos 2002). 
While cellular proteins are genetically programmed, the fatty acid composition of the 
cell membranes is greatly dependent on dietary intake (Leemans et al. 2009). 
Linoleic acid and α-linolenic are known to be the precursor for eicosanoid 
(prostaglandins, thromboxane and leukotrienes) production (Riediger et al. 2009). It 
is proposed that due to the increased amounts of n-6 fatty acids in the Western diet, 
the eicosanoid metabolic products are formed in larger quantities than those formed 
from n-3 fatty acids. The eicosanoids derived from n-6 fatty acids are biologically 
very active even in small quantities and therefore, when they are formed in large 
amounts; they could contribute to the formation of allergic and inflammatory 
disorders (Mickleborough et al. 2009; Simopoulos 2002). 
 
After adjusting for confounders, the association between the intakes of arachidonic 
acid, total n-3 and n-6 and asthma were shown as non-significant. However, the 
association between the level of n6:n3 in non-asthmatics (2.78) and those with 
asthma at eight and 14 years (3.38) remained significant (p=0.030). 
 
4.4  COMPARISON OF THE RESULTS OF TWO STUDIES 
 
In Study One a protective association between higher consumption of vitamin C and 
asthma was observed. In the same study, a protective association between higher 
intake of berry fruits with atopy and wheezing episodes was also found, however, in 
Study Two no significant associations between asthmatic symptoms and 
consumption of these fruits and nutrients were observed. 
 
The analysis of fatty acid intake in Study One used red blood cell fatty acid content, 
while in Study Two fatty acid intake was estimated from the food consumed during 
the day as they were recorded in food frequency questionnaires. Therefore, the 
information on fatty acids in Study One may be more applicable as they are objective 
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measurements rather than relying on memories of the participants or their parents. 
However, the food frequency questionnaires used in both studies were based on the 
Commonwealth Scientific and Industrial Research. These questionnaires were 
validated in adults (Yearsley, Last & Ward 1999) and had previously been applied in 
children (Oddy et al. 2004b). Therefore, the outcome data measurements were based 
on validated methods and questionnaires. 
 
In Study One, we found a number of significant associations between the level of 
individual fatty acids in red blood cells and asthmatic outcomes. In crude analysis 
docosapentaenoic acid (22:5n3) in red blood cells was positively associated with 
asthma, BHR and wheezing episodes. However, after adjusting for confounders (age, 
sex, BMI and total energy intake), no significant associations between the level of 
docosapentaenoic acid and any of the asthmatic symptoms was found.  
 
In Study One a significant protective association between the adjusted level of 
docosahexaenoic acid (DHA) (22:6n3) and BHR was shown. 
 
In both studies the ratio of n6:n3 fatty acids was demonstrated to have a significant 
detrimental association with asthmatic symptoms.  
 
Besides having two different methods for collecting data on fatty acids levels in these 
two studies as discussed, we also had a larger number of red blood cell samples 
(n=1329) in Study One compared to the number of food frequency questionnaires 
(n=335) in Study Two. Therefore, it could be argued that there was a better 
probability to discover associations between fatty acids and asthma in Study One as 
opposed to Study Two. However, we could look for the differences longitudinally in 
Study Two and explore any possible differences in the cohort over the period of six 
years. 
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4.5  STRENGTH AND LIMITATIONS OF THE TWO STUDIES 
 
Food frequency questionnaires were used for collection of dietary intake data in both 
studies. The use of food frequency questionnaires has become the primary method 
for measuring dietary intake in epidemiological studies (McNamara, Sullivan & 
Richtand 2008; Willett 1998). The main advantages of using food frequency 
questionnaires were that they are easy for the subjects to complete and their 
processing can readily be computerised. The food frequency questionnaire in our 
study was validated in adults (Yearsley, Last & Ward 1999) and has earlier been 
validated and applied for fish intake against serum fatty acids samples in the eight 
year follow-up in children in the Raine study (Oddy et al. 2004b). 
 
One of the limitations of this study was that it relied on the use of participants’ long-
term memories to record usual intake of a wide range of foods. Therefore, the 
existence of recall bias cannot be excluded as it has been documented in other 
epidemiological studies relying on the participants long-term memories (Broadfield 
et al. 2004; Huang, Lin & Pan 2001). 
 
The presence of the temptation to exaggerate intake of foods perceived as healthy by 
the participants and under-reporting of food that may be perceived as unhealthy was 
another limitation. Nutrients may synergistically provide comprehensive modulatory 
inflammatory reactions (Yeum et al. 2009). Therefore, any effects of diet observed 
on asthma may have come from combined interactions of foods in diet and not the 
result of a single nutrient or food. 
 
The Western Australian Pregnancy Cohort Study had a large number of participants, 
and thus provided sufficient power to detect statistically significant differences 
between adolescents with and without asthma. There was only one group in Study 
Two (asthma at 14 years) that contained a very small number of participants (n=6). 
The small number of the participants in this group resulted in a large variation in the 
intake of foods and nutrients as demonstrated by a large Standard Error of Mean 
(SEM) in this group. Therefore, the intake of foods in this group may not represent a 
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precise estimate of the intake of these nutrients and hence the differences observed 
between this group and the others may not be reliable. 
 
4.6 DIETARY RECOMMENDATIONS 
 
Based on our findings it is recommended to include more berry fruits in the diets of 
children and adolescents. We also suggest including more fruits containing high 
levels of vitamin C in the diets.  It is also recommended to reduce the ratio of n6:n3 
fatty acids by including more foods which are high in n-3 fatty acids (whole grains, 
fatty fish, flax seeds and soy bean) and reducing foods that are high in n-6 fatty acids 
(poppy seed oil, palm oil, sunflower oil, soybean oil, coconut oil, peanut oil, wheat 
germ oil, grape seed oil, macadamia oil, pistachio oil and sesame oil). The most 
widely available dietary source of EPA and DHA is cold water oily fish, such as 
salmon, herring, mackerel, anchovies and sardines. Oils from these fish have a 
profile of around seven times as much n-3 as n-6 (Antonijevic et al. 2007). It is 
however advisable that a dietician be consulted to address individual requirements 
for dietary aspects of increasing n-3 fatty acids. 
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CHAPTER FIVE 
5.1  CONCLUSIONS  
 
The objective of this thesis was to gain insight into possible associations between the 
intake of dietary antioxidants, n-3 and n-6 fatty acids as well as red blood cell level 
of these fatty acids with asthmatic traits in children and adolescents.  
 
In the following sections, I provide suggestions for future research and the final 
summary of this study. 
 
5.2  FUTURE STUDIES  
 
There are inconsistencies in the evidence of the roles of different nutrients on asthma 
in different populations (Almqvist et al. 2007; Emecen et al. 2009; Leemans et al. 
2009; McKeever 2007; McNamara, Sullivan & Richtand 2008; Mickleborough, 
Ionescu & Rundell 2004; Oddy et al. 2004a; Riediger et al. 2009; Schmitz & Ecker 
2008; Takaoka & Norback 2008). One likely reason for this irregularity in the 
evidence is that assortments of different methods both in biomedical and 
epidemiological investigations have been used to measure nutrients and fatty acids. 
Therefore, future studies should concentrate on providing standard methods in 
measurements of biological and population variables (such as the validated FFQ that 
was used in this study). These methods could be applied in a uniform format across 
different populations worldwide.  
 
Larger epidemiological cohort studies may be required to ascertain the mechanisms 
implicated by fatty acids in immune system regulation throughout the life course, and 
to establish a better understanding of the association between total fatty acid intake 
and respiratory health.  
 
More investigations are necessary to search for differences in the diets of children in 
countries with lower incidence of asthma compared with Western countries aiming to 
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establish the possible effects of other nutrients which could have an impact in 
reducing the risk of asthma and atopic disease in those countries. 
 
The changes in lifestyle that have occurred in developed countries compared to 
developing countries have not been limited to the changes in diets and other factors, 
such as differences in the level of physical activity. These differences may have 
contributed to increases in the prevalence of asthma and other allergic diseases 
compared with developing countries. Despite the fact that there is a recent study 
which rules out the role of physical activity (Castro-Rodriguez et al. 2008), more 
evidence should be gathered. This can be achieved by studying details of physical 
activity in children and adolescents in a large scale study and exploring possible 
associations between asthma and different level of these activities as well as 
nutrition.  
 
5.3  FINAL SUMMARY 
 
This research was conducted to investigate the hypothesis that consumption of 
antioxidants nutrients, n-3 fatty acids, fresh fruits and vegetables with a high content 
level of antioxidants will reduce asthmatic symptoms in adolescents. This study was 
relied on the use of participants’ long-term memories to record the intake of a wide 
range of foods. The existence of recall bias cannot be excluded in this study. 
 
We found some evidence that a decreased in consumption of some fresh fruits (berry 
fruits) may be associated with asthmatic symptoms.  
 
Most of the dietary antioxidants did not show a protective effect on asthma in 14 year 
old adolescents. This may be due to the fact that there are autoimmune components 
involved in the manifestation of asthma that cannot be modulated by dietary intake of 
fruits and vegetables. We found that by increasing intake of vitamin C we may 
reduce the risk of developing asthma. Higher level of docosahexaenoic acid in RBC 
membrane was associated with a reduced risk of BHR.  
 
 160 
We also demonstrated that an increase in the ratio of n6:n3 was associated with more 
asthmatic symptoms. The adjusted ratio of n6:n3 showed a detrimental association 
with asthma and wheezing episodes. We propose that the ratio of n6:n3 in diet may 
play a modulatory role in the expression of asthma, suggesting that promotion of 
increased total n-3 and reduced n-6 in the diet may protect against asthmatic traits in 
childhood and early adolescence. Further studies are required to confirm these 
findings given the limitation of this study. 
 
There are numerous questions remaining related to the inherent complexities 
concerning the role of diet in modulation of asthmatic symptoms. It remains unclear 
to what extent ALA is converted to EPA and DHA in human body. 
 
In Study Two the number of adolescents in group C (asthma at 14 years only) was 
very low (n=6) and therefore, the results concerning this group have to be interpreted 
with caution due to the low statistical power (11.4%) of the study. 
 
In conclusion, there are still many uncertainties and inconsistencies on the role of 
diet on asthma and allergies. One of the major reasons that studies into the diet and 
its role in the development of allergies remains so inconclusive may be the 
complexity of the interaction between nutrients and the immune system.  
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